Document:

EX-10.5

 Exhibit 10.5 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

AMENDED PATENT LICENSE AGREEMENT 

LSU FILE LSUHSC-S-
07-006 and LSUHSC-S-09-015 

This Agreement is effective as of the 12th day of May, 2015 (the “Effective Date”), between
BioNTech AG, a corporation incorporated in Germany, with offices located at An der Goldgrube 12, D-55131 Mainz, Germany (“LICENSEE”); the Board of Supervisors of Louisiana State University and
Agricultural and Mechanical College, a public constitutional corporation, organized and existing under the laws of the State of Louisiana (“LSU”); and Uniwersytet Warszawski (the University of Warsaw), a Polish nonprofit corporation
(“UW”); LSU and UW sometimes to be referred to, collectively, individually or independently, as “LICENSOR” or “LICENSORS.” 

UW and LICENSEE have entered on the 15th day of November 2010 into a separate Research Cooperation
Agreement [***] (“RESEARCH COOPERATION AGREEMENT”). Therein UW and LICENSEE agreed to cooperate in the synthesis and characterization of chemically modified cap analogs and their evaluation on the efficacy of
RNA-based immunotherapies in pre-clinical and clinical studies (“COOPERATION”) and UW granted LICENSEE certain rights in patent applications already filed as
well as in future sole inventions of UW and joint inventions of UW and LICENSEE resulting from the COOPERATION. UW and LICENSEE agreed that any remuneration for the rights granted is already covered by the considerations as set out in clause 2 of
this agreement. 
 This agreement replaces the “Patent License Agreement LSU FILE
LSUHSC-S- 07-006 and
LSUHSC-S-09-015” of BioNTech AG (LICENSEE), Uniwersytet Warszawski (UW) and Louisiana State University (LSU) made of 15th day of March, 2011, effective on 16th day of December. This agreement also replaces the “Amendment NO. 1 to Patent License Agreement” referring to said “Patent License Agreement LSU
FILE LSUHSC-S- 07-006 and
LSUHSC-S-09-015” effective on 1st day of January, 2013. This named two
agreements are herein after referred to as “PRIOR AGREEMENTS” [***]. 
 ARTICLE 1 – DEFINITIONS 

1.1 “AFFILIATE” of LICENSEE shall mean a company or other person controlling, controlled by, or under common control with LICENSEE, where
“control” shall mean the direct or indirect control by ownership or otherwise of more than fifty percent (50%) of the outstanding voting shares or voting rights, or other similar measure of control. 

1.2 “FIELD OF USE” means all fields of use. 

1.3 “FIRST COMMERCIAL SALE” means the first sale of any LICENSED PRODUCT or the first commercial use of any LICENSED PROCESS by LICENSEE or a
SUBLICENSEE, other than a sale of a LICENSED PRODUCT or the use of a LICENSED PROCESS for use in trials, such as field trials or clinical trials, being conducted to obtain FDA or other governmental approvals to market LICENSED PRODUCTS or otherwise
commercially use LICENSED PROCESSES. 

  
 1 

 1.4 “COOPERATION PATENT RIGHTS” shall mean UWs legal rights under the patent laws of the
United States or relevant foreign countries for all of the following: 
  

	 	(a)	 the United States and foreign patents and/or patent applications which will be or have been filed for sole or
joint inventions resulting from the COOPERATION and/or for inventions from previous research projects between UW and LICENSEE as set out in Section 8.6 of the RESEARCH COOPERATION AGREEMENT (“COOPERATION INVENTIONS”); non-provisional applications claiming priority under 35 U.S.C. § 119(e) from any provisional applications filed for COOPERATION INVENTIONS, continuations, and continuations-in-part of any of the above applications; the United States and foreign patents and/or patent applications filed for COOPERATION INVENTIONS;
non-provisional applications claiming priority under 35 U.S.C. § 119(e) from any provisional applications filed for COOPERATION INVENTIONS; divisionals, continuations, and
continuations-in-part of any of the above applications 

  

	 	(b)	 United States and foreign patents issued from the applications described above in part (a) as well as
utility models, extensions or supplemental protection certificates (SPCs) thereof or equivalent patent term extensions; 

  

	 	(c)	 claims in all foreign patent applications, and in resulting patents, that are directed to subject matter
specifically described in the United States patents and/or patent applications described in (a) and/or (b) above; 

  

	 	(d)	 any reissued or reexamined patents based upon the United States patents described in (a) and/or (b).

 1.5 “LICENSED PRODUCT(S)” means a product or part of a product in the licensed FIELD OF USE: 

 

	 	(a)	 for which, absent this Agreement, the making, using, importing or selling, would infringe, induce infringement,
or contribute to infringement of an issued or unexpired claim contained in the PATENT RIGHTS in the country in which any such product or product part is made, used, imported, offered for sale or sold; or 

 

	 	(b)	 that is manufactured using a LICENSED PROCESS or is employed to practice a LICENSED PROCESS.

  
 2 

 1.6 “LICENSED PROCESS(ES)” means any process or method that is covered in whole or in part
by an issued or unexpired claim contained in the PATENT RIGHTS. 
 1.7 MARKET EXCLUSIVITY means that there is no product equivalent to the LICENSED
PRODUCT on the market, serving for the same purpose or addressing the same needs of the same customer target group. 
 1.8 “NET SALES” means
the amount billed or invoiced on sales, rental, lease, or use, however characterized, by LICENSEE and SUBLICENSEES for LICENSED PRODUCTS and LICENSED PROCESSES, less 
  

	 	(a)	 discounts allowed in amounts customary in the trade; 

 

	 	(b)	 sales tax, tariffs, duties and use tax included in bills or invoices with reference to particular sales and
actually paid by LICENSEE to a governmental unit; 

  

	 	(c)	 outbound transportation prepaid or allowed; or 

 

	 	(d)	 amounts refunded or credited on returns. 

No deductions shall be made for the cost of collections or for commissions, whether paid to independent sales agents or employees of LICENSEE.

 Whenever the term “LICENSED PRODUCT” may apply to a product during various stages of manufacture, use, sale, or other transfer,
NET SALES shall be based on the amount derived from the sale, distribution or use of such LICENSED PRODUCT at the stage of its highest billed or invoiced value to an arms-length third party. 

If a potential SUBLICENSEE does not agree with the above NET SALES definition, LICENSEE and LSU shall mutually discuss and put forth good
faith efforts to agree upon an amendment of the above NET SALES definition, in so far as LSU is able taking into account United States Federal definitions of NET SALES. A consent to reasonable amendments shall not unreasonably be withheld or
delayed. 
 1.9 “PATENT RIGHTS” means LICENSORS’ legal rights under the patent laws of the United States or relevant foreign countries
for all of the following: 
  

	 	(a)	 the United States and foreign patents and/or patent applications listed in Appendix A; non-provisional applications claiming priority under 35 U.S.C. § 119(e) from any provisional applications listed in Appendix B; divisionals, continuations, and continuations-in-part of any of the above applications; 

  
 3 

	 	(b)	 United States and foreign patents issued from the applications described above in part (a) as well as
utility models, extensions or supplemental protection certificates (SPCs) thereof or equivalent patent term extensions;. 

  

	 	(c)	 claims in all foreign patent applications, and in resulting patents, that are directed to subject matter
specifically described in the United States patents and/or patent applications described in (a) and/or (b) above; 

  

	 	(d)	 claims in all patent applications, and in the resulting patents, that are directed to subject matter
specifically described as of the 16th day of December 2010 in the LSU Office of Technology Transfer files listed in Appendix B; and 

 

	 	(e)	 any reissued or reexamined patents based upon the United States patents described in (a), (b), and/or
(d) above. 

 1.10 “ROYALTY PERIOD(S)” means the twelve-month periods ending on the last day of December. 

1.11 “SUBLICENSEE(S)” means any person or entity sublicensed by LICENSEE under this Agreement. 

1.12 “TERRITORY” means all countries in which patent applications or patents within the PATENT RIGHTS are pending or issued. 

1.13 “VALID CLAIM” means a claim of an issued patent in the TERRITORY, which is not expired, not withdrawn nor invalidated by final judgment.
In case of pending applications a valid claim exists for the period of [***] years from the priority date of the respective patent, if no request for examination has been filed, but longest for a period of [***] years from the priority date of the
respective patent. 
 ARTICLE 2 - GRANT OF LICENSE 

2.1 Subject to the terms and conditions of this Agreement, LICENSORS hereby grant to LICENSEE an exclusive royalty-bearing license under the PATENT
RIGHTS, with the right to assign, sublicense, otherwise transfer rights pursuant to this Agreement, in the FIELD OF USE in the TERRITORY to make, have made, import, use, offer for sale and sell LICENSED PRODUCTS and LICENSED PROCESSES. 

  
 4 

 2.2 The license granted to LICENSEE shall extend to an AFFILIATE of LICENSEE as well, provided that
LICENSORS first receive written notice, signed on behalf of both LICENSEE and the AFFILIATE: (1) stating that the AFFILIATE intends to exercise such rights, and (2) agreeing that the AFFILIATE and LICENSEE shall be solidarily liable for
all obligations to LICENSORS under the Agreement arising from the activities of that AFFLIATE. The activities of the AFFILIATE under the Agreement shall then be deemed to be the activities of LICENSEE. The rights of an AFFILIATE under the Agreement
shall terminate if LICENSEE’s rights under the Agreement terminate. An AFFILIATE has the right to sublicense, assign, or otherwise transfer rights under the Agreement, if AFFILATE agrees to submit to the same obligations as LICENSEE as set out
in Section 6 of this Agreement. 
 2.3 LICENSORS retain the right, on behalf of themselves and all other
non-profit academic research institutions to practice the PATENT RIGHTS for any non-profit purpose, including sponsored research and collaborations. 

2.4 This Agreement shall extend until expiration of the last-to-expire
of the licensed PATENT RIGHTS or COOPERATION PATENT RIGHTS, unless sooner terminated as provided in another specific article of this Agreement. 
 2.5
Nothing in the Agreement shall be construed as granting by implication, estoppel, or otherwise any licenses or rights under any patents, patent applications, or know how other than the license under the PATENT RIGHTS granted in Article 2.1 or as
already granted under the RESEARCH COOPERATION AGREEMENT. 
 2.6 LSU further reserves to the United States Government all rights that may be required
by research funding agreements between LSU and the United States Government pursuant to 35 U.S.C. §200 et seq. and applicable implementing regulations. 

2.7 LICENSEE agrees that LICENSED PRODUCTS used, leased or sold in the United States shall be manufactured in compliance with 35 U.S.C.
§204, and any applicable implementing regulations. LICENSOR and LICENSEE agree to jointly petition the NIH for a waiver of the manufacturing requirement but LICENSEE understands that the decision for such a waiver will be that of the NIH.

 ARTICLE 3 - CONSIDERATION 

3.1.1 LICENSEE shall pay running royalties and fees to LICENSORS until the expiration date of the last to expire of PATENT RIGHTS or COOPERATION
PATENT RIGHTS or until this Agreement is otherwise terminated. All payments under this Agreement shall be made to LSU. LSU will make payments to University of Warsaw in accordance with Inter-Institutional Agreements executed by LICENSORS. The
University of Warsaw shall not have any claims against LICENSEE if LSU defaults in its obligation to University of Warsaw under the Inter-Institutional Agreement. 

  
 5 

 Running royalties and fees shall include: 

 

	 	(a)	 License Issue Fee of [***]. Such License Issue Fee shall be nonrefundable and is due by January 31, 2011.

  

	 	(b)	 License Amendment Fee of [***]. Such License Amendment Fee shall be
non-refundable and is due within [***] business days after the Effective Date of this Patent License Agreement. 

  

	 	(c)	 Running royalties equal to [***] of NET SALES for all LICENSED PRODUCTS that are used, sold, offered for sale,
or imported anywhere in the TERRITORY, regardless of whether other acts concerning specific LICENSED PRODUCTS occur outside the TERRITORY.    If LICENSEE makes any sales to any party affiliated with LICENSEE, or in any way
directly or indirectly related to or under the common control with LICENSEE, at a price less than the regular price charged to arm’s length third parties, the running royalties payable to LSU shall be computed on imputed NET SALES equal to the
regular price charged to arm’s-length third parties; 

  

	 	(d)	 Running royalties equal to [***] of NET SALES earned outside the TERRITORY for all LICENSED PRODUCTS that are
made anywhere in the TERRITORY and used, sold, offered for sale, or imported outside the TERRITORY, provided that there is MARKET EXCLUSIVITY for the respective LICENSED PRODUCT outside the TERRITORY. If LICENSEE makes any sales to any party
affiliated with LICENSEE, or in any way directly or indirectly related to or under the common control with LICENSEE, at a price less than the regular price charged to arm’s length third parties, the running royalties payable to LSU shall be
computed on imputed NET SALES equal to the regular price charged to arm’s-length third parties under this section (c); 

 

	 	(e)	 [***] of any consideration that is not based on NET SALES (e.g., sublicense issue fees, sublicense maintenance
fees, etc.) that LICENSEE receives from SUBLICENSEES or assignees in consideration for rights to practice under the PATENT RIGHTS or COOPERATION PATENT RIGHTS, excepting only research and development funding. If a sublicense agreement concluded by
LICENSEE does not solely relate to the PATENT RIGHTS and/or COOPERATION PATENT RIGHTS but also includes additional intellectual property or know-how, then and only then shall the above [***] royalty be reduced
to reflect the relative value of the sublicensed PATENT RIGHTS or COOPERATION PATENT RIGHTS taking into account said number of the other intellectual property and know-how licensed under the relevant
sublicensing agreement. The consideration to be paid to LSU shall be determined according to the following payment table: 

  
 6 

	 	
LICENSEE shall report to LSU any other intellectual property (technology claimed in intellectual property or know-how) having relevance for each LICENSED
PRODUCT, whereas in case of intellectual property “having relevance” shall mean that any manufacture, use, sale, offer for sale or importation of LICENSED PRODUCT would infringe at the time point of conclusion of a sublicense agreement at
least one VALID CLAIM of the intellectual property considered for calculation of the consideration payable to LSU. For the avoidance of doubt, an individual intellectual property, in regard to the counting required by the preceding table, comprises
all patent rights or know-how which relate to the same independent (provide a benefit for the product of its own) technical feature, especially all members of patent families claiming the same priority date.

  

	 	(f)	 Reimbursement of LICENSORS’ reasonable past and future out-of-pocket patenting costs related to the PATENT RIGHTS including reasonable attorneys’ fees, but not including salaries of LICENSORS employees. Such reimbursement is nonrefundable and is due by
January 31, 2011. 

 3.1.2 LICENSEE shall pay to LICENSORS an annual license maintenance fee (“Annual Fee”). This
Annual Fee shall be due on the last day of June of the years specified below. LICENSEE may credit each Annual Fee in full against all running royalties otherwise due LICENSORS for the same calendar year for which the specific Annual Fee is due. This
credit may not otherwise be carried forward or carried back for any other ROYALTY PERIOD. 
 The Annual Fees are: 

[***] 
  

	 	(1)	 [***] 

	 	(2)	 [***] 

	 	(3)	 [***] 

  
 7 

	 	(4)	 In 2015 and in each year thereafter during the term of this Agreement: [***] 

3.2 LICENSEE shall be responsible for the payment of all taxes, duties, levies, and other charges, subject to the deduction from NET SALES allowed by
Paragraph 1.7(b). 
 3.3. LICENSORS shall be responsible for the payment of all taxes, duties, levies and other charges due to LICENSORS’ receipt
of royalties and fess pursuant to Article 3.1.1. 
 3.4 LICENSEE is not obligated to pay multiple running royalties to LICENSORS if any LICENSED
PRODUCT or LICENSED PROCESS is covered by more than one claim of PATENT RIGHTS, or by more than one patent application or patent within PATENT RIGHTS. 

3.5 Payments due to LICENSORS are exclusive of value added tax, which shall, if applicable, be invoiced separately. Payments due to LICENSORS shall be
paid to the “Louisiana State University” in United States dollars in Baton Rouge, Louisiana, sent as provided in article 14 or at such other place as LSU may reasonably designate consistent with the laws and regulations controlling in any
country. At LSU’s request, LICENSEE shall remit payments either by wire transfer or by check drawn upon a United States bank. 
 3.6 In computing
running royalties, LICENSEE shall convert any revenues it receives in foreign currency into its equivalent in United States dollars at the exchange rate LICENSEE, using its standard accounting procedures, uses to make reports to relevant regulatory
and taxing authorities, as long as such accounting procedures are consistent with fair business practices and generally accepted accounting principles. 

3.7 Running royalty payments shall be made on a [***] basis with submission of the reports required by Article 4. All amounts due under this Agreement,
including amounts due for the payment of patent expenses, shall, if overdue, bear interest until payment at a per annum rate [***] percent ([***]%) above the prime rate in effect at the JP Morgan Chase Bank or its successor on the due date, or at
the highest allowed rate if a lower rate is required by law. The payment of such interest shall not foreclose LICENSORS from exercising any other rights it may have resulting from any late payment. 

3.8 All amounts paid to LICENSORS by LICENSEE under this Agreement shall be non-refundable. 

3.9 If LICENSORS and LICENSEE disagree in good faith as to whether certain payments are due to LICENSORS, then the procedures of this Section 3.9
shall be followed to place the disputed amounts into escrow. If these procedures are followed, then LICENSEE shall not be deemed to be in default for failure to make the disputed payments timely. If these procedures are not followed, however, then
LICENSEE shall be deemed to be in default for failure to make payments timely under the Agreement, regardless of whether or not it is ultimately determined that the disputed amounts were actually due under the Agreement. 

  
 8 

 3.9.1 All undisputed amounts shall be paid to LICENSORS as otherwise provided. 

3.9.2 All disputed amounts shall be paid to an escrow agent mutually acceptable to LSU and LICENSEE. Disputed amounts that are past due
shall be paid to the escrow agent within [***] days after the establishment of an escrow account with a mutually acceptable escrow agent. Disputed amounts that are not yet due but that become due during pendency of the dispute shall be paid to the
escrow agent on or before the dates those amounts are otherwise due under the Agreement. LSU shall be given prompt confirmation of the date and amount of any such payments made. 

3.9.3 The escrow agent shall place the funds in a safe, interest-bearing instrument or account jointly approved by LSU and LICENSEE; or
if LSU and LICENSEE are unable thus to agree, in a safe, interest-bearing instrument or account chosen by the escrow agent. Any interest thus received shall ultimately be distributed by the escrow agent in the same proportions as the distribution of
the principal amount. A reasonable fee for the escrow agent’s services may first be deducted from the interest. 
 3.9.4 The
escrow agent shall release the funds in escrow only in accordance with the joint, written instructions of both LSU and LICENSEE; or in accordance with an order of the court or an award of the arbitrator under Section 16.2. 

ARTICLE 4 - REPORTS 
 4.1 LICENSEE
shall provide to LICENSORS a written annual report within [***] days after each ROYALTY PERIOD closes or within [***] days after termination of this agreement. The annual report shall include: reports of progress and of the amount of capital
expended on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding [***] months, and plans for the coming year. Each annual report shall include confirmation of existing insurances in
compliance with Paragraph 11.3. 
 4.2 After the FIRST COMMERCIAL SALE, the annual report of LICENSEE according to 4.1 shall further include for that
ROYALTY PERIOD: 
  

	 	(a)	 number of LICENSED PRODUCTS manufactured and sold by LICENSEE and all SUBLICENSEES; 

 

	 	(b)	 total billings for LICENSED PRODUCTS sold by LICENSEE and all SUBLICENSEES; 

  
 9 

	 	(c)	 accounting for all LICENSED PROCESSES used or sold by LICENSEE and all SUBLICENSEES; 

 

	 	(d)	 deductions applicable as provided in the definition for NET SALES in Paragraph 1.8; and 

 

	 	(e)	 any consideration due on additional payments from SUBLICENSEES under Paragraph 3.1(c). 

LICENSEE shall include the amount of all payments due, and the various calculations used to arrive at those amounts, including the quantity, description
(nomenclature and type designation as described in Paragraph 4.3 below), country of manufacture and country of sale of LICENSED PRODUCTS. If no payment is due, LICENSEE shall so report. LICENSEE shall direct its authorized representative to certify
that each report is correct to the best of LICENSEE’s knowledge and information. Failure to provide reports as required under this Article shall be a material breach of this Agreement. 

4.3 LICENSEE covenants that it will promptly establish and consistently employ a system of specific nomenclature and type designations for LICENSED
PRODUCTS and LICENSED PROCESSES to permit identification and segregation of various types where necessary. LICENSEE shall consistently employ, and shall require SUBLICENSEES to consistently employ, the system when rendering invoices thereon. On
request, LICENSEE shall promptly explain to LSU, or its auditors, all details reasonably necessary to understand such nomenclature system, all additions thereto and changes therein. 

4.4 LICENSEE shall keep, and shall require all SUBLICENSEES to keep, true and accurate records containing data reasonably required for the computation
and verification of payments due under this Agreement. LICENSEE shall, and it shall require all SUBLICENSEES to: 
  

	 	(1)	 open such records for inspection upon prior written, reasonable notice during business hours by either LSU
auditor(s) or an independent certified accountant selected by LSU, for the purpose of verifying the amount of payments due with such inspection not occurring more than once per [***] unless required by the State of Louisiana or United States federal
agencies; and 

  

	 	(2)	 Wherever practical combine an inspection by LSU with a Licensee inspection of said records

  

	 	(3)	 retain such records for [***] years from date of origination. 

The terms of this Article shall survive any termination of this Agreement. LSU is responsible for all expenses of such inspection, except that if any
inspection reveals an underpayment greater than [***] percent ([***]%) of the amounts due LSU for any ROYALTY PERIOD, then LICENSEE shall pay all expenses of that inspection and the amount of the underpayment and interest to LSU within [***] days of
written notice thereof. LICENSEE shall also reimburse LSU for reasonable expenses required to collect any amount underpaid. 

  
 10 

 ARTICLE 5 - DILIGENCE 

5.1 LICENSEE has the responsibility to develop LICENSED PRODUCTS into marketable products. 

5.2 LICENSEE shall use commercially reasonable efforts (including, without limitation, commitment of funding and personnel) comparable to the standards
of other biotechnology companies to bring one or more LICENSED PRODUCTS to market or one or more LICENSED PROCESSES to commercial use through a thorough, vigorous and diligent program for exploiting the PATENT RIGHTS; and to continue active,
diligent marketing efforts for one or more LICENSED PRODUCTS or LICENSED PROCESSES throughout the life of this Agreement. 
 5.3 As part of the
diligence required by Paragraph 5.2, LICENSEE agrees to use best efforts to reach the following commercialization and research and development milestones anywhere in the TERRITORY for the LICENSED PRODUCTS and LICENSED PROCESSES resulting from
PATENT RIGHTS (together the “MILESTONES”) by the following dates: 
  

	 	    	 [***] 

For clarity: The lack of commercialization of LICENSED PRODUCTS in the U.S. shall not be considered a lack of effort of LICENSEE to commercialize LICENSED
PRODUCTS under Sections 5.2 and 5.3. 
 5.4. LICENSEE shall inform LICENSORS in writing, on or before the deadline for meeting any MILESTONE, whether
such MILESTONE has been met. 
 5.5 If LICENSEE fails to meet any MILESTONE within [***] days after the date specified in Paragraph 5.3, LICENSORS may
notify LICENSEE of this material breach. If LICENSEE does not achieve the MILESTONE within [***] days of receipt of this notice, LICENSORS may terminate this Agreement. 

ARTICLE 6 - SUBLICENSING 
 6.1
LICENSEE shall notify LICENSORS in writing and shall send LICENSORS a copy of every sublicense agreement and each amendment thereto within [***] days after their execution. LICENSEE shall be entitled to redact those parts of the sublicense agreement
which are not relevant for LSU’s rights or obligations hereunder in relation to such sublicense agreement, 

  
 11 

 
including LSU’s royalty rights under Section 3.1.1 (c) to (e) above and the sublicensing restrictions set forth in this Article 6. LSU may, upon written reasonable notice, during
business hours enlist an independent third party individual under a duty of obligation of confidentiality with LICENSEE and LICENSOR, to review said sublicense agreement for compliance with terms of this Amended Patent License Agreement. 

6.2 LICENSEE shall contemporaneously certify to LICENSORS in writing that each sublicense: 

 

	 	(1)	 is consistent with the terms and conditions of this Agreement; 

 

	 	(2)	 contains the SUBLICENSEE’S acknowledgment of the disclaimer of warranty and limitation on LICENSORS’
liability, as provided by Article 11 below; and 

  

	 	(3)	 contains provisions under which the SUBLICENSEE accepts duties at least equivalent to those accepted by the
LICENSEE in the following Articles: 

  

	 	4.4	 duty to keep records 

 

	 	10.4	 duty to avoid improper representations or responsibilities 

 

	 	11.1	 duty to defend, hold harmless, and indemnify LICENSORS 

 

	 	11.3	 duty to obtain and maintain insurance 

 

	 	15.4	 duty to properly mark LICENSED PRODUCTS with patent notices 

 

	 	15.6	 duty to refrain from the use of LICENSORS’ names 

 

	 	15.7	 duty to control exports and comply with applicable laws 

6.3 If LICENSEE receives from a SUBLICENSEE anything in value other than cash payments in consideration for any sublicense under this Agreement, the
notification pursuant to Paragraph 6.1 will include the assumed fair market value of such consideration and a basis for that assumed value. Unless LICENSORS jointly but not solely disagree with the assumed fair market value within [***] days of such
notification, the assumed fair market value is used for the purpose of calculating running royalties due to LICENSORS pursuant to Paragraph 3.1.1 (c). In case of disagreement the parties will settle the dispute as provided in Paragraph 15.1. Both
LICENSORS and LICENSEE will bear its own costs of such dispute resolution and each party an equal part of the costs of the arbitration. 

  
 12 

 6.4 Each sublicense granted by LICENSEE under this Agreement shall provide for its termination upon
termination of this Agreement. Each sublicense shall terminate upon termination of this Agreement unless LICENSEE has previously assigned its rights under the sublicense to LICENSORS and LICENSORS have agreed at LICENSORS’ sole discretion in
writing to such assignment. 
 6.5 LICENSEE shall cause every sublicense to provide LICENSEE the right to assign its rights under the sublicense to
LICENSORS. Any such assignment is subject to the limitations of Article 15.11 herein and, to be effective, LICENSORS must first accept at their sole discretion such assignment in writing. 

6.6 No SUBLICENSEE shall have the right to grant further sublicenses without the express written permission of LICENSORS. 

6.7 Failure of LICENSEE to meet any of the obligations in this Article 6 shall be considered a material breach or default of this Agreement under
Paragraph 12.4. 
 ARTICLE 7 - PATENT PROSECUTION AND MAINTENANCE 

7.1 LICENSORS have the right to control all aspects of drafting, filing, prosecuting, and maintaining all patents and patent applications within the
PATENT RIGHTS, including foreign filings and Patent Cooperation Treaty filings. LICENSEE shall, at its own expense, perform all actions and execute or cause to be executed all documents necessary to support such filing, prosecution, or maintenance.

 7.2 LICENSORS shall notify LICENSEE of all official communications received by LICENSORS relating to the filing, prosecution and maintenance of the
patents and patent applications within the PATENT RIGHTS, including any lapse, revocation, surrender, invalidation, interference, opposition or abandonment of any of the patents or patent applications which form the basis for the PATENT RIGHTS, and
shall allow LICENSEE to review and comment upon such communications and will make efforts to follow any suggestions and fulfill reasonable requests of LICENSEE on the drafting, filing, prosecution, and maintaining all PATENT RIGHTS. 

7.3 LICENSEE shall reimburse LICENSORS for all reasonable past and future legal fees relating to the filing, prosecution, interference proceedings and
maintenance of the PATENT RIGHTS including reasonable attorneys’ fees, but not including salaries of LICENSORS’ employees, except as specifically provided in Paragraph 7.4. Such reimbursement shall be made for each calendar quarter, and
shall be paid within [***] days of receipt of LICENSORS’ invoice and shall bear interest, if overdue, at the rate specified in Paragraph 3.7 above. 

  
 13 

 7.4 LICENSEE may elect to not reimburse LICENSORS for fees and costs related to a particular patent
application or patent within PATENT RIGHTS in a particular country, subject to the terms of this Paragraph 7.4. LICENSORS will provide LICENSEE with reasonable advance notice to allow LICENSEE to consider the action to be taken for a particular
patent application or patent within PATENT RIGHTS to make such an election. If LICENSEE makes such an election, LICENSEE shall provide reasonable notice to LICENSORS in writing. LICENSORS may then elect to continue the prosecution or maintenance of
such application or patent at LICENSORS’ sole expense, provided that such patent applications and issued patents thereafter shall be excluded from the definition of PATENT RIGHTS. 

7.5 LICENSORS shall be responsible for any remuneration of inventors of the PATENT RIGHTS that are due the inventors pursuant to a contract of
employment or otherwise and shall keep LICENSEE harmless of any such claim. 
 7.6 On a case-by-case basis, the parties may agree in writing (which includes electronic mail) that LICENSEE shall manage the prosecution and maintenance of specifically-identified patents and patent applications
within the PATENT RIGHTS in specifically-identified countries, at LICENSEE’s sole expense. In such a case LICENSORS shall provide reasonable assistance to LICENSEE’s efforts in this regard, at no out-of-pocket expense to the LICENSORS. The provisions of Paragraph 7.2 shall apply in such a case, with the roles of LICENSORS and LICENSEE reversed, mutatis mutandis. The provisions of Paragraph 7.4
shall apply in such a case, mutatis mutandis, in the event LICENSEE elects to discontinue prosecution, to discontinue maintenance, or otherwise to abandon any affected patent or patent application. 

ARTICLE 8 - ENFORCEMENT 
 8.1 Each
party shall promptly advise the other in writing of any known acts of potential infringement of the PATENT RIGHTS by a third party. LICENSEE and LICENSORS shall mutually agree on an adequate strategy, whereas LICENSEE has the first option to police
the PATENT RIGHTS against infringement by third parties within the TERRITORY in the FIELD OF USE, but LICENSEE shall notify LICENSORS in writing [***] days before filing any suit. This right to police includes defending any action for declaratory
judgment of noninfringement or invalidity; and prosecuting, defending or settling all infringement and declaratory judgment actions at LICENSEE’s expense and through counsel of LICENSEE’s selection, except that LICENSEE shall make any such
settlement only with the advice and consent of LICENSORS, which will not be unreasonably withheld. LICENSORS shall provide reasonable assistance to LICENSEE with respect to such actions, but only if LICENSEE reimburses LICENSORS for out-of-pocket expenses incurred in connection with any such assistance rendered at LICENSEE’S request. LICENSORS retain the right to participate, with counsel of their
own choosing and at their own expense, in any action under this Article 8.1. LICENSEE shall defend, indemnify and hold harmless LICENSORS with respect to any claims or counterclaims asserted by an alleged infringer reasonably related to the
enforcement of the PATENT RIGHTS, under this Paragraph 8.1, including but not limited to antitrust claims or counterclaims unless such claims or counterclaims are due to LICENSORS participation in any action under this Paragraph 8.1. 

  
 14 

 8.2 If LICENSEE undertakes to enforce or defend the PATENT RIGHTS by litigation in any country,
LICENSEE may withhold up to [***] percent ([***]%) of running royalties (as described in Paragraph 3.1.1(b)) due to LICENSORS for sales in such country in which the litigation is pending to reimburse LICENSEE’s out-of-pocket litigation expenses, including reasonable attorneys’ fees, but not including salaries of LICENSEE’s employees. Such pending litigation does not affect any other payment due to
LICENSORS under this Agreement. If LICENSEE recovers damages in the patent litigation, the award shall be applied first to satisfy LICENSEE’S unreimbursed expenses and legal fees for the litigation, next to reimburse LICENSORS for any payments
under Article 3 which are past due, and then to reimburse LICENSORS for any other unreimbursed expenses and legal fees for the litigation under Paragraph 8.1. LICENSEE shall pay ten percent (10%) of the remaining balance to LICENSORS. If LICENSEE
does not recover any damages the withheld running royalties shall be applied to satisfy LICENSEE’S unreimbursed expenses and legal fees for the litigation. Withheld running royalties beyond that required to reimburse LICENSEE’S out-of-pocket litigation expenses as described above shall be paid to LICENSORS. 

8.3 If LICENSEE declines its option to take action to abate an alleged infringement of a patent within the PATENT RIGHTS within [***] days of a request
by a LICENSOR to do so (or within a shorter period if required to preserve the legal rights of LICENSORS under applicable law), then LICENSORS have the right to take such action (including prosecution of a suit) at LICENSORS expense. LICENSEE shall
use reasonable efforts to cooperate in such action, and LICENSORS will reimburse LICENSEE for out-of-pocket expenses incurred in connection with any such assistance
rendered at LICENSORS’ request. LICENSORS have full authority to settle on such terms as LICENSORS determine, except that LICENSORS shall not reach any settlement whereby it provides a license for future activities to a third party under the
PATENT RIGHTS in the TERRITORY in the FIELD OF USE without the consent of LICENSEE, which consent shall not be unreasonably withheld by LICENSEE. LICENSOR retains one hundred percent (100%) of any recovery or settlement under this Paragraph 8.3
after reimbursement of any of LICENSEE’s out-of-pocket expenses. 

ARTICLE 9 - CONFIDENTIAL INFORMATION 

9.1 All Confidential Information disclosed, revealed or otherwise made available by one Party (“Disclosing Party”) to the other Party
(“Receiving Party”) under, or as a result of, this Agreement is furnished to the Receiving Party solely to permit the Receiving Party to exercise its rights, and perform its obligations, under this Agreement. The Receiving Party
shall not use any of the Disclosing Party’s Confidential Information for any other purpose, and shall not disclose, reveal or otherwise make any of the Disclosing Party’s Confidential Information available to any other person, firm,
corporation or other entity, without the prior written authorization of the Disclosing Party. 

  
 15 

 9.2 In furtherance of the Receiving Party’s obligations under Paragraph 9.1 hereof, the
Receiving Party shall take all appropriate steps, and shall implement all appropriate and reasonable safeguards, to prevent the unauthorized use or disclosure of any of the Disclosing Party’s Confidential Information. Without limiting the
generality of this Paragraph 9.2, the Receiving Party shall disclose any of the Disclosing Party’s Confidential Information only to those of its officers, employees, advisors, representatives, licensees, sublicensees, potential sublicensees and
financial investors that have a need to know the Disclosing Party’s Confidential Information, in order for the Receiving Party to exercise its rights and perform its obligations under this Agreement, and only if such officers, employees,
advisors, representatives, licensees, sublicensees, potential sublicensees and financial investors are notified of the terms regarding confidentiality as those set out in this Agreement or are otherwise bound by obligations of confidentiality
effectively prohibiting the unauthorized use or disclosure of the Disclosing Party’s Confidential Information. The Receiving Party shall furnish the Disclosing Party with immediate written notice of any unauthorized use or disclosure of any of
the Disclosing Party’s Confidential Information by any officer, employee, advisor, representative, licensee or sublicensee of the Receiving Party, and shall take all actions that the Disclosing Party reasonably requests in order to prevent any
further unauthorized use or disclosure of the Disclosing Party’s Confidential Information. 
 9.3 The Receiving Party’s obligations under
Paragraphs 9.1 and 9.2 hereof shall not apply to the extent that the Receiving Party can prove by written or equivalent evidence that any of the Disclosing Party’s Confidential Information: 

 

	 	(1)	 passed into the public domain, or became generally available to the public through no fault of the Receiving
Party; 

  

	 	(2)	 was known to the Receiving Party prior to disclosure hereunder by the Disclosing Party; 

 

	 	(3)	 was disclosed, revealed or otherwise made available to the Receiving Party by a Third Party that is under no
obligation of non-disclosure and/or non-use to the Disclosing Party; or 

  

	 	(4)	 is required to be disclosed under applicable law, or in connection with any application by the Receiving Party
for any Regulatory Approvals; provided, however, that the Receiving Party shall furnish the Disclosing Party’s with as much prior written notice of such disclosure requirement as reasonably practicable, so as to permit the Disclosing Party, in
its sole discretion, to take appropriate action, including seeking a protective order, in order to prevent the Disclosing Party’s Confidential Information from passing into the public domain or becoming generally available to the public.

  
 16 

 ARTICLE 10 - NO WARRANTIES; LIMITATION ON LICENSORS’ LIABILITY 

10.1 LSU and University of Warsaw, their board members, officers, employees and agents make no representations or warranties that PATENT RIGHTS are or
will be held valid or enforceable, nor that the manufacture, importation, use, offer for sale, sale or other distribution of any LICENSED PRODUCTS or the use of LICENSED PROCESSES will be free from infringement of third party patent rights or other
third party rights; nor respecting the scope of any of the PATENT RIGHTS. 
 10.2 LSU AND UNIVERSITY OF WARSAW, THEIR BOARD MEMBERS, OFFICERS,
EMPLOYEES AND AGENTS MAKE NO REPRESENTATIONS, AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUME NO RESPONSIBILITIES
WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR SUBLICENSEES OF LICENSED PRODUCTS OR LICENSED PROCESSES. 

10.3 LICENSEE AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED PRODUCTS AND LICENSED PROCESSES. In no event shall LSU or University
of Warsaw, including their board members, officers, employees and agents, be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits or other economic loss or damage with respect to LICENSED
PRODUCTS or LICENSED PROCESSES, to LICENSEE, SUBLICENSEES or any other person or entity regardless of legal theory. The above limitations on liability apply even though LICENSORS, their board members, officers, employees or agents may have been
advised of the possibility of such damage. 
 10.4 LICENSEE shall not, and shall require that its SUBLICENSEES do not, make any statements,
representations or warranties whatsoever to any person or entity, or accept any liabilities or responsibilities whatsoever from any person or entity that are inconsistent with this Article 10. 

ARTICLE 11 - INDEMNITY; INSURANCE 

11.1 LICENSEE shall defend, indemnify and hold harmless and shall require all SUBLICENSEES to defend, indemnify and hold harmless LICENSORS, their
board members, officers, employees and agents, from and against any and all claims of any kind arising out of or related to the exercise of any rights granted LICENSEE under this Agreement or the breach of this Agreement by LICENSEE. 

11.2 LICENSORS are entitled to participate at their option and expense through counsel of their own selection, and may join in any legal actions related
to any such claims, demands, damages, losses and expenses under Paragraph 11.1 above. 

  
 17 

 11.3 LICENSEE shall at its sole cost and expense, obtain and maintain in full force and effect during
the continuance of this Agreement and thereafter in accordance with Section 11.4 hereof, commercial general liability insurance with coverage. Within [***] days of execution of this Agreement, LICENSEE shall provide LICENSORS with written
notice of the amount of insurance LICENSEE intends to obtain and which LICENSEE believes to be consistent with industry practice for the respective stage of development of LICENSED PRODUCTS or LICENSED PROCESSES. LICENSORS shall have the right to
review this amount and shall have the right to require LICENSEE to increase the amount, consistent with what LICENSORS believe is current industry practice. In case of disagreement, the parties will settle the dispute as provided in Paragraph 15.1.
Both LICENSORS and LICENSEE will bear its own costs of such dispute resolution and each party an equal part of the costs of the arbitration. LICENSEE shall furnish to LICENSORS a certificate of insurance evidencing that it has obtained the amount
and type of insurance required pursuant to this Paragraph. 
 11.4 LICENSEE’s indemnification obligation under Article 11.1 and LICENSEE’s
obligation to maintain general liability insurance under Article 11.3 hereof, shall survive the expiration or termination of this Agreement for any reason whatsoever for a period of [***] years after the date of expiration or termination hereof.

 ARTICLE 12 - TERM AND TERMINATION 

12.1 This Agreement, unless earlier terminated as provided herein, shall expiry on the expiration date of the last to expiry of the PATENT RIGHTS or
COOPERATION PATENT RIGHTS. 
 12.2 If LICENSEE ceases to carry on its business (or that part of its business pertaining to LICENSED PRODUCTS and
LICENSED PROCESSES), then this Agreement shall terminate upon written notice by LICENSORS. 
 12.3 If LICENSEE fails to make any payment due to
LICENSORS, LICENSORS shall have the right to terminate this Agreement jointly but not solely effective on [***] days’ written notice, unless LICENSEE makes all such payments within the [***] day period to LSU or as set out in Article 3.9 of
this Agreement to an escrow agent. If LICENSEE has not made all such payments to LSU by the time the [***] day period expires, LICENSORS may terminate this Agreement upon written notice to LICENSEE. 

12.4 Upon any material breach or default of this Agreement by LICENSEE other than those occurrences listed in Paragraphs 12.2 and 12.3 (the terms of
which shall take precedence over this Paragraph 12.4, where applicable), LICENSORS shall have the right to terminate this Agreement effective on [***] days’ written notice to LICENSEE jointly but not solely unless LICENSEE cures the material
breach or default before the [***] day period expires. 

  
 18 

 12.5 In the event LICENSEE brings a civil action seeking, through ordinary, declaratory or any other
form of relief, to invalidate any PATENT RIGHTS under this Agreement, LICENSORS may immediately terminate this Agreement jointly but not solely upon written notice to LICENSEE. 

12.6 LICENSEE has the right to terminate this Agreement at any time on [***] days’ written notice to either LICENSORS, with or without cause. In
such a case, LICENSEE shall: 
  

	 	(a)	 pay all amounts due LICENSORS through the effective date of the termination; 

 

	 	(b)	 submit a final report in compliance with Paragraph 4.2; 

 

	 	(c)	 return any confidential or trade secret materials provided to LICENSEE by LICENSORS in connection with this
Agreement; or, with prior written approval by LICENSORS, destroy such materials, and certify in writing that such materials have all been returned or destroyed ; and 

 

	 	(d)	 suspend its use of the LICENSED PROCESS(ES) AND LICENSED PRODUCT(S). 

12.7 Upon any termination of this Agreement, and except as expressly provided herein to the contrary, all rights and obligations of the parties
hereunder shall cease, except any previously accrued rights and obligations and further as follows: 
  

	 	(1)	 Obligations to pay running royalties and other sums accruing hereunder through the day of termination, and to
make a final report under Paragraph 4.2; 

  

	 	(2)	 LICENSORS’ rights to inspect books and records as described in Article 4, and LICENSEE’s obligations
to keep such records for the required time; 

  

	 	(3)	 Obligations to hold harmless, defend and indemnify LSU and the University of Warsaw and their board members,
officers, employees and agents, and to maintain insurance, and all other obligations under Article 11; 

  

	 	(4)	 Any cause of action or claim of LICENSEE or LICENSORS accrued or to accrue because of any breach or default by
the other party hereunder; 

  

	 	(5)	 The provisions of Articles 1, 9, 14 and 15; and 

 

	 	(6)	 All other terms, provisions, representations, rights and obligations contained in this Agreement that by their
sense and context are intended to survive until performance thereof by either or both parties. 

  
 19 

 ARTICLE 13 - REGISTRATION AND RECORDATION 

13.1 If the terms of this Agreement, or any assignment or license under this Agreement are or become such as to require that the Agreement or license
or any part thereof be registered with or reported to a national or supranational agency of any area in which LICENSEE or SUBLICENSEES would do business, then LICENSEE will, at its own expense, undertake such registration or report. Prompt notice
and appropriate verification of the act of registration or report or any agency ruling resulting from it will be supplied by LICENSEE to LICENSORS. 

13.2 LICENSEE shall also carry out, at its expense, any formal recordation of this Agreement or any license herein granted that the law of any country
requires as a prerequisite to enforceability of the Agreement or license in the courts of any such country or for other reasons, and shall promptly furnish to LICENSORS appropriately verified proof of recordation. 

ARTICLE 14 - NOTICES 
 14.1 Any
notice, request or report required or permitted under this Agreement shall be effective when deposited in the United States Mail, first class prepaid to the address set forth below, or such other address as such party specifies by written notice
given in conformity herewith. Any notice, request or report given by any other means is not effective until actually received by an authorized representative of a party. 

					
		 	TO LSU:	  	[***]
		 		  	
		 		  	
		 		  	
		 		  	
		 		  	
			
		 	TO UW:	  	[***] 
		 		  	
		 		  	
		 		  	
		 		  	
		 		  	
			
		 	TO LICENSEE:	  	[***] 
		 		  	
		 		  	
		 		  	
		 		  	

  
 20 

 ARTICLE 15 - MISCELLANEOUS PROVISIONS 

15.1 LICENSORS and LICENSEE shall attempt to resolve any dispute controversy or claim arising under, out of or relating to this Agreement and any
subsequent amendments of this Agreement, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination, as well as non-contractual claims, arising
out of or relating to this Agreement through negotiations between senior executives of the parties, who have authority to settle the same. 
 If the matter
has not been resolved by the executives within [***] days of the initiation of the negotiations, or if any party does not participate in the negotiations, the dispute may be referred to arbitration by any party. The dispute, controversy or claim
shall then be referred to and finally determined by binding arbitration in Baton Rouge, Louisiana in accordance with the CPR’s Rules for Non-Administered Arbitration of Patent and Trade Secret Disputes
then in effect, before a sole arbitrator in case of a dispute according to Paragraph 6.3 or 11.3, or before three arbitrators in all other cases. 
 Nothing
in this clause shall be construed as prohibiting a party or its AFFILIATE from applying to a court for interim injunctive relief. 
 This clause does not
apply to disputes, controversy or claims solely relating to COOPERATION PATENTS, the rights granted thereunder or payments made therefore. 
 15.2
LICENSORS and LICENSEE agree that this Agreement sets forth their entire understanding concerning the subject matter of this Agreement, and that no modification of the Agreement will be effective unless LSU, the University of Warsaw and LICENSEE all
agree to it in writing. LICENSEE shall reimburse LICENSORS for any legal expenses incurred in connection with negotiating any amendments to this Agreement that may be requested by LICENSEE, regardless of whether the amendment is ultimately executed
by the parties. 
 15.3 If a court of competent jurisdiction or an arbitrator finds any term of this Agreement invalid, illegal or unenforceable, that
term will be curtailed, limited or deleted, but only to the extent necessary to remove the invalidity, illegality or unenforceability, and without in any way affecting or impairing the remaining terms. 

15.4 LICENSEE agrees to mark all LICENSED PRODUCTS sold in the United States with all applicable United States patent numbers. All LICENSED PRODUCTS
shipped to or sold in other countries shall be marked to comply with the patent laws and practices of the countries of manufacture, use and sale. 

15.5 No waiver by either party of any breach of this Agreement, no matter how long continuing nor how often repeated, is a waiver of any subsequent
breach thereof, nor is any delay or omission on the part of either party to exercise or insist on any right, power, or privilege hereunder a waiver of such right, power or privilege. 

  
 21 

 15.6 LICENSEE agrees to refrain from using and to require SUBLICENSEES to refrain from using the name
of LSU or the University of Warsaw in publicity or advertising without the prior written approval of LSU and the University of Warsaw. Reports in scientific literature and presentations of joint research and development work are not considered to be
“publicity” for this purpose. Notwithstanding this provision, without prior written approval of LICENSORS, LICENSEE and SUBLICENSEES may use LICENSORS’ name in any submission to a government agency as required by law. 

15.7 LICENSEE shall comply with all applicable laws and regulations and shall be solely responsible for any violation of such laws and regulations by
LICENSEE or its SUBLICENSEES, and shall defend, indemnify and hold harmless LSU and the University of Warsaw and its board members, officers, employees and agents if any legal action of any nature results from the violation 

15.8 The relationship between the parties is that of independent contractors. Neither party is an agent or employee of the other in connection with the
exercise of any rights hereunder, and neither has any right or authority to assume or create any obligation or responsibility on behalf of the other. 

15.9 Neither party hereto is in default of any provision of this Agreement for any failure in performance resulting from acts or events beyond the
reasonable control of such party, such as Acts of God, acts of civil or military authority, civil disturbance, war, strikes, fires, natural catastrophes or other “force majeure” events. 

15.10 LICENSEE may not assign this Agreement other than to one of its Affiliates without the prior written consent of LICENSORS and shall not pledge any
of the license rights granted in this Agreement as security for any creditor. Any attempted pledge of any of the rights under this Agreement or any attempted assignment of this Agreement without the prior written consent of LICENSORS will be void
from the beginning. No assignment by LICENSEE will be effective until the intended assignee agrees in writing to accept all of the terms and conditions of this Agreement. 

15.11 If during the term of this Agreement, LICENSEE makes or attempts to make an assignment for the benefit of creditors, or if proceedings in
voluntary or involuntary bankruptcy or insolvency are instituted on behalf of or against LICENSEE, or if a receiver or trustee is appointed for the property of LICENSEE, LICENSORS may, at their option, terminate this Agreement and revoke the
license(s) herein granted by written notice to LICENSEE. LICENSEE shall notify LICENSORS of any such event mentioned in this Paragraph 15.11 as soon as reasonably practicable, and in any event within [***] days after any such event. 

  
 22 

 15.12 Whereas LSU and the University of Warsaw are academic institutions, LICENSORS shall be free to
make such publications as LICENSORS sees fit concerning the technology disclosed in the PATENT RIGHTS. 
 15.13 If it becomes necessary for one party
to employ the services of an attorney for the protection and enforcement of its rights under the Agreement, or to compel performance of the other party’s obligations under the Agreement, upon final judgment or award by a court of competent
jurisdiction or by an arbitrator, the court or arbitrator in its discretion may order the defaulting party to pay the other party’s reasonable attorney’s fees at both trial and appellate levels. 

15.14 LICENSORS will entertain requests by LICENSEE to allow LICENSORS employees, acting independently of their employment at LSU or the University of
Warsaw, to serve as consultants to LICENSEE. The terms and conditions of such a consulting agreement shall be negotiated between LICENSEE and the prospective consultant, and shall be consistent with the rules, regulations, and policies of LSU or the
University of Warsaw. It is understood that LSU or the University of Warsaw employees who act as consultants may not ordinarily grant rights in intellectual property to an outside employer. 

15.15 During the term of the Agreement, LICENSORS will offer to LICENSEE an exclusive license in any sole or joint inventions and patent rights filed
therefore (hereinafter “IMPROVEMENTS”) developed by one of the inventors of PATENT RIGHTS that are covered by claims of PATENT RIGHTS unless such sole or joint inventions are covered by the regulations of the RESEARCH COOPERATION AGREEMENT
under terms and conditions that are comparable to the standards of licensing agreements between academic institutions and biotechnology companies. LICENSEE shall have [***] days during which to accept said offer. If LICENSEE does not accept said
offer within said period, LICENSORS shall be free to solely or jointly negotiate an exclusive or non-exclusive license agreement with a third-party. LICENSORS should not enter into an exclusive or non-exclusive license agreement on terms that are more favourable to the third party than the terms previously offered to LICENSEE with respect to PATENT RIGHTS. 

ARTICLE 16 - PRIOR AGREEMENTS 

16.1 With its Effective Date, this Agreement abrogates and replaces the PRIOR AGREEMENTS. Furthermore this agreement contains all arrangements between
the parties regarding the PATENT RIGHTS and replaces all other prior, oral or written agreements. 

  
 23 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

							
	LICENSEE	  	 BOARD OF SUPERVISORS OF
 LOUISIANA
STATE UNIVERSITY AND
 AGRICULTURAL AND MECHANICAL
 COLLEGE
[***]

				
	By	  	         [***]
	  	By	  	         [***]

	(authorized representative)	  	(authorized representative)
			
	[***]	  		  	[***]
				
	Title:	  	[***]	  	Title:	  	[***]
		
	Date 6/8/15	  	Date 5/13/15
			
	[***]	  		  	
				
	By	  	         [***]
	  		  	
	(authorized representative)	  		  	
			
	Typed Name: [***]	  		  	
				
	Title:	  	[***]	  		  	
			
	Date 5/25/15	  		  	

  
 24 

 APPENDIX A 

RESEARCH COOPERATION AGREEMENT 

[***] 

  
 25 

 APPENDIX B 

TO THE LICENSE AGREEMENT FOR LSU FILE 

LSUHSC-S- 07-006 

and 

LSUHSC-S-09-015 

12th DAY OF May, 2015 
 BETWEEN
BIONTECH AG, 
 THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND 

AGRICULTURAL AND MECHANICAL COLLEGE , 

AND THE UNIVERSITY OF WARSAW 

PATENTS AND PATENT APPLICATIONS WITHIN THE PATENT RIGHTS 

[***] 

  
 26 

 APPENDIX C 

PRIOR AGREEMENTS 
 [***] 

  
 27EX-10.6

 Exhibit 10.6 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

LICENSE AND COLLABORATION AGREEMENT 

by and between 

BioNTech AG 
 and

 Genmab A/S 

Effective as of: 19th May 2015 

 Execution Version 

 

 LIST OF EXHIBITS 
  

			
	Exhibit 1	  	 Terms for Unilateral Development

		
	Exhibit 2	  	 Biontech Patents

		
	Exhibit 3	  	 Genmab Patents

		
	Exhibit 4	  	 Antibody Panel

		
	Exhibit 5	  	 Research Plan

		
	Exhibit 6	  	 Development Plan and Budget

		
	Exhibit 7	  	 Company Announcement and Media Release

  
 2 of 85 

 Execution Version 

 

 LICENSE and COLLABORATION AGREEMENT 

This License and Collaboration Agreement (Agreement) is made and entered into as of 19th May 2015 (Effective Date) by and between 
 BioNTech AG, a German
corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (Biontech) 
 and 

Genmab A/S, CVR no. 21023884, a Danish corporation having its principal office at Bredgade 34E, P.O. Box 9068, DK-1260 Copenhagen K, Denmark, (Genmab). 
 (Biontech and Genmab each a Party
and together the Parties) 
 PREAMBLE 

WHEREAS, the Parties desire to jointly research, develop and commercialize polypeptide-based bispecific antibodies using Genmab’s
proprietary DuoBody® platform technology against certain target combinations in combination with Genmab’s proprietary inert format technology for the treatment of cancer. 

WHEREAS, the Parties have previously entered into a Letter of Intent (LOI) dated 19 January 2015 and a Materials Transfer
Agreement dated 19 January 2015 (the MTA) (the LOI and the MTA together referred to as the Prior Agreement). 

WHEREAS, the joint research, development and commercialization shall be based on a 50/50 sharing of costs and profits, whereby either Party
shall have the right to exit its participation in further development costs at certain pre-defined opt-out points during development. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereby agree as follows: 

 

	1.	 DEFINITIONS 

  

	1.1	 Adverse Event means any unfavorable and unintended medical occurrence in a human patient
or subject who is administered a Collaboration Product or Unilateral Product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease temporally associated with the use of such Collaboration
Product or Unilateral Product, whether or not considered related to such Collaboration Product or Unilateral Product.  

  
 3 of 85 

 Execution Version 

 

	1.2	 Affiliate shall mean, with respect to any person or entity, any other person or entity
which directly or indirectly controls, is controlled by, or is under common control with such person or entity. A person or entity shall be regarded as in control of another person or entity if it owns, or directly or indirectly controls, more than
fifty percent (50%) of the voting stock or other ownership interest of the other person or entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other person or entity by
any means whatsoever. 

  

	1.3	 Alliance Manager has the meaning set forth in Section 8.1. 

 

	1.4	 Antibody means a polypeptide-based antibody or a derivative thereof identifiable by a
unique amino acid sequence [***]. 

  

	1.5	 Applicable Law means any law or statute, any rule or regulation issued by a government
authority (including courts and Regulatory Authorities), any GxP regulations or guidelines as well as and any judicial, governmental, or administrative order, judgment, decree or ruling, in each case as applicable to the subject matter and the
parties at issue. 

  

	1.6	 Approved Subcontractor means a subcontractor engaged by a Party that has been approved by
the Joint Research Committee or Joint Steering Committee, as applicable, to perform specific obligations of the subcontracting Party. 

  

	1.7	 Assigned Patents shall have the meaning set forth in Sections 9.1f and 9.1h.

  

	1.8	 Back-up Candidate shall mean a Clinical Candidate
that has been selected by the Joint Steering Committee as back-up candidate for a Collaboration Product or by the Continuing Party as a back-up candidate for a
Unilateral Product in accordance with Section 2.9. 

  

	1.9	 Bidding Criteria has the meaning set forth in Section 15.9c. 

 

	1.10	 Biontech has the meaning set forth in the introduction to this Agreement.

  

	1.11	 Biontech Antibodies mean the Antibodies proprietary to Biontech listed in the Research
Plan. 

  

	1.12	 Biontech Improvement Technology is defined in Section 9.1c. 

 

	1.13	 Biontech Know-How means any and all technical
information, processes, formulae, data, inventions, methods, chemical compounds, biological or physical materials, know-how and other trade secrets, in each case that are not in the public domain, that relate
to or are useful to research, develop, use, manufacture or commercialize the Biontech Antibodies, to the extent not disclosed or claimed by a Biontech Patent. Biontech Know-How shall include all Biontech
Improvement Technology and Biontech’s interest in any Collaboration IP and Assigned Patents (in each case to the extent not disclosed or claimed by a Biontech Patent). 

 

	1.14	 Biontech Patents means:  

  
 4 of 85 

 Execution Version 

 

	 	a.	 any Patent Rights listed in Exhibit 2 to this Agreement to the extent that they claim Biontech
Antibodies, which shall be amended from time to time to reflect any other Patent Rights; 

  

	 	b.	 any Patent Rights covering Biontech Improvement Technology; and 

 

	 	c.	 Biontech’s interest in any Joint Patents and in any Patent Rights claiming Assigned Patents.

  

	1.15	 BiontechTechnology means the Biontech Patents and the Biontech Know-How. 

  

	1.16	 Biontech Unilateral Product means a Unilateral Product which is being Developed and
Commercialized solely by Biontech. 

  

	1.17	 Bispecific Antibody means an Antibody comprising antigen-binding sites of two different
monoclonal Antibodies. The term Bispecific Antibody further includes the subtypes of [***] Antibodies having additional binding affinities to antigens or cells expressing such antigens. 

 

	1.18	 BLA means a Biologics License Application or equivalent submission filed with the FDA
and/or EMA in connection with seeking Marketing Approval of a Collaboration Product or Unilateral Product, or an equivalent application filed with any equivalent regulatory agency or governmental authority in any jurisdiction other than the United
States. 

  

	1.19	 Budget shall mean the budget attached to the Research Plan or Development Plan or
Commercialization Plan, as applicable. 

  

	1.20	 Calendar Quarter means any of the three month periods beginning on January 1,
April 1, July 1 or October 1 of any year. 

  

	1.21	 Cap during Divestment is defined in Section 15.4. 

 

	1.22	 Ceased Product is defined in Section 14.3. 

 

	1.23	 Claims has the meaning set forth in Section 13.1a. 

 

	1.24	 Clinical Candidate means any Bispecific Antibody targeting any of the Target Combinations.

  

	1.25	 Collaboration Accounting Policies means the accounting policies as agreed to by the
Parties and approved by the Joint Steering Committee to be used in determining Shared Costs and Shared Profits, which will be, in all material respects, consistent with IFRS and any Applicable Laws. 

 

	1.26	 Collaboration IP has the meaning set forth in Section 9.1c. 

  

	1.27	 Collaboration Product means a Clinical Candidate which the Parties have selected for
further joint development in Phase B. 

  

	1.28	 Collaboration Product Trademark has the meaning set forth in Section 9.11.

  
 5 of 85 

 Execution Version 

 

	1.29	 Collaboration Targets [***] 

 

	1.30	 Commercialization means (i) all activities directed to the marketing, detailing,
promotion (including co-promotion), advertising, selling and distribution of a Collaboration Product in a country or region after all Marketing Approvals have been obtained in such country or region (including
making, having made, using, importing, selling, having sold, offering for sale, and having offered for sale such Collaboration Product), and will include marketing research, customer service, administering and commercially selling such Collaboration
Product, post-approval clinical trials and other additional research and development activities undertaken solely and to the extent necessary to meet local regulatory requirements, importing, exporting or transporting such Collaboration Product for
commercial sale, and all regulatory compliance with respect to the foregoing; it being understood and agreed that such activities may occur pre- or post-launch of such Collaboration Product; and (ii) the
conclusion of one or more Partnership Agreements. When used as a verb, “Commercialize” means to engage in Commercialization. 

  

	1.31	 Commercialization Agreement is defined in Section 4.5. 

 

	1.32	 Commercialization Plan means, with respect to a Collaboration Product, a
commercialization plan to be prepared and agreed between the Parties, and updated by the Joint Commercialization Committee, once such committee is in place, and endorsed by the Joint Steering Committee which describes the envisaged form of
Commercialization (e.g. through own sales forces, third party sales forces, conclusion of Partnership Agreements, etc.), the responsibilities of each Party, timelines, budgets for Commercialization costs, target volumes, territories and other
relevant items agreed between the Parties. The Commercialization Plan shall be carried out by the Joint Commercialization Committee and shall be updated at least annually by the Joint Commercialization Committee, once such committee is in place, and
all changes to the Commercialization Plan must be approved by the Joint Steering Committee. 

  

	1.33	 Commercially Reasonable Efforts means the level of efforts and resources that a similarly
situated company in the biotechnology industry would normally use to accomplish a similar objective, and in particular with respect to a product: to develop, manufacture and commercialize a product of similar market potential at a similar stage in
its development or product life cycle taking into account all relevant factors then prevailing, including without limitation efficacy, competition, intellectual property position, likelihood of Marketing Approval, profitability, alternative products
and product candidates and other relevant factors. 

  

	1.34	 Confidential Information means all information, data, documents including Know-how and the subject-matter of any unpublished invention, or any material in tangible form that is disclosed or made available under this Agreement by the Disclosing Party to the Receiving Party and that is
marked as “Confidential” at the time it is disclosed or delivered to the Receiving Party (or, if disclosed orally, is identified as confidential when disclosed and such disclosure is confirmed in writing within thirty (30) days by the
Disclosing Party) or ought in good faith to be treated as confidential taking account of its content or the circumstances of disclosure. The term Confidential Information shall also include the existence and contents of this Agreement.

  
 6 of 85 

 Execution Version 

 

	1.35	 Continuing Party is defined in Section 14.6. 

 

	1.36	 Control means, with respect to any information or intellectual property right, possession
by a person or entity of the ability to grant the right to access or use, or to grant a license or a sublicense to, or to use such information or intellectual property right as provided for herein without violating the terms of any agreement or
other arrangement with any other person or entity. 

  

	1.37	 Development means, with respect to a Collaboration Product, any and all drug development
activities and manufacturing activities undertaken pursuant to the relevant Development Plan in order to develop a Collaboration Product up to and including obtaining Marketing Approval for such Collaboration Product for an indication and to perform
manufacturing scale up to enable commercial scale manufacturing prior to launch (except that inventory build shall be considered a Commercialization activity). These activities shall include preclinical research, stability testing, toxicology
testing, formulation activities, reformulation activities, process development, manufacturing scale up activities, development stage manufacturing, quality assurance/quality control development, clinical studies (including Phase III Studies and
other studies (e.g., pharmacovigilance programs and outcome studies) that the Joint Steering Committee considers necessary or economically justifiable and other activities to obtain the applicable Marketing Approvals; in each case in accordance with
the applicable Development Plan, as applicable. When used as a verb, Develop means to engage in Development. 

  

	1.38	 Development Plan means, with respect to a Collaboration Product, a written development
plan agreed between the Parties which describes the development and manufacturing work to be performed by each Party during Phase B, as well as the Budgets, approved Shared Costs, timelines, allocation of FTEs and other relevant items agreed between
the Parties, as set forth in Exhibit 6. 

  

	1.39	 Development Project Manager has the meaning set forth in Section 8.4.

  

	1.40	 Disclosing Party is defined in Section 11.1. 

 

	1.41	 Divesting Party has the meaning set forth in Section 15.2. 

 

	1.42	 Divestment shall mean the economic valorization of the value of the rights and obligations
of a Party under this Agreement by that Party, by granting the rights to Develop and/or Commercialize a Collaboration Product to an independent Third Party in any legal way possible, including but not limited to by licensing, assigning or
transferring such rights. When used as a verb, Divest means to engage in Divestment. 

  

	1.43	 Divestment Executive has the meaning set forth in Section 15.9a.

  

	1.44	 Divestment Notice has the meaning set forth in Section 15.2. 

 

	1.45	 Divestment Process has the meaning set forth in Section 15.2. 

 

	1.46	 Dual- or Triple-Binder [***] 

  
 7 of 85 

 Execution Version 

 

	1.47	 DuoBody Platform means Genmab’s proprietary technology that is generally applicable
to the discovery, modification, optimization, generation and manufacturing of Bispecific Antibodies of the IgG subtype, [***] 

  

	1.48	 Effective Date is defined in the introductory paragraph of this Agreement.

  

	1.49	 EMA means the European Medicines Agency, and any successor agency thereto.

  

	1.50	 Establishment of Clinical Proof of Concept means the point in time during Development,
where the [***] from the first Phase I/II Clinical Trial becomes available. 

  

	1.51	 EU means all the countries in the Territory that as of the receipt of the European
Marketing Approval for a Collaboration Product are members of the European Union. 

  

	1.52	 Events of Force Majeure has the meaning set forth in Section 16.6.

  

	1.53	 Exclusive Negotiation Period has the meaning set forth in Section 15.2.

  

	1.54	 Fall Back Terms has the meaning set forth in Section 14.4c). 

 

	1.55	 FDA means the U.S. Food and Drug Administration, or any successor agency thereto.

  

	1.56	 Field means the treatment of cancer in humans.  

 

	1.57	 Financial Representative has the meaning set forth in Section 7.5.

  

	1.58	 First Commercial Sale means, on a Unilateral Product-by-Unilateral Product basis, the first sale of the Unilateral Product for which revenue has been recognized by a Party or any of its Affiliates to any Third Party after all required Marketing
Approvals have been granted. For the avoidance of doubt, First Commercial Sale shall not include the transfer or sale of any Unilateral Product (i) by a Party to an Affiliate, Sublicensee or Third Party Collaborator unless the Affiliate,
Sublicensee or Third Party Collaborator is the last entity in the distribution chain of the Unilateral Product, (ii) for use in clinical trials or non-clinical development activities (e.g., material
transfer agreements) or a bona fide charitable purpose, or (iii) for compassionate use. 

  

	1.59	 FTE means a full-time employee of a Party working over the course of a twelve
(12) month period, or several employees of a Party collectively working the equivalent of such full-time employee. FTEs shall be calculated based on the time an employee of the Parties spends working on a billable effort as recorded by such
Parties’ project time reporting system. An FTE is measured on the basis of a total of [***] hours per year for employees. 

  

	1.60	 FTE Rates shall mean the rates set forth in Sections 7.2 and Exhibit 1, as
applicable.  

  

	1.61	 FTO Notification has the meaning set forth in Section 10.1 of this Agreement.

  
 8 of 85 

 Execution Version 

 

	1.62	 Generic Product means (a) for a product sold in the United States, a
biological product approved under the Public Health Service Act 351(k) that is highly similar to a Unilateral Product, notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences
between the generic product and the Unilateral Product in terms of the safety, purity and potency; (b) for a product sold in the EU, a biological product approved under Article 10(4) of Directive 2001/83/EC and Section 4, Part II,
Annex I to such Directive based on the demonstration of the similar nature to the Unilateral Product; and (c) for a generic product sold outside the United States and the EU, a biological product approved under a similar regulatory
pathway as in the United States and in the EU, if such pathway exists. 

  

	1.63	 Genmab has the meaning set forth in the introduction to this Agreement.

  

	1.64	 Genmab Antibodies mean the Antibodies proprietary to Genmab listed in the Research Plan,
if any. 

  

	1.65	 Genmab Improvement Technology is defined in Section 9.1c. 

 

	1.66	 Genmab Know-How means all technical information,
processes, formulae, data, inventions, methods, chemical compounds, biological or physical materials, know-how and other trade secrets, in each case, that relate to or are useful to research, develop,
manufacture or commercialize the Genmab Antibodies, the DuoBody Platform and/or the [***] Technology, to the extent not disclosed or claimed by a Genmab Patent. Genmab Know-How shall include all Genmab
Improvement Technology and Genmabs’ interest in any Collaboration IP and Assigned Patents (in each case to the extent not disclosed or claimed by a Genmab Patent). 

 

	1.67	 Genmab Patents means:  

 

	 	a.	 any Patent Rights listed in Exhibit 3 to this Agreement to the extent that they claim Genmab Antibodies, the
DuoBody Platform or the Inert Format Technology, which shall be amended from time to time to reflect any other Patent Rights; 

  

	 	b.	 any Patent Rights covering Genmab Improvement Technology; and 

 

	 	c.	 Genmab’s interest in any Joint Patents and in any Patent Rights claiming Assigned Patents.

  

	1.68	 Genmab Technology means the Genmab Patents and the Genmab
Know-How. 

  

	1.69	 Genmab Unilateral Product means a Unilateral Product which is being developed and
commercialized solely by Genmab. 

  

	1.70	 Good Clinical Practice or GCP shall mean any and all laws, rules,
regulations, guidelines and generally accepted standards and requirements regarding the ethical conduct of clinical trials, including without limitation the U.S. Code of Federal Regulations (CFR) Title 21, ICH GCP Guidelines E6(R1), current step 4
version, dated 10 June 1996, as amended from time to time, national legislation implementing European Community Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member
States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, European Community Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for
good clinical practice as regards to investigational medicinal products for human use. 

  
 9 of 85 

 Execution Version 

 

	1.71	 Good Laboratory Practice or GLP shall mean any and all laws, rules,
regulations, guidelines and generally accepted standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results, including without limitation the CFR Title 21, national legislation
implementing European Community Directive 2004/9/EC of 11 February 2004 on the inspection and verification of good laboratory practice (GLP) as amended and European Community Directive 2004/10/EC of 11 February 2004 on the harmonization of
laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances as amended, OECD Series on Principles of Good
Laboratory Practice and Compliance Monitoring. 

  

	1.72	 Good Manufacturing Practice or GMP shall mean any and all laws, rules,
regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products, including without limitation the CFR Title 21, ICH GMP Guidelines Q7, current step 4 version, dated
10 November 2000, as amended from time to time, national legislation implementing European Community Directive 91/356/EEC of 13 June 1991 laying down the principles and guidelines of good manufacturing practice for medicinal products for
human use as amended by European Community Directives 2003/94/EC, the Rules Governing Medicinal Products in the European Community, Volume 4, including annexes. 

 

	1.73	 GxP means GCP, GLP or GMP or any combination thereof, as applicable.

  

	1.74	 IFRS means the international financial reporting standards. 

 

	1.75	 IND means an Investigational New Drug application filed with the FDA, EMA or their
equivalent in any country where a regulatory filing is required or obtained for commencement of human clinical trials of a pharmaceutical product. 

  

	1.76	 Indication means an application for a label or label expansion indicating the applicable
drug for an initial, expanded or additional patient population, or indicating the drug for use in combination with another treatment or drug, or different route of administration in each case that requires a pivotal clinical trial for Marketing
Approval. For the avoidance of doubt, the Parties acknowledge that there may be more than one Indication for any given histology or tumor type. By way of example, and not limitation, mono-therapy, various combination therapies, front-line treatment
and maintenance treatment of the same histology or tumor type are different Indications for the purposes of this Agreement. 

  

	1.77	 Indemnified Party shall have the meaning set forth in Section 13.3.

  

	1.78	 Indemnitees shall have the meaning set forth in Section 13.1. 

 

	1.79	 Indemnitor shall have the meaning set forth in Section 13.3. 

 

	1.80	 [***] Technology means Genmab’s proprietary [***] technology to control the immune
response induced by antibodies [***] 

  
 10 of 85 

 Execution Version 

 

	1.81	 Infringement Attack has the meaning set forth in Section 10.2. 

 

	1.82	 Infringement Proceedings has the meaning set forth in Section 9.9d.

  

	1.83	 Interested Party shall have the meaning set forth in Section 2.11.

  

	1.84	 IP Budget has the meaning set forth in Section 9.6d. 

 

	1.85	 Joint Commercialization Committee is defined in Section 8.5. 

 

	1.86	 Joint Development Team has the meaning set forth in Section 8.4.

  

	1.87	 Joint Divestment Process has the meaning set forth in Section 15.9. 

  

	1.88	 Joint Patents means any patents and patent applications claiming Collaboration IP.

  

	1.89	 Joint Research Committee means the joint research committee established under
Section 8.2. 

  

	1.90	 Joint Steering Committee has the meaning set forth in Section 8.3.

  

	1.91	 Lead Commercialization Party has the meaning set forth in Section 4.3.

  

	1.92	 Lead IP Party has the meaning set forth in Section 9.6a. 

 

	1.93	 Lead Regulatory Party means, with respect to a country or region, the Party with the main
responsibility for carrying out regulatory activities in accordance with Section 5. 

  

	1.94	 Liabilities has the meaning set forth in Section 13.1a. 

 

	1.95	 Major Market Country means any of the following: [***] 

 

	1.96	 Marketing Approval means any regulatory approval of any Regulatory Authority or other
government authority of any country or jurisdiction in the world that is necessary to be obtained before the commercial sale of a pharmaceutical product for an Indication in that country or jurisdiction. 

 

	1.97	 Material Adverse Change means a change in circumstances or events relating to a
Collaboration Product Developed under this Agreement, that a Party reasonably believes materially adversely affects the net present value of such Collaboration Product, where such Party could not reasonably previously have known about such change.
Such changes in circumstances could include, for example, the approval for marketing of a competing product, a successful challenge to the validity of a patent covering such Collaboration Product or new clinical data relating to the Collaboration
Product which raise serious concerns with respect to safety and/or efficacy of the Collaboration Product.  

  
 11 of 85 

 Execution Version 

 

	1.98	 Net Sales means the gross amounts invoiced in arms-length transactions by a Party or any
of its Affiliates, Third Party Collaborators or Sublicensees to Third Party customers for sales of a Collaboration Product or Unilateral Product, less the following deductions for: 

 

	 	a.	 discounts (including trade, quantity and cash discounts) actually allowed, cash and non-cash coupons, retroactive price reductions, and charge-back payments and rebates granted to any Third Party (including to governmental entities or agencies, purchasers, reimbursers, customers, distributors,
wholesalers, and group purchasing and managed care organizations or entities); 

  

	 	b.	 credits or allowances, if any, on account of price adjustments, shelf stock adjustment, recalls, claims,
damaged goods, rejections or returns of items previously sold (including products returned in connection with recalls or withdrawals) and amounts written off by reason of uncollectible debt, provided that if the debt is thereafter paid, the
corresponding amount will be added to the Net Sales of the period during which it is paid; 

  

	 	c.	 product-related administrative fees, rebates or other similar allowances granted (including to governmental
authorities, purchasers, reimbursers, customers, distributors, wholesalers, and managed care organizations and entities) which effectively reduce the selling price or gross sales; and 

 

	 	d.	 insurance, customs charges, freight, postage, shipping, handling, and other transportation costs; and

  

	 	e.	 import taxes, export taxes, excise taxes, sales taxes, value-added taxes, consumption taxes, duties or other
taxes levied on, absorbed, determined and/or imposed with respect to sales of Collaboration Products (excluding income taxes of any kind). 

If a Party receives non-cash consideration or in the case of transactions not at arm’s length, Net
Sales will be calculated based on the fair market value of such consideration or transaction, at the time of the transaction, assuming an arm’s length transaction made in the ordinary course of business. Notwithstanding the foregoing, Net Sales
shall not be imputed to any transfer of the Collaboration Product or Unilateral Product for use in clinical trials, non-clinical development activities (e.g. material transfer agreements) or other development
activities with respect to the Collaboration Product or Unilateral Product by or on behalf of the respective Party, for bona fide charitable purposes or for compassionate use, if no monetary consideration is received for such transfers. 

 

	1.99	 Non-Divesting Party has the meaning set forth in
Section 15.2. 

  

	1.100	 Non-Lead Party has the meaning set forth in
Section 9.6b. 

  

	1.101	 Non-Interested Party has the meaning set forth in
Section 2.11. 

  

	1.102	 Opt-Out Date is defined in Section 14.1.

  

	1.103	 Opt-Out Notice is defined in Section 14.1.

  

	1.104	 Opt-Out Party is defined in Section 14.1.

  

	1.105	 Opt-Out Point is defined in Section 14.1.

  
 12 of 85 

 Execution Version 

 

	1.106	 Partnership Agreement means a license agreement to be concluded jointly by both Parties
(or by one of the Parties with approval of the other Party) with a Third Party (Third Party Collaborator) under which such Third Party Collaborator obtains an exclusive or non-exclusive (as
agreed between the Parties and the Third Party Collaborator in accordance with Section 4.8) license or other right to a Collaboration Product and related Collaboration IP and assumes the obligation to Commercialize such Collaboration Product in
certain defined parts of the Territory. 

  

	1.107	 Patent Right means (a) all patent applications filed or having legal force in any
country or jurisdiction, including all provisional patent applications; (b) all patents that have issued or in the future will be issued from such applications, including without limitation method, process, utility, model and design patents and
certificates of invention; and (c) all divisionals, continuations, continuations in part, supplement protection certificates, reissues, reexaminations, renewals, extensions or additions to any such patent application and patents.

  

	1.108	 Paying Party has the meaning set forth in Exhibit 1. 

 

	1.109	 Phase I Clinical Trial means, a human clinical trial that is conducted to evaluate the
preliminary safety, tolerability and pharmacokinetics effect of a drug in healthy volunteer subjects or patients in accordance with the requirements of 21 CFR 312.21(a) or foreign equivalents. Typical elements of a Phase I Clinical Trial are
described in more detail in Section 3.1.3.1 of ICH Topic E8 (GENERAL CONSIDERATIONS FOR CLINICAL TRIALS). The final design of Phase I Clinical Trials for a Collaboration Product will be agreed by the Joint Steering Committee.

  

	1.110	 Phase I/II Clinical Trial means a human clinical trial which has the following two
(2) main objectives: (i) determining preliminary safety and (ii) determining preliminary efficacy parameters in appropriate patients. Such Phase I/II Clinical Trial will often be split into two (2) parts, where the first part is
intended to determine the maximum tolerated dose, and the second part is intended to determine preliminary efficacy parameters and additional safety data. The final design of Phase I/II Clinical Trials for a Collaboration Product will be agreed by
the Joint Steering Committee. 

  

	1.111	 Phase II Clinical Trial means a potentially controlled human clinical trial involving a
sufficient number of patients with the disease or condition of interest to obtain sufficient efficacy and safety data of a candidate drug in the targeted patient population to support a Phase III Clinical Trial of a candidate drug for its intended
use, and to define the optimal dosing regimen, such as trials referred to in 21 C.F.R.§312.21(b) and foreign equivalents. Typical elements of a Phase II Clinical Trial are described in more detail in Section 3.1.3.2 of ICH Topic E8
(GENERAL CONSIDERATIONS FOR CLINICAL TRIALS). The final design of Phase II Clinical Trials for a Collaboration Product will be agreed by the Joint Steering Committee. 

 

	1.112	 Phase III Clinical Trial means a controlled, and usually multi-center, clinical trial,
involving patients with the disease or condition of interest intended to obtain sufficient efficacy and safety data to support Marketing Approval of a candidate drug whether or not designated as “Phase III”, such as trials referred to in
21 C.F.R. §312.21(c) and foreign equivalents. Typical elements of a Phase III Clinical Trial are described in more detail in Section 3.1.3.3 of ICH Topic E8 (GENERAL CONSIDERATIONS FOR CLINICAL TRIALS). The final design of Phase III
Clinical Trials for a Collaboration Product will be agreed by the Joint Steering Committee. 

  
 13 of 85 

 Execution Version 

 

	1.113	 Phase A means the research and evaluation phase pursuant to Section 2.

  

	1.114	 Phase B means the preclinical and clinical development phase pursuant to Section 3.

  

	1.115	 Preferred Clinical Candidate has the meaning set forth in Section 2.10 of the
Agreement. 

  

	1.116	 Prior Agreement has the meaning set forth in the preamble of the Agreement.

  

	1.117	 Profit means the profits resulting from the Commercialization of a Collaboration Product,
which shall be equal to the Net Sales received by a Party from the Commercialization of a Collaboration Product: 

  

	 	a.	 less manufacturing costs for the Collaboration Product sold, 

 

	 	b.	 plus profits received from Partnership Agreements in relation to the Collaboration Product,

 provided, however, that any costs that would otherwise be included as a Commercialization expense, but which, pursuant
to the definition of “Net Sales”, are deducted from gross sales to determine the Net Sales of a Collaboration Product, shall not also be deducted as a Commercialization expense and thereby counted twice. For the avoidance of doubt, Profits
received from Partnership Agreements shall include without limitation all up-front, milestone and royalty payments, but exclude (i) any arms’ length research and development funding paid by the Third
Party Collaborator in consideration for research and development activities to be performed under the Partnership Agreement and (ii) any value added or other taxes paid by the Third Party Collaborator to a Party in connection with such
Partnership Agreement. Further details of the Profit calculation shall be agreed in the Commercialization Agreement. 
  

	1.118	 Program Inventions has the meaning set forth in Section 9.1b. 

 

	1.119	 Proposed IND Submission has the meaning set forth in Section 3.7.

  

	1.120	 Publication has the meaning set forth in Section 11.6. 

 

	1.121	 Receiving Party is defined in Section 11.1. 

 

	1.122	 Region means either Asia (including, but not limited to India), the EU, North America (US,
Mexico and Canada), South and Central America or ROW (including, but not limited to Russia, Australia, New Zealand, Africa, Middle East). 

  

	1.123	 Regulatory Authority means any federal, national, multinational, state, county, city,
provincial, or local regulatory agency, department, bureau or other governmental entity with authority over the marketing, commercialization, manufacture or sale of a pharmaceutical product in the Territory, including the FDA in the United States
and the EMA in the EU. 

  
 14 of 85 

 Execution Version 

 

	1.124	 Research and Development Costs means the actual costs and expenses incurred by a Party for
research and Development activities in Phase A and Phase B, including: 

  

	 	a.	 direct labor at the agreed FTE Rate plus agreed travel expenses pursuant to the Travel Policy of such
employees, 

  

	 	b.	 direct research and development costs paid to consultants, independent contractors and Third Party service
providers, 

  

	 	c.	 direct costs of supplies, equipment and materials and related expenditures (including taxes and duties),

  

	 	d.	 patent filing, prosecution and maintenance costs (but not defense and enforcement costs, unless otherwise set
forth in this Agreement), 

  

	 	e.	 scale-up and other manufacturing costs (solely up to and including scale-up activities prior to production of successful consistency batches which is understood to be the first production of batches of a Collaboration Product that may be used for Commercialization),

  

	 	f.	 Third Party contract costs required to perform Development activities related to the relevant Collaboration
Product, 

  

	 	g.	 regulatory costs, including costs for IND and BLA filing and other costs for obtaining Marketing Approvals,

  

	 	h.	 license payments (including but not limited to upfront payments, milestone payments and license maintenance
fees) to Third Parties as necessary for Development and Commercialization of Collaboration Products 

 in each case
(a) to (e) calculated in accordance with the Collaboration Accounting Policies, consistently applied and only to the extent such costs are directly attributable to the furtherance of a Research Plan or Development Plan, but excluding
expenditures relating to general overhead, managerial, legal, financial and administrative expenses. For the avoidance of doubt, to the extent costs or salaries are partly directly attributable to a Research Plan or Development Plan and partly
attributable to other activities of a Party, such costs and salaries shall constitute Research and Development Costs on a pro rata basis. 
  

	1.125	 Research Plan means the written research plan agreed between the Parties which describes
the work to be performed by each Party during Phase A as well as budgets, timelines, allocation of FTEs and other relevant items agreed between the Parties. The Research Plan shall be updated at least annually as shall be set forth in Exhibit
5. 

  

	1.126	 Royalty Reports has the meaning set forth in Exhibit 1. 

  
 15 of 85 

 Execution Version 

 

	1.127	 Royalty Term means on a Unilateral Product-by-Unilateral Product and country-by-country basis, the period commencing on the First Commercial Sale of the relevant
Unilateral Product and ending on the later to occur of: 

  

	 	a.	 the [***] anniversary of the date of the First Commercial Sale of such Unilateral Product in such country;

  

	 	b.	 the expiration of the last to expire Valid Patent Claim of any Patent Right included in the [***] or the [***]
(in case of an opt-out by Genmab) or [***] (in case of an opt-out by Biontech) that would be infringed by the manufacture, use, sale, offer for sale or import of the
Unilateral Product in such country, if not for the licenses or assignments of intellectual property granted hereunder; and 

  

	 	c.	 the expiration of [***] for such Unilateral Product in such country. 

 

	1.128	 Selection of a Clinical Candidate has the meaning set forth in Section 2.9.

  

	1.129	 Serious Adverse Events means any Adverse Event occurring at any dose in response to the
administration of a Collaboration Product or Unilateral Product that: (a) results in death or threatens life; (b) results in persistent or significant disability/incapacity; (c) results in or prolongs hospitalization; (d) results
in a congenital anomaly or birth defect; or (e) is otherwise medically significant. 

  

	1.130	 Shared Cost is defined in Section 7.3a. 

 

	1.131	 Shared Profits is defined in Section 7.3b. 

 

	1.132	 Sublicensee means any person or entity that is granted a sublicense under (a) the
Biontech Technology by Genmab or its Affiliates or (b) the Genmab Technology by Biontech or its Affiliates in accordance with the terms of this Agreement. 

 

	1.133	 Target Combination means each of the combinations of two distinct targeted antigens
selected from the Collaboration Targets as specifically set forth in the Research Plan; each distinct antigen defined by its unique UniProt/Swiss-Prot number. 

 

	1.134	 Term has the meaning set forth in Section 16.1.  

 

	1.135	 Territory means the world. 

 

	1.136	 Third Party means any person or entity other than the Parties and their Affiliates.

  

	1.137	 Travel Policy means the policy as agreed to by the Parties and approved by the Joint
Steering Committee to be used for travel costs and expenses incurred as part of a Party’s activities under the applicable Research Plan or Development Plan, subject however to Sections 7.5 and 8.6. 

 

	1.138	 Unilateral Product has the meaning set forth in Section 14.6. 

  
 16 of 85 

 Execution Version 

 

	1.139	 Valid Patent Claim means (a) an unexpired claim of an issued patent (including any
extension thereof pursuant to patent term extension or a supplementary protection certification) which has not been found to be unpatentable, invalid or unenforceable by an unreversed and unappealable decision (including a decision that was not
appealed within the time allotted for an appeal) of a court or other authority in the subject country; or (b) a claim of an application for a patent that has been pending for less than [***] years as calculated from the earliest priority date.

  

	2.	 PHASE A – RESEARCH AND EVALUATION 

 

	2.1	 Goal of Phase A. The goal of Phase A is to jointly discover, research and develop in
accordance with the Research Plan, Clinical Candidates against the Target Combinations for further preclinical and clinical development in Phase B, on the basis of a 50/50 cost sharing. During the initial term of Phase A (as defined in
Section 2.4), the Parties expect to identify [***] Clinical Candidates. For the avoidance of doubt, these numbers of expected Clinical Candidates are non-binding estimates only and the collaboration
between the Parties in Phase A shall not be subject to any binding minimum or maximum number of Clinical Candidates. The Parties agree that this Agreement shall replace the Prior Agreement upon execution, and that any initial research (as defined
under the Prior Agreement) conducted under the Prior Agreement shall be deemed covered by Phase A and the terms and conditions thereof, and any rights and obligations of the Parties under the Prior Agreement shall be replaced with the rights and
obligations of the Parties set forth in this Agreement. In case of discrepancy between this Agreement and the Prior Agreement, this Agreement shall prevail. 

  

	2.2	 Research Plan. Within [***] days after the Effective Date, the Parties shall prepare and
agree an initial Research Plan, which shall be endorsed by the Joint Research Committee and added to Exhibit 5. On an annual basis, or more frequently as necessary and agreed by the Parties, but no later than by 30 September (in order
for the Parties to prepare their respective budgets for the coming [***] calendar years) the Joint Research Committee shall review the Research Plan in order to make annual updates to the Research Plan for the then current calendar year, if any,
plus the following two (2) calendar years. Furthermore, each Party may recommend changes to the Research Plan at any time; provided, however, that such changes shall be effective only upon the approval by the Joint Research Committee.

  

	2.3	 FTE Allocation During Phase A. The Parties intend to contribute and commit the required
resources to meet the objectives as stipulated by the Joint Research Committee and in the applicable Research Plan. Details in relation to the number and allocation of FTEs during Phase A shall be set forth in the Research Plan. For the avoidance of
doubt, the allocation of FTEs pursuant to the Research Plan shall not alter the 50/50 cost sharing in Phase A as set forth in Section 7.3a. 

  

	2.4	 Subcontracting During Phase A. Either Party may perform some or all of its obligations
under the Research Plan through any of its Affiliates or one or more Approved Subcontractors; provided, that (a) none of the rights of the other Party hereunder are diminished or are otherwise adversely affected as a result of such
subcontracting and (b) the Affiliate or Approved Subcontractor undertakes in writing all obligations of confidentiality and non-use regarding both Parties’ Confidential Information which are
substantially the same as those undertaken by the Parties hereunder. In the event that a Party performs one or more of its obligations under the Research Plan through any such Affiliate or Approved Subcontractor, then such Party

  
 17 of 85 

 Execution Version 

 

	 	
shall at all times be responsible for the performance by such Affiliate or Approved Subcontractor of such Party’s obligations hereunder. Provided that the Research Plan specifically includes
reference to such Affiliate or Approved Subcontractor and the activities and services to be carried out by such Affiliate or Approved Subcontractor, then the Party subcontracting does not need to consult with the other Party before entering into an
agreement with such Affiliate or Approved Subcontractor, provided that the terms of this Section 2.4 are adhered to. 

  

	2.5	 Duration of Phase A. The joint research and development activities in Phase A are
scheduled for an initial term of [***] years starting on the Effective Date. The Parties shall discuss in good faith an extension of Phase A at the latest [***] months before the end of the initial term, provided that any extension of Phase A shall
require the written mutual agreement between the Parties. 

  

	2.6	 General Obligations of the Parties in Phase A. During Phase A, each Party shall

  

	 	a.	 use its Commercially Reasonable Efforts to discover, research and develop Clinical Candidates and to perform
its respective activities pursuant to the Research Plan, and 

  

	 	b.	 perform its activities under the Research Plan in good scientific manner, and in compliance with all
requirements of Applicable Laws, and 

  

	 	c.	 contribute such personnel, equipment, facilities and other resources as reasonably necessary to perform its
obligations under the Research Plan and to achieve efficiently the objectives thereof, provided that each Party shall only be obliged to contribute those FTEs set forth in Section 2.3 above and in the Research Plan, 

 

	 	d.	 provide the other Party with such materials, information and other assistance required to be provided under the
Research Plan. 

  

	2.7	 Results and Reporting Under Phase A. Each Party shall keep the other Party fully informed
as to its progress, results (including the development of any technology or Program Inventions), status and plans for performing and implementing the Research Plan. Such information shall be given by periodic, informal oral reports, and by a
quarterly written report, which may be in the form of a power point presentation during meetings of the Joint Research Committee, delivered not later than thirty (30) days following the end of every Calendar Quarter during which any activities
are performed under the Research Plan. 

  

	2.8	 Records. Each Party shall maintain records, in sufficient detail and in good scientific
manner appropriate for patent and regulatory purposes, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in its performance of the Research Plan. Each Party shall make such records available
to the other Party for inspection upon reasonable written request of the other Party (but not more than once per calendar year) for the purpose of ensuring the Party’s compliance with its research obligations hereunder. Upon request, each Party
shall deliver to the other Party copies of all records described in this Section 2.8. All such records shall be jointly owned. 

  
 18 of 85 

 Execution Version 

 

	2.9	 Liability. In connection with the conduct of the Development activities, hereunder, each
Party shall be responsible for, and hereby assumes, any and all risks of personal injury or property damage attributable to the negligent acts or omissions of that Party or its Affiliates, and their respective directors, officers, employees and
agents. 

  

	2.10	 Nomination of Collaboration Products. Each Party may at any time during Phase A propose
that one or more Clinical Candidates which meet the relevant specifications defined in the Research Plan is/are nominated by the Joint Research Committee as Collaboration Product(s) for further preclinical and clinical development in Phase B (such
proposal to be considered Selection of a Clinical Candidate for the purpose of the financial terms set forth in Exhibit 1). Upon such proposal, the Joint Research Committee will (i) review and confirm whether the proposed
Clinical Candidate(s) meet the relevant specifications defined in the Research Plan, (ii) if several proposed Clinical Candidates targeting the same Target Combination meet such specifications: decide which of these Clinical Candidates is best
suited for further preclinical and clinical development (Preferred Clinical Candidate), and (iii) decide whether the Preferred Clinical Candidate(s) shall be developed as Collaboration Product(s). The Joint Research Committee
shall make the decisions according to (i) to (iii) in good faith and shall not take into consideration whether any of these decisions would trigger the payment according to Section 7.1d. For the avoidance of doubt, if only one proposed
Clinical Candidate targeting a certain Target Combination meets the relevant specifications defined in the Research Plan, such Clinical Candidate shall automatically be the Preferred Clinical Candidate for such Target Combination. If and when the
Joint Research Committee decides that a Preferred Clinical Candidate shall be developed as Collaboration Product (as documented in the minutes of the Joint Research Committee), the Parties obligations under the Research Plan shall terminate, and
Phase B shall be initiated with respect to such Preferred Clinical Candidate. For the avoidance of doubt, neither Party may propose to the Joint Research Committee a Clinical Candidate targeting a Target Combination for which a Preferred Clinical
Candidate has already been selected. 

  

	2.11	 Unilateral Development. 

 

	 	a.	 If a Party (Non-Interested Party) – through the
Joint Research Committee pursuant to Section 2.10 – decides not to develop a Preferred Clinical Candidate as a Collaboration Product and move it to Phase B, the other Party (Interested Party) shall be permitted to
unilaterally continue development of the Preferred Clinical Candidate on the pre-defined terms and conditions set forth in Exhibit 1. In such case, the Preferred Clinical Candidate will become a Unilateral
Product and Section 14.6 shall apply mutatis mutandis. 

  

	 	b.	 If the Interested Party is not willing to continue development of the Preferred Clinical Candidate on the pre-defined terms and conditions set forth in Exhibit 1, a mandatory joint Divestment of the Preferred Clinical Candidate shall take place and Section 15.9 shall apply mutatis mutandis, unless the
Parties decide otherwise. If the mandatory joint Divestment fails, the Preferred Clinical Candidate will be considered a Ceased Product under Section 14.5. 

  
 19 of 85 

 Execution Version 

 

	 	c.	 If the Parties agree not to advance a certain Clinical Candidate to Phase B, then such Clinical Candidate shall
be considered a Ceased Product and Section 14.5 shall apply mutatis mutandis. 

  

	2.12	 Back-Up Candidates. Concurrently with the decision
to develop a proposed Clinical Candidate as Collaboration Product or Unilateral Product, as applicable, the Joint Research Committee (if both Parties wish to develop such Clinical Candidate) or the Interested Party (if only one Party wishes to
develop such Clinical Candidate) shall be entitled to also designate [***] further Clinical Candidate (if available) as Back-up Candidate for the respective Target Combination (and in such event, the Joint
Research Committee or the Interested Party, as applicable, may decide at any time that the Back-up Candidate shall replace the originally selected Clinical Candidate as Collaboration Product or Unilateral
Product for the purposes of this Agreement). 

  

	3.	 PHASE B – PRECLINICAL AND CLINICAL DEVELOPMENT 

 

	3.1	 Goal of Phase B. The goal of Phase B is to jointly develop on a Collaboration Product-by-Collaboration Product basis, a Collaboration Product in accordance with the applicable Development Plan through preclinical and clinical phase on the basis of a
50/50 cost sharing. 

  

	3.2	 Development Plans. Without undue delay after nomination of a Collaboration Product, and on
a Collaboration Product-per-Collaboration Product basis, the Parties shall agree on the initial Development Plan and Budget, both including clinical and manufacturing
activities until Establishment of Proof of Concept, taking into consideration either Party’s capabilities and resources. Such initial Development Plan and Budget shall be endorsed by the Joint Steering Committee and added to Exhibit 6 of
this Agreement. Each Party may recommend changes to a Development Plan at any time; provided, however, that such changes shall be effective only upon the approval by the Joint Steering Committee. 

 

	3.3	 Duration of Phase B. Phase B shall begin on a Collaboration
Product-by-Collaboration Product basis upon nomination of the respective Collaboration Product pursuant to Section 2.10 and shall end upon the earlier of (i) opt-out of a Party pursuant to Section 14 and/or Divestment of a Party’s share in the collaboration pursuant to Section 15 (in each case subject to the provisions on unilateral development by
the Continuing/Non-Divesting Party and on continued funding by the Opt-Out/Divesting Party as set forth in Sections 14 and 15), (ii) abandonment of the Phase B
Development activities by mutual agreement between the Parties, (iii) completion of all Development activities for all countries in which the Collaboration Product shall be Commercialized, (iv) conclusion of a Joint Divestment Process, and
(v) any other date specified in the applicable Development Plan. 

  

	3.4	 General Obligations of the Parties in Phase B. Each Party shall 

 

	 	a.	 use its Commercially Reasonable Efforts to develop the respective Collaboration Product during the necessary
preclinical and clinical stages and to perform its respective activities pursuant to the applicable Development Plan, 

  
 20 of 85 

 Execution Version 

 

	 	b.	 perform its activities under the applicable Development Plan in good scientific manner, and in compliance with
all requirements of Applicable Law, 

  

	 	c.	 contribute such personnel, equipment, facilities and other resources as reasonably necessary to perform its
obligations under the applicable Development Plan and to achieve efficiently the objectives thereof, provided that each Party may only incur Shared Costs as provided in Section 7.4, 

 

	 	d.	 refrain from using in any capacity in connection with the Development, manufacture or Commercialization of a
Collaboration Product, any person or entity who has been debarred pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act or a similar legislation in another jurisdiction, or who is the subject of a conviction
described in such section, and 

  

	 	e.	 provide to the other Party such materials, information and other assistance required to be provided under the
applicable Development Plan. 

  

	3.5	 Reference to Certain Provisions of Phase A. Sections 2.4, 2.7, 2.8 and 2.9 shall apply
mutatis mutandis to Phase B. 

  

	3.6	 Ad Hoc and Annual Updates to the Development Plan. On an annual basis, or more frequently
as necessary and agreed by the Parties, but no later than by 30 September (in order for the Parties to prepare their respective budgets for the coming [***] calendar years), the Joint Steering Committee shall review the Development Plan and the
related Budget in order to make annual updates to the Development Plan and Budget for the then current calendar year, if any, plus the following [***] calendar years both to be approved by the Joint Steering Committee. In the event that the Joint
Steering Committee cannot agree on an annual update to the Development Plan and Budget, then the most recent version of the Development Plan and Budget will be deemed the Development Plan and Budget for the period, until the Parties are able to
reach an agreement on any update to the Development Plan and Budget. The Parties agree that no later than [***] months prior to the anticipated Establishment of Clinical Proof of Concept, the Parties, via the Joint Development Team and the Joint
Steering Committee, shall agree on an update to the Development Plan, including the Budget, to cover the period after Establishment of Clinical Proof of Concept, such plan to cover various clinical scenarios depending on whether Establishment of
Clinical Proof of Concept shall be followed by Phase II Clinical Trial(s) or a pivotal clinical trial. Such update to the Development Plan and Budget shall form the basis of any continued Development after the Establishment of Clinical Proof of
Concept by both Parties or during a Divestment Process by the Non-Divesting Party, if applicable. 

  

	3.7	 Preparation of IND. The Parties shall jointly be responsible via the Joint Steering
Committee for producing the initial version of the proposed IND submission as well as a work plan and budget for the clinical phase of the Development of a Collaboration Product, including but not limited to the CMC costs. Once such an IND
submission package has been agreed on by the Joint Steering Committee, Proposed IND Submission for the purposes of Section 14 and the financial terms set forth in Exhibit 1 shall be deemed reached. 

  
 21 of 85 

 Execution Version 

 

	3.8	 Third Party as Supplier. In the case where the Joint Steering Committee elects to
designate a Third Party to be responsible for manufacturing of a Collaboration Product (or any component thereof), one Party or both Parties, to be determined by the Joint Steering Committee, shall enter into a supply agreement with such Third Party
on customary and reasonable terms and conditions. The Joint Steering Committee shall determine the strategy, timing and other matters relating to identifying such Third Party and entering into the supply agreement. At such time as the Joint Steering
Committee determines to recruit a Third Party, the Joint Steering Committee shall determine whether to designate a Party to take the lead in negotiating and entering into the supply agreement or to allocate such responsibilities between the Parties.
If one Party is designated to take the lead in negotiating such agreement, such Party shall provide the other Party with term sheets and substantive agreement drafts during the negotiations (including any proposed execution version) for review and
comment and the designated Party shall not enter into any such supply agreement (or any amendment, waiver or other modification thereof) without the written approval of the other Party, which approval shall not be unreasonably withheld. No
contractual or other obligations will be entered into vis-à-vis a Third Party and the Joint Steering Committee will not designate nor authorize a Party to enter
into such obligations, before such obligations have been financially covered in the Budget. 

  

	3.9	 Companion Diagnostic and Biomarkers. To the extent that biomarker analysis or a companion
diagnostic will be required as per the Research Plan or the Development Plan, the Joint Research Committee or the Joint Steering Committee, as applicable, will consider Biontech’s capabilities for biomarker testing and diagnostic development as
well as alternative proposals and will make the decision as to whether Biontech in the sole interest of the applicable Collaboration Product shall be the preferred choice to determine biomarkers and develop a companion diagnostic. If Biontech is
selected by the Joint Steering Committee to determine biomarkers and develop a companion diagnostic for the applicable Collaboration Product, Biontech will use Commercially Reasonable Efforts to develop a companion diagnostic to be tested in
clinical trials and shall have the exclusive right to manufacture and commercialize such companion diagnostic. The costs incurred by Biontech in developing such a companion diagnostic shall be considered Shared Costs for the purposes of this
Agreement and shall be included in the then current Budget. However, any costs incurred or profit obtained during the commercial manufacturing or commercialization of any such companion diagnostic by Biontech shall be incurred and obtained at
Biontech’s sole expense and benefit, and shall not be considered Shared Costs nor Shared Profits.  

  

	4.	 COMMERCIALIZATION 

 

	4.1	 General. The Parties agree to jointly Commercialize Collaboration Products and share
equally all Commercialization expenses (as further defined in the Commercialization Agreement) and Profits. 

  

	4.2	 Strategy and Commercialization Plans. The Joint Commercialization Committee shall decide
on an overall Commercialization strategy (including the overall marketing and pricing strategy), which shall be submitted to the Joint Steering Committee for endorsement. The Parties shall in due time during Phase B but no later than [***] days
after the initiation of the first Phase III Clinical Trial, on a Collaboration Product-by-

  
 22 of 85 

 Execution Version 

 

	 	
Collaboration Product basis, agree through the Joint Commercialization Committee on an initial Commercialization Plan, such plan also to be submitted to endorsement to the Joint Steering
Committee. Each Party may recommend changes to a Commercialization Plan at any time; provided, however, that such changes shall be effective only upon the approval by the competent Joint Commercialization Committee and the Joint Steering Committee.
The Joint Commercialization Committee shall be authorized to execute any activities or decisions with regard to the Commercialization Plan, provided that such activities or decisions are within the latest Commercialization Plan as endorsed by the
Joint Steering Committee. The Parties shall instruct their representatives in the Joint Commercialization Committee to use reasonable efforts to reach consensus on matters under the governance and decision-authority of the Joint Commercialization
Committee. 

  

	4.3	 Lead Commercialization Party. At least [***] months prior to the anticipated start of any
pivotal trial that may be used for BLA filing to a Regulatory Authority, the Parties will agree as part of the Commercialization Agreement on which Party will become Lead Commercialization Party for which Region. Within the framework
of the overall Commercialization strategy, cf. Section 4.2 above, the Lead Commercialization Party shall be responsible for setting-up and operating the distribution network in its Region, including, but
not limited to, the following: warehousing and distribution logistics, supply and packaging, invoicing and collection, preparing of marketing materials, handling reimbursement issues as well arranging for medical affairs functions to support the
commercial endeavors in such Region. The Lead Commercialization Party shall in addition be responsible for preparing, supervising, implementing and adapting the regional marketing strategy for the relevant Region in compliance with the overall
marketing strategy as approved by the competent Joint Commercialization Committee and endorsed by the Joint Steering Committee pursuant to Section 4.2. Regional marketing strategy includes, but is not limited to, key opinion leader development,
pre-launch advisory board meetings, primary market research with customers, health economic and reimbursement studies, local customary discounts, local advertising strategy, competitor analysis, un-met need analysis, local product positioning, other promotional strategies (such as sampling, give-away items, PR) and prescribing guideline inclusion. Notwithstanding the above, the Parties agree that Genmab
shall book worldwide sales. 

  

	4.4	 Co-Promotion. Notwithstanding the existence of a
Lead Commercialization Party for each Region, both Parties may utilize their sales representatives on a 50/50 basis to co-promote Collaboration Products in any Region pursuant to the provisions of the
Commercialization Agreement. 

  

	4.5	 Commercialization Agreement. The Parties shall negotiate in good faith and enter into a
separate global commercialization agreement (the Commercialization Agreement) at least [***] months prior to the anticipated start of any pivotal trial that may be used for BLA filing to a Regulatory Authority, which shall be
consistent with the applicable provisions of this Agreement, reflect any mechanism or structure agreed upon by the Joint Steering Committee and shall include customary provisions relating to joint Commercialization, including, among others, the
following matters: amendment to and updates of the Commercialization Plan, report and audit rights, co-promotion (including, among others, performance metrics, sales force compensation strategies, division of
the 

  
 23 of 85 

 Execution Version 

 

	 	
applicable Region between the Parties’ respective sales forces on a 50/50 basis, sales force training), co-branding, marketing, recalls and medical
inquiries, commercialization expenses, further details on the calculation of Profits, labeling, public statements and other information concerning the Collaboration Product, liability, indemnification, use of subcontractors and the responsibilities
and powers of the Joint Commercialization Committee and the Lead Commercialization Party. 

  

	4.6	 General Commercialization Obligations. During the Commercialization phase, each Party
shall 

  

	 	a.	 use its Commercially Reasonable Efforts to Commercialize the Collaboration Products and to perform its
respective activities pursuant to the applicable Commercialization Plan and Commercialization Agreement, as applicable, and in accordance with all Applicable Laws, including GxPs; 

 

	 	b.	 contribute such personnel, equipment, facilities and other resources as reasonably necessary to perform its
obligations under the applicable Commercialization Plan and to achieve efficiently the objectives thereof; and 

  

	 	c.	 provide to the other Party such materials, information and other assistance required to be provided under the
applicable Commercialization Plan. 

  

	4.7	 Divestment to Third Party. During a Divestment Process, a Third Party which is interested
in licensing or acquiring the Divesting Party’s share of a Collaboration Product may through the Divesting Party approach the Non-Divesting Party in order to attempt to
re-negotiate the allocation of Commercialization responsibilities for Regions. The Non-Divesting Party may at its sole discretion enter into, and conduct, such
negotiations in good faith. 

  

	4.8	 Partnership Agreements. If a Collaboration Product is planned by the Joint
Commercialization Committee to be Commercialized wholly or partly through Partnership Agreements, unless expressly set forth otherwise in the applicable Commercialization Plan, the following principles shall apply: 

 

	 	a.	 Each Party shall use Commercially Reasonable Efforts to identify Third Parties which may be interested in
concluding a Partnership Agreement and shall disclose such Third Parties to the other Party for further evaluation and discussion. 

  

	 	b.	 Unless otherwise agreed, the Lead Commercialization Party for the Region to which the potential Partnership
Agreement pertains shall be responsible for initiating and engaging in discussions with the potential Third Party Collaborator (including without limitation all business and scientific meetings) and for negotiating the respective Partnership
Agreement, provided that such Party shall (i) keep the other Party at all times fully informed as to the status of any discussions or negotiations with the potential Third Party Collaborator, (ii) notify the other Party reasonably in
advance of any meetings (whether in person, per telephone or otherwise) with the potential Third Party Collaborator and the other Party shall have the right (but not the obligation) to attend and participate in all such meetings, (iii) closely
cooperate with the other Party in the preparation and negotiation of the Partnership Agreement (and any term sheets or similar documents relating to such 

  
 24 of 85 

 Execution Version 

 

	 	
Partnership Agreement), (iv) promptly provide the other Party with copies of all relevant drafts and mark-ups of the Partnership Agreement (or any term
sheets or similar documents relating to such Partnership Agreement) that are exchanged in the course of the negotiations, and (v) consult with the other Party as to the terms of the Partnership Agreement (or any term sheets or similar documents
relating to such Partnership Agreement) and incorporate any reasonable suggestions or requirements. 

  

	 	c.	 No Partnership Agreement may be concluded without approval of both Parties (such approval not to be
unreasonably withheld). 

  

	5.	 REGULATORY MATTERS 

 

	5.1	 General 

 

	 	a.	 The Joint Steering Committee shall be responsible for the overall regulatory strategy and for overseeing,
monitoring and coordinating the actions of the Parties, in particular the design of any pivotal clinical trial intended to support Marketing Approval in the Major Market Countries. Genmab shall be the Lead Regulatory Party for the Territory. Unless
otherwise agreed by the Joint Steering Committee, the Lead Regulatory Party shall be responsible for all regulatory actions, communications and filings and submissions to, all applicable Regulatory Authorities with respect to a given Collaboration
Product. 

  

	 	b.	 Unless otherwise agreed by the Joint Steering Committee, the Lead Regulatory Party shall be named
“Sponsor” of the regulatory filing as per 21 CFR 312.3 (Part B) and/or 21 CFR 312.50 or similar rules and regulations with respect to a given Collaboration Product. The Parties will work together to transfer and assign all regulatory
documents, contracts, materials and information that relates to a Collaboration Product to the Lead Regulatory Party or its designees to the extent necessary for the Lead Regulatory Party to assume such role. 

 

	5.2	 Ownership of Marketing Approvals. Unless otherwise proposed by the Joint Steering
Committee and agreed to by the Parties, the Lead Regulatory Party shall own all INDs, BLAs and other Marketing Approvals for a Collaboration Product (but, for the avoidance of doubt, all dossiers submitted to any Regulatory Authority and all
data and information contained therein shall be jointly owned by the Parties). The Lead Regulatory Party shall promptly license, transfer, provide a letter of reference with respect to, or take other action necessary to make available such Marketing
Approvals (including INDs and BLAs) to the other Party as may be reasonably necessary to enable such other Party to fulfill its research, Development and Commercialization obligations or perform its Commercialization rights hereunder.

  

	5.3	 Regulatory Coordination 

 

	 	a.	 Responsibilities of Lead Regulatory Party. Subject to oversight by the Joint Steering Committee, the
Lead Regulatory Party shall oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, all applicable Regulatory Authorities with respect to a Collaboration Product. The Lead Regulatory Party shall
also be responsible for interfacing, corresponding 

  
 25 of 85 

 Execution Version 

 

	 	
and meeting with the applicable Regulatory Authorities with respect to a Collaboration Product. The Lead Regulatory Party will use its Commercially Reasonable Efforts to include up to two
(2) representatives of the other Party in all meetings and material telephone discussions between representatives of the Lead Regulatory Party and such Regulatory Authority related to a Collaboration Product.  

 

	 	b.	 Review of Correspondence. The Lead Regulatory Party shall regularly inform the other Party of its
current and planned regulatory activities and shall provide the other Party with drafts of any material documents and other material correspondence to be submitted to a Regulatory Authority pertaining to a Collaboration Product, sufficiently in
advance of submission so that the other Party may review and comment on such documents or other correspondence and have a reasonable opportunity to influence the substance of such submissions. The Lead Regulatory Party shall promptly provide the
other Party with copies of any documents or other correspondence received from or submitted to a Regulatory Authority pertaining to a Collaboration Product. 

  

	5.4	 Assistance. Each Party shall cooperate with the other Party to provide all reasonable
assistance and take all actions reasonably requested by the other Party that are reasonably necessary to enable such Party to comply with any regulatory requirements under Applicable Law with respect to each Collaboration Product, including
(a) obtaining and maintaining Marketing Approvals, (b) submitting annual reports, (c) performing pharmacovigilance activities and (d) sharing any relevant regulatory intelligence. Such assistance and actions shall include, among
other things, notifying the other Party within [***] hours of any information it receives from a Regulatory Authority which (i) raises any material concerns regarding the safety or efficacy of the Collaboration Product, (ii) indicates or
suggests a potential material liability for either Party to Third Parties arising in connection with the Collaboration Product or (iii) is reasonably likely to lead to a recall or market withdrawal of the Collaboration Product.

  

	5.5	 Adverse Events relating to Collaboration Products or Unilateral Products 

 

	 	a.	 Reporting to Government Authorities. Each Party shall, and shall cause its respective Affiliates to,
furnish timely notice as required by Applicable Law (i.e., currently not later than [***] calendar days for deaths and immediately life threatening Adverse Events and not later than [***] calendar days for Serious Adverse Events) to all competent
governmental agencies in those parts of the Territory in which it is the Lead Regulatory Party of all Adverse Events identified or suspected with respect to any Collaboration Products administered, distributed, marketed and sold under authority of
any IND or Marketing Approval. Each Party shall provide the other Party with all necessary assistance in complying with all Adverse Event reporting requirements established by, or required under, any applicable IND and/or Marketing Approval in the
Territory. Accordingly, each Party shall provide the other with timely information, in accordance with the time frames set forth below, on any Serious Adverse Events relating to any Collaboration Product to the extent that such Serious Adverse
Events could affect the Marketing Approval for the Collaboration Product, or relate to the safety, efficacy or potency of the Collaboration Product. The Parties agree that with regards to the Unilateral Products, the obligations set forth in this
Section 5.5a shall only apply to the Continuing Party. 

  
 26 of 85 

 Execution Version 

 

	 	b.	 Reporting to Other Party. Each Party shall, and shall cause its respective Affiliates to, furnish the
other Party written notice of all Serious Adverse Events regarding any Collaboration Product reported to such Party or its Affiliates. Each Party shall also use its Commercially Reasonable Efforts to obtain, and to furnish to the other Party hereto,
such information reasonably sufficient to permit that other Party to evaluate such Serious Adverse Events of the Collaboration Product, including, but not limited to, information about the affected patients, the circumstances surrounding the Serious
Adverse Events, the consequences thereof and the sources of information. Each Party shall retain all documents, reports, studies and other materials relating to any and all such Serious Adverse Events, as the case may be. Upon reasonable written
notice, each Party shall permit the other Party hereto to inspect, and to make copies of, all such documents, reports, studies and other materials, subject to all Applicable Laws regarding patient confidentiality, data protection and privacy. The
Parties agree that with regards to the Unilateral Products, the obligations set forth in this Section 5.5b shall only apply to the Continuing Party. 

  

	 	c.	 Pharmacovigilance Agreement. Without limiting the generality of the foregoing, no later than [***]
months prior to the anticipated filing of the first IND for a Collaboration Product, the Parties shall enter into a pharmacovigilance agreement detailing each Party’s pharmacovigilance responsibilities in connection with the Collaboration
Product. The pharmacovigilance agreement will prevail in case of discrepancy with the provisions set forth in sub-sections (a) and (b) above with regards to Collaboration Products. 

 

	6.	 EXCLUSIVITY 

	    	 [***] 

  

	7.	 FINANCIAL PROVISIONS 

 

	7.1	 Upfront Payment. As consideration for entering into this Agreement and contributing
Biontech’s Technology and the existing projects to the collaboration hereunder, Genmab shall pay to Biontech the following non-refundable upfront payments: 

 

	 	a.	 Ten million US dollars ($10,000,000) within [***] of the Effective Date; and 

 

	 	b.	 One million US dollars ($1,000,000) within [***] following agreement by the Parties that at least one of the
antibodies in the current available panel as attached hereto in Exhibit 4 targeting [***] that are not covered by the claims in the relevant third party patents identified by the Parties prior to the execution of this Agreement; and

  
 27 of 85 

 Execution Version 

 

	 	c.	 One million US dollars ($1,000,000) within [***] following the conclusion by the Parties that at least one of
the [***] in the current available panel as attached hereto in Exhibit 4 is non-agonistic. Agonistic [***] antibodies are defined to be able to activate the [***] signaling by binding to the [***],
which is physiologically expressed on T-cells. Agonistic anti-[***] without further need for [***]. For the avoidance of doubt, the decision on which and how many of the antibodies of the panel in Exhibit
4 will be tested for being non-agonistic will be made by the Joint Research Committee. 

  

	 	d.	 Three million US dollars ($3,000,000) within [***] following the date on which the Joint Research Committee for
the first time and in accordance with Section 2.10 (as documented by the minutes of the Joint Research Committee) selects a Preferred Clinical Candidate which wholly or partly is derived from [***] developed by or on behalf of Biontech;
and such Preferred Clinical Candidate is either (i) advanced to a Collaboration Product pursuant to Section 2.10 or a Unilateral Product (whether a Genmab Unilateral Product or a Biontech Unilateral Product) pursuant to
Section 2.11; or (ii) successfully Divested to a Third Party. [***]: 

 [***] 

Furthermore, Phase A may lead to the identification of [***] listed in Exhibit 4; these antibodies will likewise qualify for the payment of
the three million US dollars according to this Section 7.1d if Biontech demonstrates using flow cytometry that [***]. 
 For the
avoidance of doubt, the payment under this Section 7.1d shall not be considered a milestone payment, and shall not become due nor payable upon the achievement of any other milestones set forth in this Agreement, but only upon occurrence of the
events set forth in this Section 7.1d. 
  

	7.2	 FTE Rate. The Parties agree that the mutual annual rate per FTE of either Party who
performs research, Development, consultation or support work under any Research or Development Plan is [***]. Commencing upon the [***] anniversary of the Effective Date and upon every anniversary thereafter, the fee will be adjusted in accordance
with the percentage change over the applicable annual period in the consumer price inflation in the euro area as measured by the Harmonised Index of Consumer Prices (“HICP”). 

 

	7.3	 Allocation of Research and Development Costs, Commercialization Costs and Profits. Unless
otherwise set forth in this Agreement, 

  

	 	a.	 all Research and Development Costs incurred by the Parties in the performance of the Research Plan or any
Development Plan as well as all Commercialization costs according to the provisions of the respective Commercialization Plan and/or Commercialization Agreement (collectively the Shared Costs) shall be shared equally by the Parties; and

  

	 	b.	 all Profits received by the Parties from the Commercialization of Collaboration Products shall be accounted for
by the Parties and shared equally between them (Shared Profits). 

  
 28 of 85 

 Execution Version 

 

	7.4	 Control of Shared Costs by Joint Research Committee or Joint Steering Committee or Joint
Commercialization Committee. The Parties are obligated to each fund fifty percent (50 %) of costs associated with the research and Development of a Collaboration Product and equally share all Commercialization costs. The Parties shall only
be entitled to incur Shared Costs which are either (i) set forth in the annual Research Plan, the applicable annual Development Plan or the applicable Commercialization Plan, (ii) have been agreed and approved in advance by the competent
Joint Research Committee, Joint Steering Committee or Joint Commercialization Committee, as applicable, or (iii) are in accordance with the Travel Policy. The Joint Steering Committee, if such committee is in place, if not the Joint Research
Committee shall review on a quarterly basis the Research and Development Costs and the Commercialization costs, as applicable, against the Budget for such expenses in the applicable calendar year. If in the course of such quarterly review,
the Joint Steering Committee determines that the actual amounts incurred for Research and Development Costs or Commercialization costs are likely to be higher than budgeted or if either Party reasonably considers that it is likely to exceed the
Budget of any Shared Costs set forth in the applicable Research Plan or Development Plan or Commercialization Plan or approved by the competent Joint Research Committee or Joint Steering Committee or Commercialization Committee, as applicable, it
shall promptly notify the competent Joint Research Committee or Joint Steering Committee or Commercialization Committee thereof and shall provide such Joint Research Committee or Joint Steering Committee or Commercialization Committee with details
of the additional Shared Costs that it expects to incur and the reason for such increase. The Joint Research Committee or Joint Steering Committee or Commercialization Committee shall then review the information submitted and may, if appropriate,
amend the Research Plan or the affected Development Plan or the affected Commercialization Plan for the Collaboration Product to permit such overrun or to reduce such activities such that no overrun is expected. If the Joint Research Committee or
Joint Steering Committee or Commercialization Committee does not approve the additional Shared Costs, the requesting Party shall have the right to incur such costs on its own behalf (so that the relevant costs items will not form part of the Shared
Costs mechanism agreed hereunder). However, if the budget overrun is due to a delay or an advance in timing as to the planned activities, which activities are in accordance with the Research Plan or the relevant Development Plan or the relevant
Commercialization Plan, then such excess Research and Development Costs or Commercialization costs shall be shared equally by the Parties regardless of which Party has incurred such costs. For the avoidance of doubt, if a Joint Steering
Committee or Joint Commercialization Committee is in place for a certain Collaboration Product, then all matters set forth in this Section 7.4 pertaining to such Collaboration Product, shall be handled by the such Joint Steering Committee or
Commercialization Committee, as applicable, whereas all other matters, if any, pertaining to Shared Costs on Clinical Candidates shall be handled by the Joint Research Committee. 

 

	7.5	 Financial Representatives. Each Party will appoint a representative (a Financial
Representative) with expertise in the areas of accounting, cost allocation, budgeting and financial reporting. Such Financial Representatives shall work under the direction of the Joint Steering Committee and provide services to and consult
with the Joint Steering Committee, in order to address the financial, budgetary and accounting issues which arise in connection with the Development Plan or the Commercialization. Each Financial Representative may be replaced at any time by the
represented Party by 

  
 29 of 85 

 Execution Version 

 

	 	
providing written notice thereof to the other Party. The Financial Representatives will meet at least once each Calendar Quarter or as they or the Joint Steering Committee may agree. The
Financial Representatives shall agree upon the timing and agenda for all regular meetings. The location of regularly scheduled meetings shall alternate between the offices of the Parties, unless otherwise agreed. Meetings may be held telephonically
or by video conference. One of the Financial Representatives shall record (or cause to have recorded) the minutes of the meeting in writing. Such minutes shall be circulated to the other Financial Representative promptly following the meeting for
review, comment and approval. If no comments are received within [***] days of the minutes’ receipt by the other Financial Representative, unless otherwise agreed, they shall be deemed to be approved by such Financial Representative. Following
their approval, the minutes shall be provided to each Party’s Alliance Manager. Each Party shall bear its own costs associated with its Financial Representative, including without limitation travel time and travel expenses, preparation for
meetings, reading and approving meetings minutes. 

  

	7.6	 Shared Costs Reports. Following the Effective Date, within [***] calendar days after the
end of every Calendar Quarter, each Party’s Financial Representative shall deliver to the competent Joint Research Committee or Joint Steering Committee or Commercialization Committee, as applicable a written report showing in reasonable detail
the Shared Costs that it has incurred during such Calendar Quarter. The Shared Costs Reports will be in such form as the Joint Steering Committee may reasonably agree from time to time. Within [***] days of the receipt of both Parties’ Shared
Costs Reports, the Joint Steering Committee (or the Party appointed by the Joint Steering Committee) shall provide to each Party one consolidated financial report for the Shared Costs consistent with Collaboration Accounting Principles. The Joint
Research Committee or Joint Steering Committee or Commercialization Committee, as applicable shall review such reports and shall determine any compensation amount due by one Party to the other for such Calendar Quarter to reflect the equal sharing
agreed under Section 7.3a. The Party entitled to any such compensation amount shall invoice the relevant compensation amount (plus any value-added tax, if applicable) to the other Party. Invoices are payable within [***] days after receipt.
Notwithstanding the procedure described in this Section 7.6above, the Parties agree that during Phase A, each Party will no later than twenty-eight (28) calendar days after the end of every Calendar Quarter automatically issue and send to
the other Party an invoice corresponding to fifty percent (50%) of the costs incurred by the invoicing Party, provided that such incurred costs are in accordance with the activities approved by the Joint Research Committee as set forth in
Section 7.4. 

  

	7.7	 Profit Reports and Payment. The Parties shall mutually agree, through the Joint Steering
Committee, a mechanism or structure under which they will share equally (50:50) in all Shared Profits created by each Collaboration Product. In reaching this agreement the Parties shall also define and mutually agree, through the Joint Steering
Committee, the appropriate arrangements for making reports and payments between the Parties. 

  
 30 of 85 

 Execution Version 

 

	7.8	 Audit. 

 

	 	a.	 Shared Costs and Shared Profits Records. For so long as any research, Development and/or
Commercialization activities are conducted hereunder and for a period of [***] years thereafter, each Party shall keep and maintain, and shall require its Affiliates to keep and maintain, accurate and complete cost records of activities performed by
each such Party (including Shared Costs and Shared Profits incurred and FTEs utilized) in connection with its research, Development and Commercialization activities hereunder. Not more than once per calendar year, each Party shall have the right to
engage an independent certified public accounting firm of internationally recognized standing and reasonably acceptable to the other Party, which shall have the right to examine in confidence the relevant books, records or other relevant reports, of
such other Party and its respective Affiliates as may be reasonably necessary to determine and/or verify the accuracy of the reports submitted to the Joint Steering Committee, Joint Research Committee or Commercialization Committee, as applicable,
in connection with the performance of a Party’s Development obligations and Commercialization rights hereunder. 

  

	 	b.	 Audit Procedure. Such examination shall be conducted, and each Party shall make its records available,
during normal business hours, after at least [***] days prior written notice shall have been provided by the other Party, as applicable, and shall take place at the facility(ies) where such records are maintained. Each such examination shall be
limited to pertinent books, records and reports for any year ending not more than [***] months prior to the date of request; provided, that, no Party shall be permitted to audit the same period of time more than once. Before permitting such
independent accounting firm to have access to such books and records, the non-requesting Party may require such independent accounting firm and its personnel involved in such audit to sign a confidentiality
agreement (in form and substance reasonably acceptable to such Party) as to any confidential information which is to be provided to such accounting firm or to which such accounting firm will have access while conducting the audit under this
paragraph. The accounting firm shall provide both Biontech and Genmab with a written report stating whether the reports submitted by Biontech or Genmab, as applicable, are correct or incorrect and the specific details concerning any discrepancies.
Such accounting firm may not reveal to the other Party any information learned in the course of such audit other than the amount of any such discrepancies. Each Party agrees that all such information shall be Confidential Information of the other
Party and further agrees to hold in strict confidence all information disclosed to it in accordance with Section 11. 

  

	 	c.	 Cost of Audit. The Party initiating such audit shall bear the full cost of such audit unless such audit
discloses that the actual expenses incurred in the conduct of the other Party’s obligations under the Research Plan or a Development Plan, as applicable, are lower than that reported by such Party by [***] percent ([***]%) or more, in which
case the other Party shall reimburse the initiating Party for all costs incurred by the initiating Party in connection with such audit. Furthermore, the amount in excess of the actual expenses shall be deducted from the Shared Costs reported by that
Party and reconciled between the Parties. 

  
 31 of 85 

 Execution Version 

 

	7.9	 Dispute Resolution. In the event of any dispute between the Parties in relation to
the determination of Shared Costs or Shared Profits or either Party’s share in the Shared Costs or Shared Profits, the Parties shall appoint an international firm of independent certified accountants as Third Party expert to decide on the issue
in dispute (and if the Parties cannot agree on such expert, each party shall appoint one accounting firm and both accounting firms so appointed shall select the relevant expert). The Third Party expert shall be entitled to request any information
and documents from either Party that it deems relevant for rendering its decision, and each Party shall be obliged to provide such information and documents as quickly as possible. Prior to rendering a decision, the Third Party expert shall provide
each Party with reasonable opportunity to comment on its preliminary findings. The decision of the Third Party expert shall be final and binding upon both Parties. The costs of the Third Party expert shall be borne by the losing Party or, if the
Third Party expert does not fully confirm either Parties view, shall be shared on a pro rata basis between the Parties as reasonably determined by the Third Party expert. 

 

	7.10	 General Payment Terms. All payments under this Agreement shall be made in
United States Dollars (except for any FTE costs to be reimbursed by one Party to the other hereunder under the cost sharing mechanism which shall be made in Euro) and are exclusive of applicable statutory value-added tax (VAT), if any, which shall
be listed separately on each invoice. Each payment under this Agreement shall be made by electronic transfer in immediately available funds via bank wire transfer to such bank account as the respective Party shall designate in writing to the other
Party. All amounts accruing in a currency other than United States Dollars or Euro, as applicable, will be expressed in such currency and converted to United States Dollars or Euro, as applicable, using the exchange rate mechanism generally applied
by such Party, provided that such mechanism is in compliance with IFRS. The conversion calculations will be provided in any statement reporting converted amounts. Any undisputed payments or portions thereof due hereunder which are not paid on the
date such payments are due under this Agreement will bear interest at a rate equal to five (5) percent points above the then-applicable base lending rate of the European Central Bank, or (b) the maximum rate permitted by law, calculated on
the number of days such payment is delinquent, compounded monthly using a three hundred sixty five (365) day year. 

  

	7.11	 Tax Matters. Except as otherwise provided below, all amounts due from any paying Party to
any receiving Party under this Agreement are gross amounts. The paying Party shall be entitled to deduct the amount of any withholding taxes payable or required to be withheld by it, its Affiliates, licensees, or Sublicensees (as applicable) to the
extent such paying Party, its Affiliates, licensees, or Sublicensees (as applicable) actually pay such withheld amounts to the appropriate governmental authority on behalf of the receiving Party. The paying Party shall use Commercially Reasonable
Efforts to minimize any such taxes, levies or charges required to be withheld on behalf of the receiving Party. The paying Party promptly shall deliver to the receiving Party proof of payment of all such taxes, levies and other charges, together
with copies of all communications from or with such governmental authority with respect thereto, and shall cooperate with the receiving Party in seeking any related tax credits that may be available to the receiving Party with respect thereto.

  
 32 of 85 

 Execution Version 

 

	8.	 GOVERNANCE 

  

	8.1	 Alliance Managers. Each Party shall appoint a person to coordinate its part of the
activities under this Agreement (Alliance Manager). The Alliance Managers shall be the primary contacts between the Parties with respect to all activities performed under this Agreement and shall be responsible for overseeing the
operation of the collaboration and the organization of the committees. The Alliance Managers will meet in person or per telephone or video conference as necessary to fully comply with their responsibilities. They shall report to the Joint Research
Committees and Joint Steering Committee. Either Party may change its Alliance Manager upon written notice to the other Party. The Alliance Managers shall have no authority to amend or modify the terms and conditions of the Research Plan, any
Development Plan or of this Agreement. 

  

	8.2	 Joint Research Committee. Within [***] days following the Effective Date, the Parties
shall establish a joint research committee (Joint Research Committee). The Joint Research Committee shall have a total of up to [***] members. Up to [***] members of the Joint Research Committee shall be appointed by Genmab, and up to
[***] members of the Joint Research Committee shall be appointed by Biontech. Each Joint Research Committee member shall have sufficient authority to ensure acceptance and execution of Joint Research Committee decisions within its organization. Each
Party may appoint substitutes or alternates for its Joint Research Committee members at any time by written notice the other Party. The Parties may mutually agree to change the size of the Joint Research Committee at any time. The Joint Research
Committee shall be established for the entire term of Phase A as set forth in Section 2.5. For the avoidance of doubt, the Joint Research Committee may co-exist with one or several Joint Steering
Committees. 

  

	 	a.	 Responsibilities of the Joint Research Committee. The Joint Research Committee shall be responsible for
directing, coordinating and supervising the research and development activities of the Parties during Phase A. In particular, the Joint Research Committee shall 

 

	 	(i)	 review and endorse the initial Research Plan proposed by the Parties according to Section 2.2;

  

	 	(ii)	 review and update the Research Plan on an ongoing basis as set forth in Section 2.2,

  

	 	(iii)	 receive regular reports from each Party’s Alliance Manager on, and monitor, the conduct, progress and
results of each Party’s activities under the Research Plan, 

  

	 	(iv)	 agree in advance, review and approve the Shared Costs that the Parties are entitled to incur in Phase A,

  

	 	(v)	 resolve any issues referred to it by the Parties in accordance with Section 17.9. 

  
 33 of 85 

 Execution Version 

 

	 	b.	 Meetings of the Joint Research Committee. Meetings of the Joint Research Committee shall be scheduled
from time to time by mutual agreement of the Parties or upon request of one Party, but in no event less than once every [***] months. The meetings may be held in person, per telephone or video conference. The chair shall alternate at [***] month
intervals between representatives of each Party, starting with a Genmab representative as the chair. The Alliance Manager of the Party hosting any Joint Research Committee meeting shall attend the meeting and record the minutes of the meeting in
writing. Such minutes shall be circulated to the other Party’s Alliance Manager no later than [***] calendar days following the meeting for review, comment and approval of the other Party. If no comments are received within [***] calendar days
of the receipt of the minutes by a Party, unless otherwise agreed, they shall be deemed to be approved by such Party. Furthermore, if the Parties are unable to reach agreement on the minutes within [***] calendar days of the applicable meeting, the
sections of the minutes that have been mutually agreed between the Parties by that date shall be deemed approved and, in addition, each Party shall record in the same document its own version of those sections of the minutes on which the Parties
were not able to agree. 

  

	 	c.	 Decisions of the Joint Research Committee. A quorum of at least [***] Joint Research Committee member
appointed by each Party shall be present at or shall otherwise participate in each Joint Research Committee meeting. Each Party has one vote in the decisions of the Joint Research Committee. Decisions of the Joint Research Committee shall be
unanimous. If the members of the Joint Research Committee cannot agree on a particular issue, the issue shall be escalated pursuant to Section 17.9. The Joint Research Committee shall have no authority to amend or modify the terms and
conditions of this Agreement. 

  

	8.3	 Joint Steering Committee. No later than [***] days after the first initiation of
Phase B for a Collaboration Product (as documented in the minutes of the Joint Research Committee), the Parties shall establish a joint steering committee (Joint Steering Committee) having a total of up to [***] members which shall
have sufficient authority to ensure acceptance and execution of Joint Steering Committee decisions within its organization. Up to [***] members of the Joint Steering Committee shall be appointed by Genmab, and up to [***] members of the Joint
Steering Committee shall be appointed by Biontech. Each Party may appoint substitutes or alternates for its Joint Steering Committee members at any time by written notice the other Party. The Parties may mutually agree to change the size of the
Joint Steering Committee at any time. 

  

	 	a.	 Responsibilities of Joint Steering Committee. The Steering Committee shall be responsible for directing,
coordinating and supervising the research and Development activities of the Parties during Phase B. In particular, the Joint Steering Committee shall 

  

	 	(i)	 review and approve strategies for the Development of each Collaboration Product; 

 

	 	(ii)	 review and endorse the initial Development Plan and Budget proposed by the Parties according to
Section 3.2; 

  

	 	(iii)	 review and agree the Development Plan as proposed by the Joint Development Team, including the Budget for a
Collaboration Product and authorize necessary updates or amendments thereto; 

  
 34 of 85 

 Execution Version 

 

	 	(iv)	 receive regular reports from the Joint Development Team on, and monitor, the conduct, progress and results of
each Party’s activities under the applicable Development Plan; 

  

	 	(v)	 agree in advance, review on a quarterly basis and approve the Shared Costs that the Parties are entitled to
incur in Phase B; 

  

	 	(vi)	 review and approve the regulatory strategies for each Collaboration Product in the Territory, including design
of the pivotal studies that are intended to support Marketing Approval in such territories and ensuring that such strategies are compatible; 

  

	 	(vii)	 review and discuss the goals and strategy for the manufacture of the Collaboration Product;

  

	 	(viii)	 approve protocols for, and prioritization of, clinical trials and indications for the Collaboration Product;

  

	 	(ix)	 review and approve the regulatory strategies for the Collaboration Product in the Territory;

  

	 	(x)	 review and endorse the goals and strategy for the Commercialization of the Collaboration Product as submitted
by the Joint Commercialization Committee and approve an initial Commercialization Plan for the Collaboration Product as well as oversee the Joint Commercialization Committee, once such is established; 

 

	 	(xi)	 review and endorse the overall IP strategy as prepared by the Joint IP Committee; 

 

	 	(xii)	 oversee and handle a Joint Divestment Process as set forth in Section 15.9; 

 

	 	(xiii)	 oversee the Joint Development Team and all subcommittees, if any, as deemed necessary; 

 

	 	(xiv)	 serve as the forum for the settlement of disputes or disagreements that are unresolved by the Joint Development
Team or any of the subcommittees; 

  

	 	(xv)	 approve the Collaboration Accounting Policies and the Travel Policy; 

 

	 	(xvi)	 resolve any issues referred to it by the Parties in accordance with Section 17.9, and

  

	 	(xvii)	 review the various possibilities and decide upon the nomination of a company for the development of companion
diagnostics, if any. 

  

	 	b.	 For the avoidance of doubt, the Joint Steering Committee shall have no responsibilities with respect to any
Unilateral Products. 

  
 35 of 85 

 Execution Version 

 

	 	c.	 Subcommittees. The Joint Steering Committee may, from time to time, establish subcommittees not already
dealt with pursuant to this Agreement. The Joint Steering Committee may determine the charter, composition and other provisions relating to any such subcommittee in its discretion. 

 

	 	d.	 Role after End of Development and Commercialization. The Joint Steering Committee shall continue to
operate after the end of all Development and/or Commercialization activities for the last Collaboration Product to the extent needed in order to deal with any subsequent issues. Following the end of such Development and/or Commercialization, the
Joint Steering Committee shall however not be obliged to convene at the times stipulated above, but merely when needed in order to address the issues at hand. Once the Joint Steering Committee unanimously decides that its responsibilities have been
exhausted, then the Joint Steering Committee may dissolve itself. 

  

	 	e.	 Meetings and Decisions of the Joint Steering Committee. Sections 8.2b and 8.2c shall apply mutatis
mutandis to the Joint Steering Committee. 

  

	8.4	 Joint Development Team. Concurrently with the establishment of the Joint Steering
Committee or as soon as possible after an additional Collaboration Product has been selected by the Joint Research Committee pursuant to Section 2.10, as applicable, on a Collaboration Product-by-Collaboration Product basis, the Parties shall – on a project level – establish a joint development team, to coordinate and implement all activities for the Development of a Collaboration
Product according to the Joint Development Plan (the Joint Development Team). One representative from each Party shall be designated as that Party’s Development Project Manager to act as the primary Joint Development
Team contact for that Party. The Joint Development Team shall consist of such number of representatives of each Party as are reasonably necessary to accomplish the goals of the Joint Development Team hereunder. Either Party may replace any or all of
its representatives at any time upon notice to the other Party 

  

	 	a.	 Joint Development Team Responsibilities. The Joint Development Team shall perform the following
functions: 

  

	 	(i)	 oversee and manage the work under, monitor the progress of, and implement the Development Plan, including
compliance with budget and timelines; 

  

	 	(ii)	 develop an overall strategy and detailed plans for the Development of Collaboration Product for review by the
Joint Steering Committee; 

  

	 	(iii)	 formulate any changes to the Development Plan (including allocation of Development activities between the
Parties) and the budget for review and approval by the Joint Steering Committee, such plan to always take into account the potential Development scenarios in the [***] year Development of the Collaboration Product, even to the extent such
Development scenarios extend beyond completion of the first Phase I/II Clinical Trial; 

  

	 	(iv)	 make recommendations for further Development of the Collaboration Product, including Development of the
Collaboration Product for indications that are not contemplated in the then current Development Plan; 

  

	 	(v)	 review forecasts of clinical supplies requirements for Development, review the supply of Collaboration Product
for Development; 

  
 36 of 85 

 Execution Version 

 

	 	(vi)	 discuss and exchange information regarding the conduct of ongoing clinical trials; 

 

	 	(vii)	 exchange information regarding the Collaboration Product and facilitate cooperation and coordination between
the Parties relating to the Development of the Collaboration Product as they exercise their respective rights and meet their respective obligations under the Development Plan and this Agreement; 

 

	 	(viii)	 provide status updates to the Joint Steering Committee regarding Development activities; and

  

	 	(ix)	 perform such other functions as appropriate to further the purposes of this Agreement as determined by the
Parties. 

  

	 	b.	 Meetings and Decisions of the Joint Development Team. Sections 8.2b and 8.2c shall apply mutatis
mutandis to the Joint Development Team, except for the fact that it is not the Alliance Manager, but instead the Development Project Manager of the current Party in the chair of the Joint Development Team that shall record the minutes of the
meeting in writing. Also, in the event that the Joint Development Team members do not reach consensus with respect to a matter that is within the purview of the Joint Development Team within [***] calendar days after they have met and attempted to
reach such consensus, such matter shall be presented to the Joint Steering Committee for resolution. 

  

	 	c.	 Duration of Joint Development Team Operations. The Joint Development Team will be in existence
commencing upon its date of formation and shall continue in existence until the date on which both Parties have completed all their activities as provided for in the Development Plan, unless the Joint Steering Committee agrees to extend the term
further. 

  

	8.5	 Joint Commercialization Committee. The Parties shall in due time during Phase B but no
later than thirty (30) days after initiation of the first Phase III Clinical Trial with respect to a Collaboration Product, establish a joint commercialization committee (Joint Commercialization Committee). The Joint
Commercialization Committee shall have a total of up to [***] members. Up to [***] members of a Joint Commercialization Committee shall be appointed by Genmab, and up to [***] members of a Joint Commercialization Committee shall be appointed by
Biontech. Each Joint Commercialization Committee member shall have sufficient authority to ensure acceptance and execution of Joint Commercialization Committee decisions within its organization. Each Party may appoint substitutes or alternates for
its Joint Commercialization Committee members at any time by written notice the other Party. The Parties may mutually agree to change the size of the Joint Commercialization Committee at any time. 

 

	 	a.	 Responsibilities of Joint Commercialization Committee. The Joint Commercialization Committee shall be
responsible for coordinating and supervising the Commercialization of the respective Collaboration Product. In particular, the Joint Commercialization Committee shall 

  
 37 of 85 

 Execution Version 

 

	 	(i)	 review and approve the Commercialization Plan and authorize necessary updates or amendments thereto,

  

	 	(ii)	 agree on the overall strategy for Commercialization of a Collaboration Product, including but not limited to
pricing and marketing matters, 

  

	 	(iii)	 review and approve the Shared Profits reported by the Parties in accordance with Section 7.7, and

  

	 	(iv)	 resolve any issues referred to it by the Parties in accordance with Section 17.9. 

 

	 	b.	 For the avoidance of doubt, the Joint Commercialization Committee shall have no responsibilities with respect
to any Unilateral Products. 

  

	 	c.	 Meetings and Decisions of the Joint Commercialization Committee. Sections 8.2b and 8.2c) shall apply
mutatis mutandis to the Joint Commercialization Committee. 

  

	8.6	 Costs. Each Party shall bear its own costs associated with its own personnel, the
preparation for, holding of, and participation in any meetings under this Section 8, travel time, travel expenses and other expenses relating to Alliance Managers, Joint Research Committee, Joint Steering Committee, Joint Development Team and
Joint Commercialization Committee meetings as well as the writing, reading and approving of minutes from such committee meetings. 

  

	9.	 INTELLECTUAL PROPERTY 

 

	9.1	 Ownership 

 

	 	a.	 Ownership of [***] Technology and [***] Technology. Genmab shall during the Term of this
Agreement and thereafter exclusively own all right, title and interest in and to the [***] Technology. Biontech shall during the Term of this Agreement and thereafter exclusively own all right, title and interest in and to the [***] Technology.

  

	 	b.	 Disclosure of Program Inventions. Each Party shall promptly disclose to the other Party the making,
conception or reduction to practice of any inventions directly arising out of activities conducted under this Agreement or the Prior Agreement (Program Inventions). 

 

	 	c.	 Ownership of [***] Inventions. All right, title and interest in all Program Inventions shall be
owned as follows:  

  

	 	(i)	 Except as set forth in subsections (ii) and (iii) below, Genmab and Biontech shall jointly own all [***]
Inventions (Collaboration IP). 

  

	 	(ii)	 Genmab shall own all [***] Inventions that are not [***] and that are invented solely or jointly by employees,
agents or consultants of Genmab and/or Biontech and solely relate to the [***] Technology ([***] Improvement Technology). To the extent that any such Program Inventions relating solely to the [***] Technology shall have been invented
by Biontech and/or are owned by Biontech, Biontech hereby assigns all of its right, title and interest therein to Genmab.  

  
 38 of 85 

 Execution Version 

 

	 	(iii)	 Biontech shall own all [***] Inventions that are not [***] and that are invented solely or jointly by
employees, agents or consultants of Genmab and/or Biontech and solely relate to the [***] Technology ([***] Improvement Technology). To the extent that any Program Inventions relating solely to the [***] Technology shall have been
invented by Genmab and/or are owned by Genmab, Genmab hereby assigns all of its right, title and interest therein to Biontech.  

  

	 	d.	 Terms of Joint Ownership. The Collaboration IP shall, subject to the terms and conditions of this
Agreement, be equally and undividedly owned by the Parties, but a Party cannot exploit or transfer its interest in the Collaboration IP, unless specifically permitted under this Agreement or otherwise agreed in writing. A Party shall not assign,
mortgage, sell or otherwise transfer or dispose of any of its right, title or interest in any Collaboration IP without the other Party’s prior written consent (not to be unreasonably withheld or delayed), save that such consent shall not be
required in respect of any transfer to: (a) an Affiliate of the Party; or (b) a Third Party successor or purchaser of all or substantially all of its business or assets to which the Agreement relates, whether in a merger, sale of stock,
sale of assets or other similar transaction; or (c) a Third Party that through a Divestment Process pursuant to the Agreement acquires, by purchase or license, rights to further develop or commercialize the related Collaboration Product;
provided that, in each case, any such transfer shall be made subject to the license granted to the other Party pursuant to the Agreement, as applicable, and that the Affiliate or Third Party, as applicable, agrees, by written notice to the other
Party, to be bound by the terms of such license and all other terms of this Agreement to the extent that such terms are applicable to the assigned Collaboration IP. Nothing herein shall entitle a Party to take any other action under the
Collaboration IP other than explicitly permitted in the Agreement, and the other Party is entitled to oppose any exploitation of the Collaboration IP falling outside the scope of the Agreement. Notwithstanding the above, the Parties may have an
interest in using the Collaboration IP outside the collaboration in combination with its own products such as for Biontech RNA vaccines, TLR ligands and/or cell therapies. Upon the request of a Party, the Joint Steering Committee or Joint Research
Committee, if no Joint Steering Committee is in place, shall arrange for negotiations in good faith of a license under the Collaboration IP for such purposes on reasonable terms. 

 

	 	e.	 Filing of Patent Applications. Unless otherwise agreed by the Joint IP Committee, any patent application
disclosing, covering or claiming Collaboration IP shall not be filed until the respective Clinical Candidate has been selected as a Collaboration Product. 

  

	 	f.	 Assignment of Collaboration IP following Completion of a Divestment Process. If a Non-Divesting Party is successful in negotiating an acquisition of the Divesting Party’s share of a Collaboration Product by the Non-Divesting Party in accordance with
Section 15, then the Non-Divesting Party shall be the sole owner going forward of the Collaboration IP related to such acquired Collaboration Product and the 

  
 39 of 85 

 Execution Version 

 

	 	
Divesting Party shall arrange for the transfer of (i) all of its rights, title and interest in any such Collaboration IP, and (ii) all substantive documentation pertaining to such
former Collaboration Product, if any. Following assignment of the applicable Collaboration IP to the Non-Divesting Party (the Assigned Patents), the Non-Divesting Party shall be solely
responsible for the further preparation, filing, prosecution and maintenance of any Assigned Patents at its own costs. The Divesting Party may negotiate in good faith licenses to use the Assigned Patents outside of the collaboration hereunder; the
last two sentences of Section 9.1d shall apply mutatis mutandis. Should the Continuing Party decide not to file or to abandon or let lapse an Assigned Patent regarding such Unilateral Product, the Continuing Party shall notify the Opt-Out Party of such decision at least [***] calendar days prior to the expiration of any deadline relating to such activities, and the Opt-Out Party shall thereafter have
the right, but not the obligation, to assume responsibility for filing, prosecuting and maintaining such Assigned Patent, at its sole expense. If the Opt-Out Party does elect to pursue such filing, prosecution
or maintenance of such Assigned Patent, then it shall notify the Continuing Party of such election, and the Continuing Party shall execute such documents of transfer or assignment and perform such acts as may be reasonably necessary to preserve and
transfer to the Opt-Out Party free of charge all its right, title and interest to any such Assigned Patent in such country. Biontech agrees and acknowledges that Genmab shall remain the sole owner of the
DuoBody Platform and the Inert Format Technology, and that any activities by Biontech as the Non-Divesting Party under this Section 9.1f that pertains to the DuoBody Platform and/or the Inert Format
Technology shall at all times be subject to Genmab’s prior consultation, review and written consent, such consent not to be unreasonably withheld. 

  

	 	g.	 Divestment to a Third Party. If the Divesting Party’s share of a Collaboration Product is divested
to a Third Party following a successful completion of a Divestment Process, the Non-Divesting Party will, unless otherwise agreed with the Third Party, be the Lead IP Party (as defined below) for any
Collaboration IP going forward. 

  

	 	h.	 Assignment of Collaboration IP for Unilateral Products. In case of an
opt-out pursuant to Section 14, the Continuing Party shall be the sole owner of Collaboration IP solely related to the relevant Unilateral Product. Such Collaboration IP shall be regarded as Assigned
Patents and Section 9.1f shall apply mutatis mutandis to such Collaboration IP. Biontech agrees and acknowledges that Genmab shall remain the sole owner of the DuoBody Platform and the [***] Technology, and that any activities by
Biontech as the Continuing Party under this Section 9.1h that pertains to the DuoBody Platform and/or the [***] Technology shall at all times be subject to Genmab’s prior consultation, review and written consent, such consent not to be
unreasonably withheld. 

  

	 	i.	 Ceased Products. With regards to Collaboration IP on Ceased Product(s), provided that such Ceased
Product(s) have not previously been a Collaboration Product for which Development has been ceased, the Parties agree to [***] 

  
 40 of 85 

 Execution Version 

 

	9.2	 License to Genmab. For the purpose of the Research under Phase A and subsequently on a
Collaboration Product-by-Collaboration Product basis and subject to the terms of this Agreement, Biontech hereby grants Genmab a worldwide, co-exclusive (with Biontech and subject to the exclusivities set forth in Section 6), royalty-free license, including the right to sublicense in the course of subcontracting (as approved by the Joint Steering
Committee), under the Biontech Technology to (a) perform its obligations hereunder with respect to activities under the Research Plan and each Collaboration Product in accordance with the relevant Development Plan, (b) to conclude
Partnership Agreements in accordance with the procedures set forth in Section 4.7 and (c) to research, Develop, have Developed, make, have made, import, use, offer for sale, have sold and sell such Collaboration Product within the Field in
the Territory. The license for a Collaboration Product shall continue, on a country-by-country basis, for so long as there are Development or Commercialization
activities contemplated. Biontech hereby agrees and acknowledges that Genmab has granted a sublicense for the purpose of performing the Research Plan and further Development activities to its wholly owned subsidiary, Genmab B.V., the Netherlands.

  

	9.3	 License to Biontech. For the purpose of the Research under Phase A and subsequently on a
Collaboration Product-by-Collaboration Product basis and subject to the terms of this Agreement, Genmab hereby grants to Biontech a worldwide, co-exclusive (with Genmab and subject to the exclusivities set forth in Section 6), royalty-free license, including the right to sublicense in the course of subcontracting (as approved by the Joint Steering
Committee), under the Genmab Technology to (a) perform its obligations hereunder with respect to activities under the Research Plan and each Collaboration Product in accordance with the relevant Development Plan, (b) to conclude
Partnership Agreements in accordance with the procedures set forth in Section 4.7 and (c) to research, Develop, have Developed, make, have made, import, use, offer for sale, have sold and sell such Collaboration Product within the Field in
the Territory. The license for a Collaboration Product shall continue, on a country-by-country basis, for so long as there are Development or Commercialization
activities contemplated. The licenses granted to Biontech under this Section 9.3 with regards to the DuoBody Platform are only granted for the [***]. Use of other [***] under the DuoBody Platform can only take place upon Genmab’s prior
written consent. The license granted under the Inert Format Technology is to the embodiment wherein the [***] 

  

	9.4	 No Further Rights. This Agreement shall not be construed to convey any right or license to
Biontech to use and/or exploit the Genmab Technology or to Genmab to use and/or exploit the Biontech Technology except as specifically stipulated in this Agreement. 

 

	9.5	 Joint IP Committee. 

 

	 	a.	 Within [***] days of the Effective Date, the Parties shall establish a joint IP committee (the Joint IP
Committee). The Joint IP Committee shall have a total of [***] members. [***] members of the Joint IP Committee shall be appointed by Genmab, and [***] members of the Joint IP Committee shall be appointed by Biontech. Each Joint IP Committee
member shall have sufficient authority to ensure acceptance and execution of Joint IP Committee decisions within its organization. Each Party may appoint substitutes or alternates for its Joint IP Committee members at any time by written notice the
other Party. The Parties may mutually agree to change the size of the Joint IP Committee at any time. 

  
 41 of 85 

 Execution Version 

 

	 	b.	 The Joint IP Committee shall convene with no less than [***] weeks’ notice unless shorter notice is
required under the circumstances, for example in order to allow the Lead IP Party necessary time to act towards the authorities. The Joint IP Committee shall hold meetings at least [***] times per year, or as otherwise agreed in writing between the
Parties. Unless otherwise agreed in writing, such meetings shall alternate between a location selected by Genmab and a location selected by Biontech or take place via telephone or video conference or such other means as may be agreed in writing
between the Parties. The meetings shall be prepared and convened by the chairman of the Joint IP Committee. The chair shall alternate at [***] month intervals between representatives of each Party, starting with a Genmab representative as the chair.
Within [***] of every meeting, the chairman shall prepare and send minutes of the meeting to the other members of the Joint IP Committee. The minutes shall be considered as approved by the members of the Joint IP Committee, unless the chairman has
received objections and/or comments to the minutes within [***] after the minutes have been sent to the members of the Joint IP Committee. With respect to the decisions of the Joint IP Committee and costs, Sections 8.2c and 8.6 shall apply
mutatis mutandis. 

  

	 	c.	 The Joint IP Committee shall prepare an overall IP strategy for all Collaboration IP to be endorsed by the
Joint Steering Committee. In particular, the Joint IP Committee shall discuss and decide on all material issues pertaining to the governance of the Collaboration IP, including, but not limited to, the filing, prosecution, maintenance, defense and/or
enforcement of the Collaboration IP, and shall agree on the IP Budget related thereto in accordance with the procedures set forth in Section 9.6d. 

  

	 	d.	 The decisions of the Joint IP Committee shall be binding on the Parties to the extent they pertain to the
overall IP strategy and the governance of the Collaboration IP. In all other respects, the Joint IP Committee may make recommendations which shall not be binding on the Parties, but the Parties shall take due account of these recommendations when
performing their rights and obligations set forth in this Agreement. 

  

	9.6	 Lead IP Party 

 

	 	a.	 Designation of Lead IP Party. The Parties agree that it is appropriate to designate one of the Parties
to be responsible for (i) implementing the decisions of the Joint IP Committee, (ii) taking emergency measures in order to prosecute, maintain and defend the Collaboration IP , provided that such measures are of a preliminary nature where
possible and shall be reviewed and approved by the Joint IP Committee without undue delay, and (iii) to act as the common representative towards the applicable authorities (such Party to be referred to as the Lead IP Party). The
Joint IP Committee shall appoint a Lead IP Party for each Program Invention which is part of the Collaboration IP, taking into consideration the capabilities of each Party’s IP department and each Party’s specific expertise with respect to
the relevant Program Invention. 

  
 42 of 85 

 Execution Version 

 

	 	b.	 Power of Attorney. The Lead IP Party is hereby granted by the other Party (the Non-Lead Party) a power of attorney to conduct all such acts which rest with the Lead IP Party as specified in these terms. The Lead IP Party is only authorized to act within the frames of the overall IP
strategy as adopted by the Joint IP Committee and all other decisions of the Joint IP Committee pertaining to the governance of the Collaboration IP. Unless otherwise agreed in writing, the Lead IP Party shall be responsible during the Term of the
Agreement. 

  

	 	c.	 Responsibilities of the Lead IP Party. The Lead IP Party shall – within the scope of its
appointment by the Joint IP Committee – be responsible for the preparation, filing, prosecution and/or maintenance of Joint Patents and/or, if applicable, any other Collaboration IP in accordance with the decisions of the Joint IP Committee and
subject always to Section 9.8c. In particular, the Lead IP Party shall, in each case in accordance with the decisions of the Joint IP Committee: 

  

	 	(i)	 prepare and file applications, including without limitation divisional applications, continuation applications,
continuation-in-part applications, and RCEs, relating to the Collaboration IP, including without limitation any Joint Patents, with applicable intellectual property
office(s) or authority(ies); 

  

	 	(ii)	 maintain Joint Patents and/or, if applicable, any other Collaboration IP, including without limitation taking
such steps as may be reasonably necessary to ensure possible patent term extensions, renewals, supplementary protection certificates etc. in respect of Joint Patents; 

 

	 	(iii)	 prosecute Joint Patents and/or, if applicable, any other Collaboration IP with national and/or regional
intellectual property offices, including appeal to the courts, and prosecution hereof; 

  

	 	(iv)	 coordinate the payment of maintenance fees and other official fees or costs with national and/or regional
intellectual property offices in respect of Joint Patents and/or, if applicable, any other Collaboration IP, and ensure that all maintenance fees are paid promptly when due, unless otherwise agreed in writing between the Parties; and

  

	 	(v)	 provide the Joint IP Committee with all material information, and copies of material correspondence to and from
patent/intellectual property offices and external patent attorneys and agents, pertaining to the filing, prosecution and maintenance of the Joint Patents and/or, if applicable, any other Collaboration IP, for review and approval. All patent filings
have to be submitted to the Joint IP Committee as soon as possible before the filing date, if possible. 

  

	 	d.	 IP Budget. The Lead IP Party shall prepare (and continuously update as appropriate) a yearly budget for
implementation of the overall IP strategy and the governance of the Collaboration IP (hereinafter, the IP Budget). The IP Budget shall be sent to the Joint IP Committee in due time to enable the Joint IP Committee to discuss and agree
on the IP Budget for the coming calendar year at a meeting that shall take place at least [***] months before the end of the previous year. 

  
 43 of 85 

 Execution Version 

 

	 	e.	 The Parties agree to act in good faith toward each other and to cooperate fully with each other in relation to
the filing, prosecution and maintenance of the Joint Patents and/or, if applicable, any other Collaboration IP taking into consideration that both Parties have ownership interests in such intellectual property rights. In case of a dispute, the
matter shall be referred to the Joint IP Committee, which in turn shall refer any unresolved matter to the Joint Steering Committee. In case actions need to be taken during such dispute period to prevent Joint Patents from going abandoned, the Lead
IP Party shall have final decision-making authority taking into due account the dispute and making efforts to keep status quo to the extent possible. 

  

	 	f.	 Assistance. The Non-Lead Party shall, as reasonably requested by
the Lead IP Party, assist the Lead IP Party and the Lead IP Party’s external patent counsel (if applicable) in the preparation, filing, prosecution and/or maintenance of Joint Patents and/or, if applicable, any other Collaboration IP, and the
Parties shall cooperate with one another jointly to maintain the Joint Patents and/or, if applicable, any other Collaboration IP in force. The Parties shall perform such acts, execute such further instruments, documents or certificates, and provide
such cooperation and assistance as may be reasonably requested by the other Party in order to give effect to the terms of Section 9.6. Such assistance shall be deemed Shared Costs for the purposes of this Agreement. 

 

	9.7	 Inventor Compensation. Each Party shall be responsible for payment of any
consideration which it is required to pay to its employees or independent consultants or subcontractors as compensation for the assignment of rights to any Program Invention according to the legal provisions applicable in the relevant country and/or
a contractual obligation. 

  

	9.8	 Patent Prosecution and Maintenance 

 

	 	a.	 Biontech Patents. Biontech shall be solely responsible for and shall solely control the preparation,
filing, prosecution, grant, maintenance and defense of all Biontech Patents excluding Biontech’s share in Joint Patents. Biontech shall, at its sole expense, prepare, file, prosecute and maintain such Biontech Patents in good faith consistent
with its customary patent policy and its reasonable business judgment, and shall consider in good faith the interests of Genmab in so doing. 

  

	 	b.	 Genmab Patents. Genmab shall be solely responsible for and shall solely control the preparation, filing,
prosecution, grant, maintenance and defense of all Genmab Patents excluding Genmab’s share in Joint Patents. Genmab shall, at its sole expense, prepare, file, prosecute and maintain such Genmab Patents in good faith consistent with its
customary patent policy and its reasonable business judgment, and shall consider in good faith the interests of Biontech in so doing. 

  

	 	c.	 Collaboration IP. The Parties shall be jointly responsible and shall jointly control the preparation,
filing, prosecution, grant, maintenance and defense of all Joint Patents and/or, if applicable, any other Collaboration IP, through the Joint IP Committee and the Lead IP Party, in accordance with the provisions of Section 9.5 and
Section 9.6. Unless otherwise agreed upon in writing between the Parties, any application for a Joint Patent and/or, if applicable, any other Collaboration IP shall be filed under the name of both Parties. 

  
 44 of 85 

 Execution Version 

 

	 	d.	 Common Interest Disclosures. With regard to any information or opinions disclosed pursuant to
this Agreement by one Party to the other regarding intellectual property and/or technology owned by Third Parties, Biontech or Genmab (or their respective Affiliates), Biontech and Genmab agree that they have a common legal interest in coordinating
prosecution of their respective patent applications, as set forth in this Section 9, and in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the development, manufacturing, marketing
and/or sale of Collaboration Products and Unilateral Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights
relating to the development, manufacturing, marketing and/or sale of Collaboration Products and Unilateral Products. Accordingly, Biontech and Genmab agree that all such information and opinions obtained by Biontech and Genmab from each other will
be used solely for purposes of the Parties’ common legal interests with respect to the conduct of the Agreement. All information and opinions will be treated as protected by the attorney-client privilege,
the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and opinions, neither Party intends to waive or limit any privilege or immunity that may apply to the shared
information and opinions. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the
conduct of one Party be deemed to apply against any other Party. 

  

	9.9	 Enforcement of Patents 

 

	 	a.	 Notification. Each Party shall promptly inform the other Party in writing of any allegation(s) or
claim(s) from or proceeding(s) initiated by a Third Party which comes to its attention and which challenges the validity or enforceability of, or the Parties’ entitlement to, either Genmab Technology, Biontech Technology or any Collaboration
IP, to the extent relevant for a Collaboration Product or a Unilateral Product for which the other Party is responsible, including without limitation (if applicable) pre-grant opposition, post-grant
opposition, re-examination, interference or revocation proceedings (whether before any applicable intellectual property office or the courts), and shall provide the other Party with any available evidence
thereof. 

  

	 	b.	 Enforcement of [***] Patents. [***] shall have the sole right, at its sole expense, but not the
obligation, to determine the appropriate course of action to enforce the [***] Patents (other than its interests in the Joint Patents) or otherwise abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce such
[***] Patents, to control any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation or other enforcement action with respect to the [***] Patents so long as this does not adversely affect
[***]’s rights under this Agreement. [***] shall fully cooperate with [***], at [***]’s sole expense, in any action to enforce the [***] Patents. All monies recovered upon the final judgment or settlement of any such suit to enforce such
[***] Patents shall be retained by [***]. 

  
 45 of 85 

 Execution Version 

 

	 	c.	 Enforcement of [***] Patents. [***] shall have the sole right, at its sole expense, to determine
the appropriate course of action to enforce [***] Patents (other than its interest in Joint Patents), or otherwise to abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce such [***] Patents, to control any
litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation or other enforcement action with respect to such [***] Patents. All monies recovered upon the final judgment or settlement of any such suit to
enforce such [***] Patents shall be retained by [***]. [***] shall fully cooperate with [***], at [***]’s sole expense, in any action to enforce the [***] Patents. 

 

	 	d.	 Enforcement of Joint Patents. 

 

	 	(i)	 If a Party becomes aware of any actual or suspected infringement or unauthorized use by a Third Party of any
Collaboration IP, then such Party shall promptly notify the other Party in writing of all the relevant facts and circumstances in connection with such infringement or unauthorized use known to that Party and shall provide the other Party with all
available evidence supporting such infringement or unauthorized use. 

  

	 	(ii)	 The Joint IP Committee shall determine any required or desirable action to any such Third Party infringement,
which action shall be then be implemented by the Lead IP Party (Infringement Proceedings). The Parties shall share equally (50:50) all costs, both internally and externally, associated with any such joint Infringement Proceedings,
unless otherwise agreed in writing. The Parties shall also share equally (50:50) any damages, royalties, settlement fees or other consideration resulting from any such joint Infringement Proceedings, unless otherwise agreed in writing.

  

	 	(iii)	 The Lead IP Party shall keep the Non-Lead Party informed of the status
of any such joint Infringement Proceedings and, upon request, shall (to the extent permitted under applicable law) provide the Non-Lead Party, at no cost to the Non-Lead
Party, with copies of all documents filed in, and all material written communications between the parties relating to, such Infringement Proceedings. The Non-Lead Party shall, at the Lead IP Party’s
request, give the Lead Party all reasonable assistance in any such joint Infringement Proceedings. 

  

	 	(iv)	 No settlement shall be entered into by the Lead IP Party without the prior written consent of the Non-Lead Party (such consent not to be unreasonably withheld or delayed). 

  

	9.10	 Assignment of Inventor’s Rights. To the extent the
assignment of inventions is not effected by statutory law (e.g. the German Employees’ Inventions Act), each Party will maintain valid and enforceable written agreements with all persons acting by or on behalf of such Party or its Affiliates
which require such person to assign to such Party their entire right, title and interest in and to all Collaboration IP, Biontech Improvement Technology (in case of Genmab) and Genmab Improvement Technology (in case of Biontech). Each Party agrees
to claim and keep valid and enforceable any invention relating to any Collaboration IP, Biontech Improvement Technology (in case of Genmab) and Genmab Improvement Technology (in case of Biontech) conceived, reduced to practice, developed, made or
created in the conduct of the activities under this Agreement. 

  
 46 of 85 

 Execution Version 

 

	9.11	 Product Trademarks. With regards to Collaboration Product(s), the Parties shall propose
and through the Joint Steering Committee select the trademark, trade dress, logos and slogans under which each Collaboration Product shall be exclusively marketed (each a Collaboration Product Trademark). Such activities shall be
handled by the Lead Commercialization Party of such Region. The Lead Commercialization Party shall register the Collaboration Product Trademark and shall take all such actions as are required to continue and maintain in full force and effect the
trademarks and the registrations thereof as well as enforce such trademarks and registrations. The Parties shall jointly own the trademarks which are specifically directed to Collaboration Products and the other Party shall execute all documents and
take all actions as are reasonably requested by the Lead Commercialization Party to effectuate such joint ownership in such trademarks unless such joint ownership would not be practicable in any such jurisdiction, in which case the Lead
Commercialization Party for the applicable Region shall have sole ownership. Collaboration Product Trademarks shall be used only pursuant to the terms of this Agreement and the Commercialization Agreement to identify, and in connection with the
marketing of, Collaboration Products and shall not be used by either Party to identify, or in connection with the marketing of, any other products. In case a Party Divests its share of a Collaboration Product to the other Party, it shall be obliged
to assign its title to and interest in the Collaboration Product Trademarks to the other Party free of charge, provided the other Party pays the out-of-pocket costs of
assignment. 

  

	10.	 INFRINGEMENT ACTIONS BROUGHT BY THIRD PARTIES 

 

	10.1	 Third Party License. Each Party shall promptly inform the other Party in writing if it
deems that a license of any intellectual property rights owned or Controlled by a Third Party is needed to Commercialize a Collaboration Product or a Unilateral Product for which the other Party is responsible (FTO Notification). If
the FTO Notification concerns a Collaboration Product, the Parties will discuss and agree any required or advisable measures in the Joint IP Committee and/or the relevant Joint Steering Committee. If the FTO Notification concerns a Unilateral
Product, the respective Continuing Party shall be solely responsible for the course of action but will closely consult with the respective Opt-Out Party. 

 

	10.2	 Collaboration Product. Each Party will notify the other Party in writing if it becomes
aware of any Third Party alleging that the performance of this Agreement infringes Third Party intellectual property rights (Infringement Attack). If an Infringement Attack is directed against the manufacture, use, handling, storage,
Development, Commercialization or other disposition of a Collaboration Product, the Parties shall consult in good faith through the Joint IP Committee with a view to agreeing any required or desirable defense to any such Infringement Attack. Each
Party shall have the right to defend itself against the Infringement Attack in accordance with the decisions and instructions of the Joint IP Committee. Notwithstanding the preceding sentence, Genmab shall be solely responsible for the defense
against Infringement Attacks directed against the use of [***] Technology [***] and Biontech shall be solely responsible for the defense against Infringement Attacks directed against the use of [***] Technology [***], in both scenarios in close
consultation with the other Party. In no event may a Party settle or otherwise consent to an adverse judgment that diminishes the rights or interests of the other Party without the express written consent of the other Party not to be unreasonably
withheld. 

  
 47 of 85 

 Execution Version 

 

	10.3	 Defense Costs. If the alleged infringement relates to a Collaboration Product and is not
subject to an indemnification pursuant to Section 13.2a, all reasonable costs associated with the defense of the Infringement Attack and approved by the Joint IP Committee, including any payment due to such Third Party as damages or in
settlement allocated to sales of the Collaboration Product, will be shared equally (50:50) between the Parties as part of the Shared Costs. Each Party will individually bear the risks and costs of infringing Third Party patents for its activities
which are outside the scope of this Agreement. 

  

	10.4	 Genmab Unilateral Product. If an Infringement Attack is directed against the manufacture,
use, handling, storage, development, commercialization or other disposition of a Genmab Unilateral Product, Genmab shall be solely responsible for the defense and all costs associated therewith, except that: 

 

	 	a.	 this shall be carried out in close consultation with Biontech, unless instructed otherwise in writing by
Biontech; and 

  

	 	b.	 Biontech shall have the first right to control at its sole cost the defense against such Infringement
Attack to the extent it is directed against the use of Biontech Technology, provided that Genmab shall be entitled to participate in such defense. If Biontech chooses not to defend against Infringement Attacks related to the Biontech Technology,
then Genmab shall have the right to control such defense on its own. 

  

	10.5	 Biontech Unilateral Product. If an Infringement Attack is directed against the
manufacture, use, handling, storage, development, commercialization or other disposition of a Biontech Unilateral Product, Biontech shall be solely responsible for the defense and all costs associated therewith, except that: 

 

	 	a.	 this shall be carried out in close consultation with Genmab, unless instructed otherwise in writing by Genmab;
and 

  

	 	b.	 Genmab shall have the first right to control at its sole cost the defense against such Infringement
Attack to the extent it is directed against the use of Genmab Technology, provided that Biontech shall be entitled to participate in such defense. If Genmab chooses not to defend against Infringement Attacks related to the Genmab Technology, then
Biontech shall have the right to control such defense on its own. 

  

	11.	 CONFIDENTIALITY 

 

	11.1	 Confidentiality and Restricted Use. Each Party (Receiving Party)
shall protect the Confidential Information of the other Party (Disclosing Party) from unauthorized use or disclosure and use at least the same standard of care as it uses to protect its own Confidential Information and to make sure
that its and its Affiliates’ employees, agents, consultant and clinical investigators only make use of the Disclosing Party’s Confidential Information for the purposes expressly authorized or contemplated by this Agreement.

  
 48 of 85 

 Execution Version 

 

	11.2	 Disclosure to Third Parties. Neither Party shall, except with the express prior
written consent of the Disclosing Party, disclose any Confidential Information of the Disclosing Party to any person or entity other than its officers, directors, employees, agents, consultants, Sublicensees and Approved Subcontractors who need to
know such information for the performance of this Agreement and who are bound by a written confidentiality agreement not less stringent than the terms of this Agreement or by professional rules of secrecy. 

 

	11.3	 Permitted Disclosures. The above confidentiality obligations shall not apply to
information which, as can be established by the Receiving Party,  

  

	 	a.	 was rightfully communicated to the Receiving Party from a Third Party; or 

 

	 	b.	 was already in the public domain or subsequently entered the public domain through no fault of the Receiving
Party and its Affiliates; or 

  

	 	c.	 was already known by the Receiving Party before the effective date of the Prior Agreement or developed
independently by the Receiving Party without reference to or reliance upon Confidential Information provided by the Disclosing Party; or 

  

	 	d.	 is to be disclosed pursuant to any Applicable Law or legal, regulatory or stock exchange requirement, provided
that the Receiving Party shall wherever possible provide prior written notice of such disclosure to the Disclosing Party and take reasonable and lawful actions to avoid or minimize the degree of disclosure. The Parties agree that nothing in this
Section 11.3d is intended to require a Party to not comply with any Applicable Law; or 

  

	 	e.	 are required to be disclosed solely to the extent reasonably necessary in a patent application claiming Program
Inventions made hereunder to be filed with the United States Patent and Trademark Office and/or any similar foreign agency, provided that the Party filing the patent shall provide at least thirty (30) days prior written notice of such
disclosure to the other Party and take reasonable and lawful actions to avoid or minimize the degree of disclosure. 

  

	11.4	 Terms of the Agreement. Genmab and Biontech shall not disclose the existence of nor any
terms or conditions of this Agreement to any Third Party without the prior consent of the other Party, except as required by Applicable Law or to comply with rules of a securities exchange or regulatory authority, in which case the Disclosing Party
shall to the extent possible provide notice to the other Party and take reasonable and lawful actions to avoid or minimize the degree of such disclosures. Notwithstanding the foregoing, each Party may disclose the existence of and terms and
conditions of this Agreement, without such consent, to advisors, existing and potential investors, licensees, assignees and/or acquirers on a need to know basis under circumstances that reasonably ensure the confidentiality thereof.

  
 49 of 85 

 Execution Version 

 

	11.5	 Press releases, references. Upon execution of this Agreement, Genmab will issue a company
announcement and Biontech intends to issue an initial media release the wordings of such announcement and release have been approved by the Parties and are set forth in Exhibit 7. In addition, each Party shall be entitled to disclose the other
Party’s name as collaboration partner under this Agreement to Third Parties and use the other Party’s name solely for such purposes. All other use of the other Party’s name in any advertising or promotional material, or any other
publicity relating to this Agreement, shall require the other Party’s prior written consent. Except for the initial media release and company announcement permitted above, neither Biontech nor Genmab will, without the prior consent of the
other, issue any press release or make any other public announcement or furnish any statement to any person or entity (other than either Parties’ respective Affiliates) concerning the existence of this Agreement, its terms and the transactions
contemplated hereby, except for disclosures expressly permitted hereunder. 

  

	11.6	 Publication regarding Collaboration Products. The Parties shall only jointly make
publications regarding any Collaboration Product(s). Neither Party may on its own publish, present or announce results of Collaboration Products developed hereunder either orally or in writing (a Publication) without complying with the
provisions of this Section 11.6. The other Party shall have [***] days from receipt of a proposed Publication to provide comments and/or proposed changes to the publishing Party. The publishing Party shall take into account the comments and/or
proposed changes made by the other Party on any Publication and shall agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which
such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential
Information and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties shall be delayed for such period as may be reasonably necessary for
deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), and/or the drafting and filing of a patent application covering such invention, provided such additional
period shall not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. For clarity, Section 11.3d, but not this Section 11.6, is intended to apply to any announcements required by
either Party under Applicable Law, including but not limited to notifications to the relevant stock exchanges. 

  

	11.7	 Publication regarding Unilateral Products. A Continuing Party may on its own make a
Publication on a Unilateral Product developed hereunder. However, the Opt-Out Party shall have [***] days from receipt of a proposed Publication to provide comments and/or proposed changes to the Continuing
Party. To the extent such comments and/or proposed changes pertain to the Opt-Out Party’s technology, the Continuing Party shall take into account the comments and/or proposed changes made by the Opt-Out Party on any Publication. If the Opt-Out Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential
Information and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties shall be delayed for such period as may be reasonably necessary for
deleting any such Confidential Information of the Opt-Out Party (if such Party has requested deletion thereof from the 

  
 50 of 85 

 Execution Version 

 

 
proposed Publication), and/or the drafting and filing of a patent application covering such invention, provided such additional period shall not exceed [***] days from the date the Continuing
Party first provided the proposed Publication to the Opt-Out Party. For clarity, Section 11.3d, but not this Section 11.7, is intended to apply to any announcements required by either Party under
Applicable Law, including but not limited to notifications to the relevant stock exchanges. 
  

	11.8	 Prior Agreement. As of the Effective Date, the above confidentiality obligations shall
supersede any oral or written confidentiality agreements concluded between the Parties prior to this Agreement. As far as under such prior confidentiality agreement or the Prior Agreement information has already been exchanged, the above provisions
of this Section 11 shall apply also to such information. 

  

	12.	 REPRESENTATIONS AND WARRANTIES 

 

	12.1	 Mutual Representations and Warranties. Each Party hereby represents and warrants to the
other Party that 

  

	 	a.	 it has the legal right to enter into and deliver this Agreement and constitutes the valid and binding
obligation of each Party; 

  

	 	b.	 the execution, delivery and performance of this Agreement as well as the licenses granted hereunder do not
conflict with any agreement, instrument or understanding, oral or written, to which such Party may be bound. 

  

	12.2	 Biontech Representations and Warranties. Biontech represents and warrants that as of the
Effective Date: 

  

	 	a.	 it has the right to grant the licenses granted herein; 

 

	 	b.	 the Biontech Technology licensed hereunder is free and clear of any security interests, claims, encumbrances or
charges of any kind; 

  

	 	c.	 it has not assigned and/or granted licenses, nor shall it assign and/or grant licenses under the Biontech
Technology to any Third Party that would restrict or impair the rights granted to Genmab hereunder; 

  

	 	d.	 to its actual knowledge no Third Party has infringed the Biontech Technology; 

 

	 	e.	 it has not received any written notice of (i) any claim that any patent or trade secret right owned or
Controlled by a Third Party would be infringed or misappropriated by the manufacture, use, sale, offer for sale or importation of Biontech Antibodies or Collaboration Products or Unilateral Products containing Biontech Antibodies, or (ii) any
threatened administrative proceedings or litigation seeking to invalidate or otherwise challenge the Biontech Patents; 

  

	 	f.	 none of the Biontech Patents are the subject of any pending
re-examination, opposition, interference or litigation proceedings; and 

  
 51 of 85 

 Execution Version 

 

	 	g.	 to the best of its knowledge it has provided all the necessary licenses under the Biontech Technology herein to
ensure the anticipated Development and Commercialization of Collaboration Products and the development and commercialization of Unilateral Products. 

  

	12.3	 Genmab Representations and Warranties. Genmab represents and warrants that as of the
Effective Date: 

  

	 	a.	 it has the right to grant the licenses granted herein; 

 

	 	b.	 the Genmab Technology licensed hereunder is free and clear of any security interests, claims, encumbrances or
charges of any kind; 

  

	 	c.	 it has not assigned and/or granted licenses, nor shall it assign and/or grant licenses under the Genmab
Technology to any Third Party that would restrict or impair the rights granted to Biontech hereunder; 

  

	 	d.	 to its actual knowledge no Third Party has infringed the Genmab Technology; 

 

	 	e.	 it has not received any written notice of (i) any claim that any patent or trade secret right owned or
Controlled by a Third Party would be infringed or misappropriated by the manufacture, use, sale, offer for sale or importation of the Genmab Antibodies, Collaboration Products or Unilateral Products containing Genmab Antibodies, the DuoBody
Platform, or the Inert Format Technology (the DuoBody Platform and the Inert Format Technology as used with the preferred mutation and embodiment) or (ii) any threatened administrative proceedings or litigation seeking to invalidate or
otherwise challenge the Genmab Patents; 

  

	 	f.	 none of the Genmab Patents are the subject of any pending
re-examination, opposition, interference or litigation proceedings; and 

  

	 	g.	 to the best of its knowledge it has provided all the necessary licenses under the Genmab Technology herein to
ensure the anticipated Development and Commercialization of Collaboration Products or the development and commercialization of Unilateral Products. 

  

	12.4	 Covenant. Each Party covenants to the other Party that it will not include any additional
intellectual property rights owned or Controlled by it or its Affiliates not currently included in the licenses granted under this Agreement in any Clinical Candidate or Collaboration Product without the prior written consent of the other Party. If
such consent is not sought or obtained, then any additional intellectual property rights included anyway shall be licensed to the other Party on a free and perpetual basis. 

 

	12.5	 Disclaimers. The Parties acknowledge and agree that the research and development to be
conducted under this Agreement is experimental in nature, and that neither Party can guarantee a successful outcome thereof. Except as expressly provided in this Agreement, the know-how, Confidential
Information and intellectual property rights provided by each Party are provided “as is” and except as otherwise expressly set forth herein, neither Party makes any representations or extends any warranties of any kind, either express or
implied, to the other Party, and each Party hereby disclaims all implied warranties, including warranties of merchantability, fitness for a particular purpose or non-infringement. 

  
 52 of 85 

 Execution Version 

 

	13.	 INDEMNITY and LIMITATION of LIABILITY 

 

	13.1	 Indemnity for Unilateral Products 

 

	 	a.	 With respect to Unilateral Products, each Party shall defend, indemnify and hold harmless the other Party, its
Affiliates and their respective directors, officers, employees and agents (collectively, the Indemnitees) from and against all liabilities, losses, damages, and expenses, including reasonable attorneys’ fees and costs,
(collectively, the Liabilities) resulting from all Third Party claims, suits, actions, terminations or demands (collectively, the Claims) that are incurred, relate to or arise out of (a) the material breach of any
material provision of this Agreement by the indemnifying Party, including [***] made by such Party in this Agreement, or (b) the gross negligence, recklessness or wilful misconduct of the indemnifying Party in connection with the performance of
its obligations hereunder. 

  

	 	b.	 Genmab shall defend, indemnify and hold harmless the Biontech Indemnitees from and against all Liabilities
resulting from all Claims that are incurred, relate to or arise out of the development, manufacture or commercialization of Genmab Unilateral Products by Genmab, its Affiliates or Sublicensees; except to the extent such Liabilities must be
indemnified by Biontech pursuant to Sections 13.1a. 

  

	 	c.	 Biontech shall defend, indemnify and hold harmless the Genmab Indemnitees from and against all Liabilities
resulting from all Claims that are incurred, relate to or arise out of the development, manufacture or commercialization of Biontech Unilateral Products by Biontech, its Affiliates or Sublicensees; except to the extent such Liabilities must be
indemnified by Genmab pursuant to Sections 13.1a. 

  

	13.2	 Indemnity for Collaboration Products 

 

	 	a.	 Each Party hereby agrees to indemnify, defend, and hold harmless the other Party’s Indemnitees from and
against any and all Liabilities, incurred as a result of any Claims relating to the manufacture, use, handling, storage, Development, Commercialization or other disposition of any Collaboration Product by the indemnifying Party, its Affiliates,
employees, agents or Sublicensees, but only to the extent such Claims result from: (a) the gross negligence, recklessness or wilful misconduct of the indemnifying Party, its Affiliates, employees, agents or Sublicensees; or (b) any
material breach by the indemnifying Party of any material provision of this Agreement, including a [***] made by such Party in this Agreement; except, in each case, to the extent of any such Claim resulting from the gross negligence or willful
misconduct of the Indemnitees. 

  

	 	b.	 Except for those Claims subject to Section 13.2a, the Parties shall share equally any Liabilities in
connection with any Claim brought against either Party by a Third Party resulting directly or indirectly from the manufacture, use, handling, storage, Development, Commercialization or other disposition of any given Collaboration Product.

  
 53 of 85 

 Execution Version 

 

	 	c.	 If either Party receives notice of a Claim with respect to any Collaboration Product, such Party shall inform
the other Party in writing as soon as reasonably practicable. The Parties shall confer through the Joint Steering Committee how to respond to the Claim and how to handle the Claim in an efficient manner. In the absence of such an agreement, each
Party shall have the right to take such action as it deems appropriate, subject to Section 13.3. 

  

	 	d.	 For the avoidance of doubt, defense against Infringement Attacks shall be solely subject to Section 10.

  

	13.3	 Procedure. A Party (the Indemnified Party) that intends to claim
indemnification under this Section 13 shall promptly provide notice to the other Party (the Indemnitor) of any Liability or action in respect of which the Indemnified Party intends to claim such indemnification, which notice shall
include a reasonable identification of the alleged facts giving rise to such Liability, and the Indemnitor shall have the right to control and participate in, and, to the extent the Indemnitor so desires, jointly with any other Indemnitor similarly
noticed, to assume the defense thereof with counsel selected by the Indemnitor. However, notwithstanding the foregoing, the Indemnified Party shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnified
Party, unless the representation of such Indemnified Party by the counsel retained by the Indemnitor would be inappropriate due to actual differing interests between such Indemnified Party and any other party represented by such counsel in such
proceedings, in which case the reasonable fees and expenses shall be paid by the Indemnitor. The Indemnified Party cannot settle any Liability for which it intends to claim indemnification by the Indemnitor without the prior written consent of the
Indemnitor. Any settlement of a Liability for which any Indemnified Party seeks to be indemnified, defended or held harmless under this Section 13 that could adversely affect the Indemnified Party shall be subject to prior consent of such
Indemnified Party, provided that such consent shall not be withheld unreasonably. 

  

	13.4	 No Liability for Indirect Losses. Neither Party shall be
liable to the other, whether in tort, contract or otherwise, for any consequential, indirect, punitive, exemplary or incidental damages, lost profits or lost business opportunities. The provisions of this Section 13.4 shall not apply to cases
of wilful misconduct, any breach of [***], or any breach of [***]. 

  

	14.	 OPT-OUT 

 

	14.1	 Opt-Out Options. No later than thirty
(30) calendar days after either Proposed IND Submission or Establishment of Clinical Proof of Concept (the Opt-Out Points), as applicable, and on a Collaboration Product-by-Collaboration Product basis, each Party (the Opt-Out Party) shall have the right to provide the other Party
with irrevocable (subject to Section 15.6) notice in writing that it wishes to discontinue its participation in the further Development and Commercialization of such Collaboration Product (the
Opt-Out Notice). The effective date of such opt-out (the Opt-Out Date) shall be the date thirty
(30) days after the date of the Opt-Out Notice. In its Opt-Out Notice the Opt-Out Party shall also notify the other Party
whether continued Development and Commercialization of the Collaboration Product can take place on the pre-defined financial terms, as set forth in Exhibit 1, or whether the Opt-Out Party wants to Divest 

  
 54 of 85 

 Execution Version 

 

 
its share of the Collaboration Product. Upon receipt of the Opt-Out Notice, the other Party shall, within thirty (30) days following its receipt of
the Opt-Out Notice, notify the Opt-Out Party in writing whether or not it elects to assume sole responsibility for, and all costs and obligations of, the continued
Development and Commercialization of such Collaboration Product, and (if the Opt-Out Party has offered that continued Development and Commercialization of the Collaboration Product can take place on the pre-defined terms set forth in Exhibit 1), whether it accepts to continue Development and Commercialization of the Collaboration Product on such pre-defined terms. 

 

	14.2	 Postponement of Opt-Out. Only applicable for opt-out in connection with Establishment of Clinical Proof of Concept, the Parties may agree in writing to postpone the window, within which a Party can opt-out of the
Development, in order to perform an additional clinical trial. The Parties agree and acknowledge that the pre-defined financial terms for opt-out at Establishment of
Clinical Proof of Concept will remain applicable for the agreed postponed opt-out point. 

  

	14.3	 Opt-Out at Proposed IND Submission. 

  

	 	a.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product may take place on the pre-defined terms in Exhibit 1, and the other Party elects to assume sole responsibility for, and all costs and obligations
of the continued Development and Commercialization of the Collaboration Product on such pre-defined financial terms, then the Collaboration Product shall become a Unilateral Product and Section 14.6 shall
apply. 

  

	 	b.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product may take place on the pre-defined terms in Exhibit 1, and the other Party is not willing to accept such
pre-defined terms, then a mandatory joint Divestment of the Collaboration Product shall take place pursuant to Section 15.9. If the mandatory joint Divestment fails, the Collaboration Product shall be
considered a Ceased Product. 

  

	 	c.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product cannot take place on the pre-defined terms in Exhibit 1, the Opt-Out Party may Divest its share of the
Collaboration Product pursuant to Sections 15.1 to 15.8, including for the avoidance of doubt the Exclusive Negotiation Period pursuant to Sections 15.2 and 15.3. If such Divestment is not successful, as an exception to Section 15.6, the Opt-Out Party may either continue the Development and Commercialization of the Collaboration Product pursuant to the conditions of this Agreement, or notify the other Party that it wishes to opt-out of the collaboration on the basis of the pre-defined terms and conditions set forth in Exhibit 1. In such scenario, Sections 14.3a) or 14.3b) shall apply respectively,
depending on whether the other Party accepts the pre-defined terms and conditions set forth in Exhibit 1. 

  
 55 of 85 

 Execution Version 

 

	14.4	 Opt-Out at Establishment of Clinical
Proof of Concept. 

  

	 	a.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product may take place on the pre-defined terms in Exhibit 1, and the other Party elects to assume sole responsibility for, and all costs and obligations
of the continued Development and Commercialization of the Collaboration Product on such pre-defined financial terms, then the Collaboration Product shall become a Unilateral Product and Section 14.6 shall
apply. 

  

	 	b.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product may take place on the pre-defined terms in Exhibit 1, and the other Party is not willing to accept such
pre-defined terms, both Parties shall be released from any further Development and funding obligation under this Agreement and the Parties shall negotiate exclusively with each other for [***] months as set
forth in Sections 15.2 and 15.3. If such negotiations are unsuccessful, the Opt-Out Party shall seek to Divest both Parties’ share of the Collaboration Product, such Divestment to be handled by the Opt-Out Party on behalf of both Parties. The Opt-Out Party shall use Commercially Reasonable Efforts to maximize the value obtained in the Divestment. The other Party shall be
allowed to submit bids during such Divestment. Section 15.5 shall apply mutatis mutandis, except that the Opt-Out Party shall be allowed to extend the Divestment period pursuant to
Section 15.5b) with additional [***] months by documenting that at the expiry of the original Divestment period term sheet(s) from one or more Third Party/ies are subject to ongoing negotiations. If the Divestment fails, the Collaboration
Product shall be considered a Ceased Product. For the avoidance of doubt, Sections 15.4 (Funding Obligations) and 15.6 (Failure to Divest) shall not apply to any Divestment pursuant to this Section 14.4b). 

 

	 	c.	 If the Opt-Out Party has notified the other Party that continued
Development and Commercialization of the Collaboration Product cannot take place on the pre-defined terms in Exhibit 1, the Opt-Out Party may Divest its share of the
Collaboration Product pursuant to Sections 15.1 to 15.8, including for the avoidance of doubt the Exclusive Negotiation Period pursuant to Sections 15.2 and 15.3. If such Divestment is not successful, as an exception to Section 15.6, the Opt-Out Party may either continue the Development and Commercialization of the Collaboration Product pursuant to the conditions of this Agreement, or notify the other Party that it wishes to opt-out of the collaboration on the basis of the pre-defined terms and conditions set forth in Exhibit 1, provided that the milestone payments applicable to opt-out at [***] shall each be reduced by [***], and the royalty rates applicable to opt-out at Establishment of Proof of concept shall each be reduced by [***] percentage
point (Fall-Back Terms). In such scenario, the Sections 14.4a) or 14.4b) shall apply mutatis mutandis, depending on whether the other Party accepts such Fall-Back Terms. 

 

	14.5	 Ceased Product. A Collaboration Product shall become a Ceased Product, if
and when (i) upon receipt of an Opt-Out Notice the other Party either notifies the Opt-Out Party that it does not elect to assume sole responsibility for, and all
costs and obligations of, the continued Development and Commercialization of the respective Collaboration Product or does not notify the Opt-Out Party in writing within thirty (30) days that it wishes to
assume sole responsibility for, and all costs and obligations of, the continued 

  
 56 of 85 

 Execution Version 

 

	 	
Development and Commercialization of the respective Collaboration Product; or (ii) in any other scenario under which a Collaboration Product shall be considered a Ceased Product and/or which
refers to this Section 14.5 pursuant to this Agreement. With respect to any Ceased Product: 

  

	 	a.	 the Parties shall decide on whether or not to attempt a joint Divestment pursuant to Section 15.9. If the
Divestment of a Ceased Product fails, or the Parties jointly decide not to attempt to Divest, the exclusivity obligations under Section 6 shall no longer apply to such Ceased Product or the relevant Target Combination; and

  

	 	b.	 both Parties shall be released from any further Development and funding obligation under this Agreement,
provided they shall work together to ensure that any ongoing activities related to a Ceased Product are properly wound down, and shall share costs related to such winding down, if any. 

 

	14.6	 Continuation of Development and Commercialization by other Party. If a party (the
Continuing Party) elects to assume sole responsibility for, and all costs and obligations of the continued Development and Commercialization of the Collaboration Product, whether on the
pre-defined terms set forth in Exhibit 1, or on other terms agreed with the Opt-Out Party pursuant to the scenarios set forth in Sections 14.3 and 14.4 , then:

  

	 	a.	 such Collaboration Product will become a Unilateral Product; 

 

	 	b.	 the Continuing Party will be entitled to continue the development and commercialization of the Unilateral
Product in its sole discretion and Sections 3 and 4 shall no longer apply, provided that the Continuing Party shall use Commercially Reasonable Efforts to further develop and commercialize the Unilateral Product, including without limitation to
achieve filing of the first IND for such Unilateral Product within [***] years after selection of the respective Clinical Candidate according to Section 2.10. The Continuing Party may extend the date by which the first IND for such Unilateral
Product should be filed by [***] year by paying to the other Party [***]. Such payment shall be made no later than [***] years after selection of the respective Clinical Candidate according to Section 2.10. If the Continuing Party materially
breaches its obligations under this Section 14.6b and fails to cure such breach within [***] days following its receipt of written notice thereof from the Opt-Out Party, the
Opt-Out Party shall have the right, exercisable by written notice to the Continuing Party, to request that the Unilateral Product as well as all rights and data relating thereto shall be Divested through a
Joint Divestment Process; 

  

	 	c.	 the Continuing Party may terminate at any time in its sole discretion the development and/or commercialization
of the Unilateral Product by written notice to the Opt-Out Party. Such termination shall not constitute a breach of applying Commercial Reasonable Efforts as set forth in Section 14.6b. In the event of
any such termination the Unilateral Product shall become a Ceased Product and Section 14.5 shall apply; 

  
 57 of 85 

 Execution Version 

 

	 	d.	 all rights and obligations of the Opt-Out Party under this Agreement
with respect to the Unilateral Product will end except for the Opt-Out Party’s continuing obligations under Sections 2.7, 2.8, 3.5 (to the extent it refers to Sections 2.7 and 2.8) and 11 or otherwise
provided for in this Section 14.6 or Exhibit 1; in particular, the licenses set forth in Section 9.2 and Section 9.3 will terminate, and will be replaced by the licenses set forth in Section 14.7; 

 

	 	e.	 the Collaboration IP solely relating to the Unilateral Product will be assigned to the Continuing Party in
accordance with Section 9.1h; 

  

	 	f.	 the prosecution, maintenance, enforcement and defense of Patent Rights solely relating to the Unilateral
Product will be subject to Sections 9.8a, 9.8b, 9.9a, 9.9c, 10.4 and 10.5; 

  

	 	g.	 the terms and conditions set forth in Exhibit 1 will apply (except to the extent the Parties have agreed
on different financial terms pursuant to the scenarios set forth in Section 14.3 and 14.4); 

  

	 	h.	 promptly after the Continuing Party’s election, the Parties will work together to transfer and assign all
regulatory documents, contracts, materials and information related to such former Collaboration Product to the Continuing Party or its designees to the extent necessary for the Continuing Party to assume such sole responsibility;

  

	 	i.	 the Opt-Out Party will not be refunded or repaid any amounts it has
paid for the Development of such former Collaboration Product; 

  

	 	j.	 for [***] after the date of the Opt-Out Notice, the Opt-Out Party shall provide development, consultation or support work for a Unilateral Product of the Continuing Party, as reasonably requested by the Continuing Party, and the Continuing Party shall pay for such
work at the then current annual rate per FTE as set forth in Exhibit 1. 

  

	14.7	 Licenses for Unilateral Products. 

 

	 	a.	 License to Genmab for Unilateral Products. On a Genmab Unilateral Product-by-Genmab Unilateral Product basis and subject to the terms of this Agreement, Biontech hereby grants to Genmab a royalty bearing (subject to the terms and conditions set forth in Exhibit 1)
license under the Biontech Technology, with the right to sublicense (through multiple tiers), to develop, have developed, make, have made, import, use, offer for sale, have sold and sell Genmab Unilateral Products within the Field in the Territory.
The license for a Genmab Unilateral Product shall be exclusive in accordance with Section 6.3. 

  

	 	b.	 Genmab’s Rights to Sublicense. Genmab shall have the right to grant a sublicense of the license
granted pursuant to subsection a above to any Affiliate or other Third Party, provided that Genmab agrees to contractually obligate any Sublicensee of a Genmab Unilateral Product to make all payments due to Biontech pursuant to this Agreement, as
well as to comply with all terms of this Agreement applicable to Genmab. For the sake of clarification, such payments shall be made to Genmab and not directly to Biontech. Genmab shall also require any such Sublicensee to agree in writing to keep
books and records and permit either Genmab or Biontech or both 

  
 58 of 85 

 Execution Version 

 

	 	
to audit the information concerning such books and records in accordance with the terms of this Agreement. If one of the Parties conducts such an audit of the books and records of a Sublicensee
without the other Party’s participation, the Party conducting the audit shall upon the other Party’s request share the results of such audit. In addition, a sublicense to an Affiliate must provide that it will automatically terminate if
the relevant Sublicensee ceases to be an Affiliate of Genmab. For sublicenses permitted hereunder, Genmab shall (a) notify Biontech of each sublicense granted (both to Affiliates and Third Parties) hereunder, and (b) provide Biontech with
the [***] of each Sublicensee (both Affiliates and Third Parties) and a description of [***] by each Sublicensee. 

  

	 	c.	 License to Biontech for Unilateral Products. On a Biontech Unilateral Product-by-Biontech Unilateral Product basis and subject to the terms of this Agreement, Genmab hereby grants to Biontech a royalty bearing (subject to the terms and conditions set forth in Exhibit 1)
license under the Genmab Technology, with the right to sublicense (through multiple tiers), to develop, have developed, make, have made, import, use, offer for sale, have sold and sell Biontech Unilateral Products within the Field in the Territory.
The license for a Biontech Unilateral Product shall be exclusive in accordance with Section 6.3. The licenses granted to Biontech hereunder with regards to the DuoBody Platform are only granted for the [***]. Use of other [***] under the
DuoBody Platform can only take place upon Genmab’s prior written consent. The license granted under the [***] Technology is to the embodiment wherein the [***] 

 

	 	d.	 Biontech’s Rights to Sublicense. Biontech shall have the right to grant a sublicense of the license
granted pursuant to subsection c above to any Affiliate or other Third Party, provided that Biontech agrees to contractually obligate any Sublicensee of a Biontech Unilateral Product to make all payments due to Genmab pursuant to this Agreement, as
well as to comply with all terms of this Agreement applicable to Biontech. For the sake of clarification, such payments shall be made to Biontech and not directly to Genmab. Biontech shall also require any such Sublicensee to agree in writing to
keep books and records and permit either Genmab or Biontech or both to audit the information concerning such books and records in accordance with the terms of this Agreement. If one of the Parties conducts such an audit of the books and records of a
Sublicensee without the other Party’s participation, the Party conducting the audit shall upon the other Party’s request share the results of such audit. In addition, a sublicense to an Affiliate must provide that it will automatically
terminate if the relevant Sublicensee ceases to be an Affiliate of Biontech. For sublicenses permitted hereunder, Biontech shall (a) notify Genmab of each sublicense granted (both to Affiliates and Third Parties) hereunder, and (b) provide
Genmab with the name and address of each Sublicensee (both Affiliates and Third Parties) and a description of the rights granted and the territory covered by each Sublicensee. 

 

	15.	 DIVESTMENT OF COLLABORATION PRODUCTS 

 

	15.1	 Divestment. Each Party may, at any time during the Development of a Collaboration Product,
seek to Divest its then current ownership share of the Collaboration Product to a Third Party and exit the collaboration hereunder without further obligations. 

  
 59 of 85 

 Execution Version 

 

	15.2	 Right of First Negotiation. A Party that wishes to Divest its ownership share of a
Collaboration Product (the Divesting Party), shall first grant the other Party (the Non-Divesting Party) a right of first exclusive negotiation to obtain exclusive, worldwide
Development and Commercialization rights to the Collaboration Product on terms and conditions that shall be negotiated in good faith at the time the Non-Divesting Party exercises its right of first
negotiation. The Divesting Party shall by written notice inform the Non-Divesting Party that it wishes to Divest its ownership share of the Collaboration Product (the Divestment Notice).
Following receipt of such notice the Non-Divesting Party shall have an option for a sixty (60) day period to negotiate exclusively with the Divesting Party to acquire the Divesting Party’s share of
the Collaboration Product (the Exclusive Negotiation Period). During the Exclusive Negotiation Period, the Parties shall negotiate in good faith to arrive at a non-binding term sheet that
includes all key financial terms for the Divestment agreement, and that specifies a closing date [***] months from the date on which such term sheet is executed by the Parties. Neither Party shall be obligated to agree to such a term sheet, to agree
to any particular terms therein, or to agree to execute a binding agreement contemplated by such a term sheet. The Non-Divesting Party may in its sole discretion waive the right to the Exclusive Negotiation
Period, in which case the Divesting Party may proceed with the desired Divestment process (the Divestment Process). 

  

	15.3	 Information to Third Parties. During the Exclusive Negotiation Period only the Non-Divesting Party will be allowed access to any data room containing Confidential Information regarding the Collaboration Product, and no Confidential Information will in any other way be disclosed to, and no term
sheet discussions can take place with any Third Parties. 

  

	15.4	 Funding Obligations During Divestment Process. During a Divestment Process, the Non-Divesting Party will have the [***] on the Joint Development Team and Joint Steering Committee with regards to any decisions on the continued Development of the Collaboration Product within the framework of the
clinical scenarios stipulated in the updated Development Plan, cf. Section 3.6. During a Divestment Process, whether initiated pursuant to Sections 14.3c, 14.4c or 15.1, the Divesting Party will remain responsible to the Non-Divesting Party for its share of the agreed Research and Development Costs as per the then current Development Plan as updated pursuant to Section 3.6 and as set forth in the then current Budget, but
subject to a cap of [***] on such Research and Development Costs to be [***] during the Divestment Process (the Cap during Divestment). Once the Cap during Divestment has been reached, and if the Divestment Process is still ongoing,
the Divesting Party may either (i) Divest its share of the Collaboration Product to the Non-Divesting Party on terms to be agreed by the Parties, or (ii) continue to fund its part of the Research and
Development Costs until the share has been Divested, in which case the Divesting Party may elect to defer payment of its funding obligations during the remainder of the Divestment Process. In such case, the Divesting Party shall notify the Joint
Steering Committee that it wishes to defer any payment of Research and Development Costs beyond the Cap during Divestment until finalization of the Divestment Process. Once the Divestment Process has been finalized, whether or not successfully, the
Divesting Party shall immediately pay its deferred share of the Research and Development Costs to the Non-Divesting Party whether such share can be covered by the proceeds from the Divestment or not. The
amount to be paid shall be calculated as deferred payment with an interest rate of [***] percent ([***]%) above EUBOR. 

  
 60 of 85 

 Execution Version 

 

	15.5	 Duration of Divestment Process. A Divestment Process shall end upon the earlier of:

  

	 	a.	 completion of a binding Divestment agreement between the Divesting Party and the
Non-Divesting Party or a Third Party; and 

  

	 	b.	 expiration of [***] months after the end of the Exclusive Negotiation Period. 

 

	15.6	 Failure to Divest. Unless otherwise specifically stipulated in this Agreement, upon
failure to conclude a binding Divestment agreement within [***] months after the end of the Exclusive Negotiation Period pursuant to Section 15.5b), the Divesting Party shall continue the Development and Commercialization of the Collaboration
Product pursuant to the terms and conditions of this Agreement. 

  

	15.7	 Bids. The Non-Divesting Party may participate as a
bidder in the Divestment Process. 

  

	15.8	 Third Party Acquirer. A Third Party that licenses or acquires the Divesting Party’s
ownership share of a Collaboration Product shall adhere to all terms and conditions of this Agreement, including but not limited to the fulfilment of its obligations under the then current Development Plan and Budget, as of the completion of the
relevant Divestment agreement. 

  

	15.9	 Joint Divestment Process. In the event that both Parties wish to opt-out of Development or Divest their respective ownership shares of a certain Collaboration Product or in any other scenario pursuant to this Agreement which provides for a joint Divestment and/or refers to this
Section 15.9, the Parties shall jointly initiate a Divestment process (the Joint Divestment Process), which shall be performed by the Parties as follows: 

 

	 	a.	 Both Parties shall upon initiation of the Joint Divestment Process be released from any further research,
Development and funding obligation under this Agreement, provided they shall work together to ensure that any ongoing activities related to the Collaboration Product to be Divested are properly wound down to the extent applicable, and shall share
costs related to such winding down, if any. 

  

	 	b.	 Unless otherwise agreed by the Parties at the time of initiation of the Joint Divestment Process, each Party
shall designate a divestment executive (Divestment Executive) who shall not be a Joint Steering Committee member, and who shall be the point of contact for such Parties in the Joint Divestment Process and who shall report to the Joint
Steering Committee. 

  

	 	c.	 The Parties may engage a Third Party advisor, on terms acceptable to both Parties, to coordinate the Joint
Divestment Process for the purpose of licensing rights to the Collaboration Product. The Divestment Executives and the Third Party advisor shall present to the Joint Steering Committee for approval detailed criteria for evaluating, comparing and
selecting potential offers, which shall include financial and nonfinancial factors (Bidding Criteria). 

  
 61 of 85 

 Execution Version 

 

	 	d.	 Neither Party may [***]. 

 

	 	e.	 The Parties shall use Commercially Reasonable Efforts to maximize the value obtained in the Joint Divestment
Process. 

  

	 	f.	 The Joint Steering Committee shall unanimously decide on which offer to accept under the Joint Divestment
Process, using the Bidding Criteria. Once the Joint Steering Committee has decided which offer to accept, the Parties shall together appoint an external legal counsel to handle, on behalf of both Parties and at a cost equally shared the drafting,
negotiation and finalization of the agreement with the Third Party that made the winning offer. Both Parties shall be signatories to the agreement with such Third Party. 

 

	 	g.	 If the Joint Divestment Process has not been finalized within [***] months after its initiation, the Parties
shall discuss in good faith the terms and conditions for continuing the Joint Divestment Process, or for continuing the Development of the Collaboration Product, or any alternative solution, including the
winding-up of the Development of the Collaboration Product. 

  

	16.	 TERM AND TERMINATION 

 

	16.1	 Term. This Agreement shall become effective on the Effective Date and shall continue until
the later of (i) the last to expire Royalty Term for a Unilateral Product and, (ii) when no Collaboration Products are being Developed and/or Commercialized any longer, unless terminated earlier in accordance with the provisions of this
Agreement (the Term). 

  

	16.2	 Termination for Breach. Either Party may terminate this Agreement in its entirety or on a
Collaboration Product-by-Collaboration Product and/or Unilateral Product-by-Unilateral
Product basis at any time by written notice to the other Party with immediate effect if: 

  

	 	a.	 the other Party materially breaches any material provision of this Agreement and fails to cure such breach
within [***] days following its receipt of written notice thereof from the terminating Party. 

  

	 	b.	 the other Party becomes insolvent, is compelled to file bankruptcy or is determined otherwise imminently
subject to control by a bankruptcy trustee or its equivalent to the laws of the jurisdiction in which such Party is doing business. Notwithstanding the foregoing, the Parties intend for this Agreement and the licenses granted herein to remain in
full force and effect so long as the non-insolvent Party remains in material compliance with the terms and conditions hereof. 

 

	16.3	 Effect of Expiration and Termination 

 

	 	a.	 Except where explicitly provided within this Agreement, termination of this Agreement (whether in its entirety
or with respect to a Collaboration Product and/or Unilateral Product) for any reason, or expiration of this Agreement, will not affect any: (i) obligations, including payment of any royalties or other sums which have accrued as of the effective
date of termination or expiration, and (ii) rights and 

  
 62 of 85 

 Execution Version 

 

	 	
obligations which, from the context thereof, are intended to survive termination or expiration of this Agreement, including the provisions of Sections 1, 2.7, 3.5 (to the extent it refers to
Section 2.7), 7.8, 7.9, 9.10, 10 (as to actions arising during the term of this Agreement or in the course of a Party practicing any licenses retained by such Party thereafter), 11, 12, 16.3a and 17. 

 

	 	b.	 Upon termination of this Agreement partly or wholly for any reason, save as expressly provided herein, all
licenses granted to each of the Parties in respect of the affected terminated Collaboration Product(s) and/or Unilateral Product(s), and all sublicenses granted to Affiliates by a Party hereunder in respect of the affected terminated Collaboration
Product(s) and/or Unilateral Product(s) will immediately cease and terminate. In the event the termination is to the Agreement in its entirety or else in respect of the affected terminated Collaboration Product(s) and/or Unilateral Product(s), the
Parties shall promptly return to one another or destroy all Confidential Information of the other Party and antibodies and other materials created under the Prior Agreement or this Agreement that are in a Party’s or its Affiliates’
possession or control in respect of the affected terminated Collaboration Product(s) and/or Unilateral Product(s). The Parties shall jointly decide how a termination of this Agreement partly or wholly shall affect any Joint Patents.

  

	16.4	 Rights of Sublicensees. Upon the termination of this Agreement any sublicenses granted by
a Party to Third Parties hereunder shall survive, provided that each sublicensee is then in full compliance with its sublicense and promptly agrees in writing to be bound by the applicable terms of this Agreement and agrees to pay directly to the
other Party or the Parties, as applicable, the same amounts that would have been due to such other Party under this Agreement with respect to such sublicense had the Agreement not been terminated. 

 

	16.5	 Winding Down. To the extent not prohibited by Applicable Law, the Parties shall wind down
any clinical trials that are underway in respect of the terminated Collaboration Product and/or Unilateral Product, taking into account the health and safety of the subjects enrolled therein and Good Clinical Practice. In the event that a Party is
Commercializing Collaboration Products and/or Unilateral Products under this Agreement, and in accordance with the foregoing provisions of this Section 16.3, a license is terminated then such Party shall be entitled to, and the licenses shall
be deemed to survive to the extent necessary for such Party to wind down the activities in an orderly manner, including the right to sell off inventory, but in no event for a period longer than six (6) months from the effective date of
termination. 

  

	16.6	 Force Majeure. No Party (or any of its Affiliates) shall be held liable or responsible to
the other Party (or any of its Affiliates), or be deemed to have defaulted under or breached the Agreement, for failure or delay by such Party in fulfilling or performing any term of the Agreement when such failure or delay is caused by or results
from causes beyond the reasonable control of the affected Party (or any of its Affiliates), including fire, floods, embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, acts of God, earthquakes, or
omissions or delays in acting by any governmental authority (collectively, Events of Force Majeure); provided, however, that the affected Party shall promptly advise the other Party of the existence of such Event of Force Majeure and
shall exert all Commercially Reasonable Efforts to 

  
 63 of 85 

 Execution Version 

 

	 	
eliminate, cure or overcome any such Event of Force Majeure and to resume performance of its obligations promptly. Notwithstanding the foregoing, to the extent that an Event of Force Majeure
continues for a period in excess of [***] months, the affected Party shall promptly notify in writing the other Party of such continued Event of Force Majeure and within [***] month of the other Party’s receipt of such notice, the Parties shall
negotiate in good faith either (i) a resolution of the Event of Force Majeure, if possible, (ii) an extension by mutual agreement of the time period to resolve, eliminate, cure or overcome such Event of Force Majeure, (iii) an
amendment of this Agreement to the extent reasonably possible, or (iv) an early termination of this Agreement. If a solution under (i) to (iv) has not been reached after [***] months of the other Party’s receipt of such notice, then
the Party not affected shall be entitled to give notice to the affected Party to terminate this Agreement, specifying the date (which shall not be less than [***] calendar days after the date on which the notice of termination is given) on which
termination will take effect. Such a termination notice shall be irrevocable, except with the consent of both Parties, and upon termination the provisions of Section 16.3 shall apply. 

 

	17.	 GENERAL PROVISIONS 

 

	17.1	 Notices. All notices, requests and other formal communications shall be made in writing
and shall be delivered or sent in each case to the respective address specified below: 

  

			
	If to Genmab:	  	Genmab A/S
		  	[***]
		
	If to Biontech:	  	BioNTech AG
		  	[***]

 Each Party shall immediately notify the other Party in the event of any changes of its address set forth
above. 
  

	17.2	 Insurance. During the Term and thereafter for the period of time required below, each
Party shall maintain on an ongoing basis comprehensive general liability insurance in the minimum amount of [***] per occurrence and [***] annual aggregate combined single limit for bodily injury and property damage liability. Commencing not later
than [***] days prior to the first use in humans of any Collaboration Product or Genmab Unilateral Product and thereafter for the period of time required below, Genmab shall obtain and maintain during respective clinical studies on an ongoing
basis products liability insurance (including contractual liability coverage on Genmab’s indemnification obligation under this Agreement) in the amount of at least [***] per occurrence and at least [***] annual aggregate combined single limit
for bodily injury and property damage liability. Commencing not later than [***] days prior to the first use in humans of any Collaboration Product or Biontech Unilateral Product, and thereafter for the period of time required below, Biontech shall
obtain and maintain during respective clinical studies on an ongoing basis products liability insurance for clinical studies (including contractual liability coverage on Biontech’s indemnification obligations under this Agreement) in the
amount of at least [***] per occurrence and at least [***] annual aggregate combined single limit for bodily injury and property 

  
 64 of 85 

 Execution Version 

 

	 	
damage liability. Upon the Effective Date and not later than [***] days prior to the first use in humans of the first Collaboration Product, Genmab Unilateral Product or Biontech Unilateral
Product, as the case may be, each Party shall provide to other Party a certificate(s) evidencing all required coverage hereunder. Each Party shall maintain such insurance coverage without interruption during the Term and for a period of at least
[***] years thereafter. Each Party shall, at the request of the other Party, provide the other Party at least [***] days’ prior written notice of any cancellation or material change in the insurance policy. For the avoidance of doubt, the term,
“product liability insurance” as used in this Section 17.2 shall not include clinical trial insurances; the Parties will each obtain and maintain clinical trial insurance to the extent required by Applicable Law. 

 

	17.3	 Entire Agreement. This Agreement, including the Exhibits to this Agreement, represents the
entire understanding between the Parties with respect to the subject matter hereof and supersedes all previous oral or written communication or agreements, and all contemporaneous oral communication and agreements between the Parties.

  

	17.4	 Form Requirement. This Agreement may only be amended, modified or supplemented by the
Parties in writing. The same applies to this Section 17.4. 

  

	17.5	 Assignment. Neither Party may assign its contractual rights and obligations or parts
thereof without the prior written consent of the other Party, except for permitted subcontracting and provided, however, that either Party may, without such consent, assign this Agreement and all of its rights and obligations hereunder (i) to
any Affiliate or (ii) in connection with the transfer or sale of all or substantially all of its business to which this Agreement relates, or in the event of its merger, consolidation, or other similar transaction. For clarification, any
assignment to Third Parties which is not expressly allowed above requires the approval of the other Party, which approval shall not be withheld unreasonably if the Third Party assignee assumes all rights and obligations of this Agreement.

  

	17.6	 Profit Sharing Rights. Either Party may transfer its share of the Shared Profits hereunder
to any Affiliate or Third Party (including for purposes of providing security to investors or financing parties), provided that the transferring Party shall remain Party to this Agreement and shall remain bound by all obligations hereunder, and that
the non-transferring Party shall not be obligated to make any payment directly to, or perform any other obligation directly towards, the receiving Affiliate or Third Party. 

 

	17.7	 Severability. If any provision of this Agreement is found to be invalid or otherwise
unenforceable, in whole or in part, the validity of the remainder of the Agreement shall not be affected. Furthermore, the Parties agree that the invalid or unenforceable provision or part thereof shall be superseded by an adequate provision that,
to the legally permitted extent, comes closest to what the Parties would have desired at the time of conclusion of the Agreement had they considered the issue concerned. 

 

	17.8	 Independent Contractor. Nothing in this Agreement shall create, or be deemed to create, a
partnership, joint venture, or the relationship of principal and agent or employer and employee between the Parties. Each Party agrees to perform under this Agreement solely as independent contractor. 

  
 65 of 85 

 Execution Version 

 

	17.9	 Dispute Resolution. Any dispute arising between the Parties in connection with this
Agreement shall be referred to the Joint Research Committee or the competent Joint Steering Committee or Joint Commercialization Committee, as applicable. If the competent committee is unable to negotiate in good faith and settle the dispute within
[***] days after being requested to do so, either Party may submit the dispute to the Parties’ [***] who shall meet in order to attempt to resolve the dispute. If the dispute is not settled, at the latest, within [***] weeks from the date that
the dispute has been escalated to the [***], either Party may pursue legal action in accordance with Section 17.10 below. For the avoidance of doubt, if the dispute is with respect to an amendment of the Research Plan or any Development Plan,
the current version of such Research Plan or Development Plan shall remain in effect until the dispute is finally settled. 

  

	17.10	 Governing Law, Arbitration. This Agreement shall be governed by the laws of England
and Wales without reference to its conflict of laws provisions. All disputes arising out or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators
appointed in the accordance with said Rules. The place of the Arbitration Tribunal shall be London, England. The language of the arbitration proceeding shall be English. 

[End of Agreement – Signatures on the following page] 

  
 66 of 85 

 Execution Version 

 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Agreement as of the
Effective Date 
  

									
	For Genmab A/S:	  		  	For Biontech AG:
					
	By:	  	 [***]
	  		  	By:	  	 [***]

					
	Name:	  	[***]	  	                        	  	Name:	  	[***]
					
		  	(Print or Type)	  		  		  	
					
	Title:	  	CEO & President	  		  	Title:	  	COO

  
 67 of 85 

 Execution Version 

 

 Exhibit 1: Terms for Continued Development in Case of an
Opt-Out 
  

	1.	 Financial Terms 

 

	1.1	 Milestone Payments 

 

	 	a.	 Allocation. As partial consideration for the licenses, rights and privileges granted to it hereunder, a
Continuing Party shall promptly inform the Opt-Out Party of the achievement of any of the below milestones and pay to the Opt-Out Party the following milestone payments
on a Unilateral Product-by-Unilateral Product basis within [***] days of the first occurrence of each event set forth below with respect to a Unilateral Product to
achieve such event, whether such events are achieved by the Continuing Party, its Affiliates, or Sublicensees, as follows: 

In case of Continuing Party developing from Selection of a Clinical Candidate: 

[***] 

  
 68 of 85 

 Execution Version 

 

 In case of Continuing Party developing from Proposed IND
Submission: 
 [***] 

  
 69 of 85 

 Execution Version 

 

 [***] 

  
 70 of 85 

 Execution Version 

 

 [***] 
  

	 	b.	 Clarifications. All milestone payments shall only become due and payable once per Unilateral Product and
Indication. If any of the development milestone events is achieved before the previous development milestones having become payable, the previous development milestones shall become due and payable with the achievement of such milestone event. If a
development milestone has not been achieved, but the Continuing Party decides to continue the development in spite of such failure to achieve the milestone, the relevant development milestone shall be deemed to be achieved. For the avoidance of
doubt, if a Unilateral Product is replaced by a Back-up Candidate only such milestones not already paid for the Unilateral Product shall become payable for the Back-up
Candidate. 

  
 71 of 85 

 Execution Version 

 

	1.2	 Royalties. 

 

	 	a.	 Royalties Payable on Net Sales of Unilateral Products. In partial consideration for the license for a
Unilateral Product granted to the Continuing Party herein, during the Royalty Term and subject to (b) below, the Continuing Party shall pay to the other Party royalties on the aggregate Net Sales of all Unilateral Products, on a country-by-country basis. Such royalties shall be paid at the following rates as set forth below: 

 

	 	(i)	 In case of Continuing Party developing from Selection of a Clinical Candidate:

 [***] 
  

	 	(ii)	 In case of Continuing Party developing from Proposed IND Submission: 

[***] 
  

	 	(iii)	 In case of Continuing Party developing from Establishment of Clinical Proof of Concept:

 [***] 
  

	 	b.	 Royalty Offsets and Reductions 

 

	 	(i)	 Subject to the royalty offset set forth in (ii) and (iii) below, the Continuing Party shall be solely
responsible for paying all amounts, including any license fees, milestones and royalties owed to Third Parties by either Genmab or Biontech on account of developing and commercializing a Unilateral Product, including any royalties owed due to use of
the Biontech Technology or Genmab Technology, without reduction of, or offset against, the royalties payable to the Opt-Out Party hereunder. 

 

	 	(ii)	 Notwithstanding Section (i) and only if Biontech has opted-out at
Establishment of Clinical Proof of Concept, on a Calendar Quarter-by-Calendar Quarter and
country-by-country basis, Genmab [***] for intellectual property rights that are necessary to ensure product compound improvements and overcome freedom to operate
obstacles (excluding for the 

  
 72 of 85 

 Execution Version 

 

	 	
avoidance of doubt intellectual property rights necessary for manufacturing formulation or processes) with respect to a Genmab Unilateral Product against the royalties that would otherwise be
payable to Biontech pursuant to Section 1.2(a) for such Genmab Unilateral Product. Notwithstanding anything to the contrary in this subsection (ii), in no event shall the royalty payments due and payable to Biontech pursuant to
Section 1.2(a) with respect to a Genmab Unilateral Product in any Calendar Quarter and country be [***]. 

  

	 	(iii)	 Notwithstanding Section (i) and only if Genmab has opted-out at
Establishment of Clinical Proof of Concept, on a Calendar Quarter-by-Calendar Quarter and
country-by-country basis, Biontech [***] by Biontech to Third Parties for intellectual property rights that are necessary to ensure product compound improvements and
overcome freedom to operate obstacles (excluding for the avoidance of doubt intellectual property rights necessary for manufacturing formulation or processes) with respect to a Biontech Unilateral Product against the royalties that would otherwise
be payable to Genmab pursuant to Section 1.2(a) for such Biontech Unilateral Product. Notwithstanding anything to the contrary in this subsection (iii), in no event shall the royalty payments due and payable to Genmab pursuant to
Section 1.2(a) with respect to a Biontech Unilateral Product in any Calendar Quarter and country be reduced by [***]. 

  

	 	(iv)	 In the event that at any time during the applicable Royalty Term, in respect to a Unilateral Product in a
specific country, the following has occurred; (a) the market share of such Product is less [***] in such country in a calendar year; and (b) the decline in such market share is attributable to the marketing or sale in such country of a
Generic Product of such Unilateral Product by a Third Party, the applicable royalty rate shall be reduced by [***] in such country for the remainder of the Royalty Term applicable for such Unilateral Product in such country. 

 

	 	(v)	 In the event that a Valid Patent Claim of a patent covering composition of matter or method of use with respect
to a Unilateral Product in the country of sale does not exist at any time during the applicable Royalty Term, the applicable royalty rate shall be [***] in such country for the remainder of the Royalty Term applicable for such Unilateral Product in
such country. 

  

	 	c.	 Reference to Certain Provisions of the Agreement. Sections 7.8 and 7.9 of the Agreement shall apply
correspondingly to royalty payments. 

  

	 	d.	 Royalty Reports, Exchange Rates 

 

	 	(i)	 Royalty Reports. During the Royalty Term, any Party paying royalties hereunder (the Paying Party)
shall furnish to the non-Paying Party, with respect to each Calendar Quarter, a written report showing, on a consolidated basis in reasonably specific detail and on a country-by-country basis, (a) the Net Sales of Unilateral Products sold by the Paying Party, its Affiliates and its Sublicensees in the Territory during the corresponding Calendar Quarter

  
 73 of 85 

 Execution Version 

 

	 	
on a Unilateral Product-by-Unilateral Product and
country-by-country basis to calculate Net Sales; (b) the royalties payable in US Dollars, if any, which shall have accrued hereunder based upon such Net Sales of
Unilateral Products; (c) the withholding taxes, if any, required by Applicable Law to be deducted in respect of such royalties; (d) the dates of the First Commercial Sale of each Unilateral Product in each country in the Territory, if it
has occurred during the corresponding Calendar Quarter; and (e) the exchange rates used in determining the royalty amount expressed in Dollars (collectively the Royalty Reports). 

 

	 	(ii)	 Report Due Date. Royalty Reports and royalty payments shall be due on the [***] day following the end of the
Calendar Quarter to which such Royalty Report relates. The Parties shall keep complete and accurate records in sufficient detail to properly reflect all gross sales and Net Sales and to enable the royalties payable hereunder to be determined. The
provisions on audit and dispute resolution in Sections 7.8 and 7.9 of the Agreement shall apply mutatis mutandis. 

  

	 	(iii)	 Exchange Rates. With respect to sales of Unilateral Products invoiced in US Dollars, the gross sales, Net
Sales, and royalties payable shall be expressed in US Dollars. With respect to sales of Unilateral Products invoiced in a currency other than US Dollars, the gross sales, Net Sales and royalties payable shall be expressed in the currency of the
invoice issued by the Party making the sale together with the US Dollars equivalent of the royalty due, calculated as described in Section 7.10 of the Agreement. 

 

	1.3	 FTE Rate. A Continuing Party shall pay the Opt-Out
Party at an annual rate of [***] per FTE who performs consultation or support work for Unilateral Products in the pre-clinical phase as requested by the Continuing Party pursuant to this Agreement and an
annual rate of [***] per FTE who performs development, consultation or support work for Unilateral Products after the pre-clinical phase as requested by the Continuing Party pursuant to this Agreement (the
FTE Fee). Such development, consultation or support work shall be at the sole discretion of the Opt-Out Party. Commencing upon the [***] anniversary of the Effective Date and upon [***]
anniversary thereafter, the fee will be adjusted in accordance with the percentage change over the applicable annual period in the consumer price inflation in the euro area as measured by the Harmonised Index of Consumer Prices (“HICP”).

  

	2.	 Other Terms 

  

	2.1	 Conduct. A Continuing Party shall comply with all Applicable Laws (including GxPs to the extent
applicable) in the development and commercialization of Unilateral Products, and shall cause its Affiliates and Sublicensees to do the same. 

  

	2.2	 Funding and Progress Reports. A Continuing Party shall be solely responsible for funding all costs of
the development and commercialization of its Unilateral Product(s). A Continuing Party shall keep the other Party’s Alliance Manager informed on a quarterly basis on the progress of development as well as any milestone projections. Annually and
no later than January 15 in the subsequent calendar year a Continuing 

  
 74 of 85 

 Execution Version 

 

	 	
Party shall send a written report on the progress of the development of its Unilateral Product(s) in the previous calendar year. Also, if the Continuing Party decides to cease development of the
Unilateral Product, the other Party’s Alliance Manager shall be informed in writing thereof with [***] calendar days. 

  

	2.3	 Manufacturing. A Continuing Party shall be responsible for all manufacturing and supply of its
Unilateral Product(s). 

  

	2.4	 Regulatory. A Continuing Party shall be solely responsible for, and shall solely own, all
applications for Regulatory Approval with respect to its Unilateral Product(s), and the Opt-Out Party shall, if applicable, have the obligation to transfer and assign any regulatory documents, contracts, etc.
that has been assigned to it pursuant to Section 5.1b of the Agreement to the Continuing Party. Should a Continuing Party desire to file an IND or an application for Regulatory Approval, or equivalents of the foregoing, for a Unilateral
Product, the Opt-Out Party agrees to provide at the Continuing Party’s request, any and all technical information the Opt-Out Party has created or possesses that is
reasonably required by the Continuing Party. The sharing of such information can be by exchange of documents and/or through telephone or personal meetings. The Continuing Party shall reimburse the Opt-Out
Party for any out of pocket costs incurred by the Opt-Out Party in providing any such information or assistance pursuant to this Section 2.4, plus an amount equal to the then current FTE Fee for personnel
engaged in such activities. If ownership of a regulatory filing for a former Collaboration Product cannot be assigned to a subsequent Continuing Party in any country, the Opt-Out Party shall grant to the
Continuing Party a permanent, exclusive and irrevocable right of access and reference to such regulatory filing for such former Collaboration Product in such country. 

 

	2.5	 Notwithstanding that a Continuing Party shall be solely responsible for the clinical development and
commercialization of its Unilateral Product(s), Section 5.5 of the Agreement shall apply to the reporting of Adverse Events and Serious Adverse Events relating to such Unilateral Product(s). 

 

	2.6	 Expiry of Royalty Term. Upon the expiration of the Royalty Term for a certain Unilateral Product, the Opt-Out Party shall grant, and shall by this provision be deemed to have granted, to the Continuing Party a royalty free, perpetual, worldwide, non-exclusive license to use
the Joint Patents, if any, Assigned Patents, and Biontech Technology or Genmab Technology, as applicable, to make, use, sell, offer for sale and import such Biontech Unilateral Product or Genmab Unilateral Product, as applicable, with no further
obligations to the Opt-Out Party. 

  
 75 of 85 

 Execution Version 

 

 Exhibit 2: Biontech Patents 

[***] 

  
 76 of 85 

 Execution Version 

 

 Exhibit 3: Genmab Patents 

[***] 

  
 77 of 85 

 Execution Version 

 

 Exhibit 4: Antibody Panel 

Table 1: List of all available antibodies [***] from BioNTech ([***] antibodies). 

[***] 

  
 78 of 85 

 Execution Version 

 

 Table 4: Current list of antibodies, which were identified to be agonistically targeting [***]
antibodies) 
 [***] 

  
 79 of 85 

 Execution Version 

 

 Table 5: Current list of antibodies, which were identified to bind to [***], but were not shown to
agonistically targeting so far ([***] antibodies) 
 [***] 

  
 80 of 85 

 Execution Version 

 

 Table 6: Current list of antibodies, which were identified to [***], but were not shown to
agonistically targeting so far ([***] antibodies) 
 [***] 

Table 7: Current list of antibodies, which were identified to [***], but were not shown to agonistically targeting so far ([***] antibodies). 

[***] 

  
 81 of 85 

 Execution Version 

 

 List of so far identified [***] or [***]: 

[***] 

  
 82 of 85 

 Execution Version 

 

 Exhibit 5: Research Plan 

[to be inserted in due course in accordance with Section 2.2 of the Agreement] 

  
 83 of 85 

 Execution Version 

 

 Exhibit 6: Joint Development Plan and Budget 

[to be inserted in due course] 

  
 84 of 85 

 Execution Version 

 

 Exhibit 7: Company Announcement and Media Release 

  
 85 of 85

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]